CINXE.COM

<!DOCTYPE html> <html id="doc" lang="en" class="page-article"> <head id="Head1">  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <script> var SCM = SCM || {}; if (SCM.AMA && SCM.AMA.DataLayerAsync) { SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array"); SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string"); } var googletag = window.googletag || {}; googletag.cmd = googletag.cmd || []; if (typeof Storage !== "undefined") { var targetingParamStr = localStorage.getItem("bcDFPTargetingParams"); if (targetingParamStr) { var targetingParameters = JSON.parse(targetingParamStr); // set page-level targeting parameters jQuery.each(targetingParameters, function (index, param) { googletag.cmd.push(function () { window.googletag.pubads().setTargeting(param.key, param.value); }); }); } } if (!googletag.pubads) { (function () { var gads = document.createElement('script'); var useSSL = 'https:' == document.location.protocol; gads.src = (useSSL ? 'https:' : 'http:') + '//securepubads.g.doubleclick.net/tag/js/gpt.js'; gads.setAttribute("async", ""); gads.setAttribute("defer", ""); var node = document.getElementsByTagName('script')[0]; node.parentNode.insertBefore(gads, node); })(); var App = App || {}; App.Ads = App.Ads || {}; App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jama'; App.Ads.Mappings = App.Ads.Mappings || {}; App.Ads.slots = App.Ads.slots || []; App.Ads.fromGoogle = !('yes' === 'yes'); App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length; googletag.cmd.push(function () { googletag.pubads() .setTargeting('environment', ['newjama']) .setTargeting('site', ['ama.jama']) .setTargeting('sect', ['scholarly']) .setTargeting('sub', ['no']) .setTargeting('device', ['Mozilla%2F4.0%20%28compatible%3B%20MSIE%207.0%3B%20Windows%20NT%206.0%3B%20SLCC1%3B%20.NET%20CLR%202.0.50727%3B%20.NET%20CLR%203.0.04506%3B%20.NET%20CLR%203.5.21022%3B%20.NET%20CLR%201.0.3705%3B%20.NET%20CLR%201.1.4322%29']) .setTargeting('usaphys', ['no']) .setTargeting('memberstat', ['no']) .setTargeting('pracset', ['']) .setTargeting('specialty', ['other']) .setTargeting('occupation', ['']) .setTargeting('useraffinity', ['']) .setTargeting('direct', ['yes']) .setTargeting('bot', ['']) .setTargeting('datacenter', ['no']) .setTargeting('selfMPA', ['']) .setTargeting('selfSpecialty', ['']); if (App.isCollection) { googletag.pubads().setTargeting('collection', ['']); } var testParam = getQueryVariable('test'); if (testParam) { googletag.pubads().setTargeting('test', [testParam]); } function getQueryVariable(variable) { var query = window.location.search.substring(1); var vars = query.split('&'); for (var i = 0; i < vars.length; i++) { var pair = vars[i].split('='); if (decodeURIComponent(pair[0]) == variable) { return decodeURIComponent(pair[1]); } } } googletag.pubads().disableInitialLoad(); googletag.enableServices(); }); } </script> <meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico"> <link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon-192x192.png" sizes="192x192"> <link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/apple-touch-icon-180x180.png"> <meta http-equiv="X-UA-Compatible" content="IE=Edge" /> <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638677764476993385"> <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" /> <meta property="og:title" content="Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic" /> <meta property="og:type" content="Article" /> <meta property="og:url" content="https://jamanetwork.com/journals/jama/fullarticle/195626" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=2147483647&Signature=KoRSY0EWUIu5HtO-w1ovDZLX24CLar6rYu05Q021zvAc4zD4tjMRtIZJcrF0j9KxvjfNWBaynkpyAh76IAREzXoT-GrLVgaiQqucHVqs9Q66ZJacqxbo8i3qzYWsd4ZoaT8crfWUCygC-7Nr4wDxkYpXb3DmwJzXr0kjdElT9uINaWVNWJpHKcDVeXzDp0mvH2RRZjvSkjqEsRAMsa6Krr5--I0d8QNaQySGL~7rxlnQ0PIQU7w2BMjhIDZTC9T~O7YxW6Qo9az~XPG7dZ41wO7PKk-PV55bhASivOEdGBYtmDSSVl~NVGPQPOLOdsIM6LjQr-Rx9ODMjX9HltjfTQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f1.gif?Expires=2147483647&Signature=guzzIKwBzvsfnWOJBHxp-xo8pwY2SQC8so14hS8bpOfXNzCbPEvmTvr7wR4CUJuJpardk9Fz5lQ85APrSiHYlmWgNdqLjnPOCl1lvgKjlXN6rBsAsZIYWMKoLN-jjBoq--nbz7ZjjJwYsWj0QWfKEvXxrU-K9OvhpjZTfuRf4Z5R9Zv8lCeY~0ezXCCrgX7M81Wovd2je~IjqnFxumc6nv9iQHmLcIi07CG~VGCS2RNRdYSRr-QRaAFBPUnKtikSoXN1e~H-EcTNfecjcTBEMuV8Dh8TMn3Bz5E8VdWR0j8OS3HKemcU2YrLZh7k89U1Upn4voLUazEpXGgus-8ipg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t2.png?Expires=2147483647&Signature=aU6G3f0BDp11LdIdI8BrqCRm9l~16KxzPkeOpj-b5ekxkBW2r-U24kJpd~HoKkVTM6sT6QiKNB4UXqArFEeHKDEOHO5gjh-bWhr9mqSraBS5zd~WgWRoACAonyqrdj-EYsf3qjFS5~s~XY~diwomsh0IE-zJU8gibosV7Lb9iTlepIjh4tc5CZjyXC986V25UKXdeekOI3aLdK5WwgQUI-kUsGbaXgapJ6IWmNfnesZpqpBEwkiUNXBnGVffpO6-LTHF~gubqzWgO~e~BdaFqsJ-ruxwdH8DVojjaM7ks3tgZct6ZMc0Lrp3hyZw4a1I4DtawKAEtwXtJh~tR1MaZw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t3.png?Expires=2147483647&Signature=qtw8qEuBqjeLZOTMKgegmq73qEJR-DPhxXTWyxmQrNTpDYr74D-e~Hl7O1jg-EkGtKKiPthk8DLp-W~QdLqK-ZOauzY5~trL216KGZoajo4x8MDL7bzGiD7pYYPGxa9~sVc3OOwWYjTxf8wCf~TFX7dFyNVQA4zA1gLGTbZbA2R63sPmGrveDh6Ey~W-LkYoRK4OSuKpB9k-Ym3vpAmFf3sa5E4e~U-zgiwQCyUYKlu~ebOAtghP7X-Xt-oazZ4eJ8hMgLnLh53hUchH4ZTtctiC~Q5D4cHq9WXkIlMQqMJmE7vDAHnZ06XSoxpnjIeEy1~YzmFFOMlpvxcaf4N~~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4a.png?Expires=2147483647&Signature=aNBIHBo~Xp1CiaQ4JK65efMo2CxyxiyAiN6tqhY6WjA2v2cBMOwPzO9Swoyv6ye-U5u6rQWMe7f4VXVJMI82b4ZTkxegRU8rn2ojCQtS8GfOt~Ry6ttkcohi0MMQgGqzaccKuFHI3NLYIvZJp7uS~cvRLllKWsM1JjAaxzLeBcZqqTdWJUc3f69ISzqpJamazDquo0AMXwMAsOk3bvQDIo8fXuCf0r4m2gZQBmpi7HbHMn~pvEDiWzt0knoqiJI1k~iorl3GfEtd73rSkLIR1i15F5Es47MEE7E49sNyf7cHKYciL61cPtPNRABxfjWKz91H8~1~ozrBdMqvLpzP4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4b.png?Expires=2147483647&Signature=TPY2ZcUNB4uBv40eHbDCPLek6fv-LJNHsa8PhFN9CynyxNhwriIGgHaCyvYZW7rmFedxCf1WlD0kNNb8FuybxstKwslR6Y2-ob6e097hNfi5fxJmXtQX8aIHxzxYmcjKIOhEOz1jkpmBSNvf-tyexx8yYV2EApI1crm95i1wDuPJamKU~2eZ9Ch5zyF2uaQa-YKoZ8F-vGIWG0-rhKOS-MOwisgmB9~IYFYX~KMdIly3Xad5Waa7WDuFe227zr3NKvRhu8qafsE4gGeIvu~xpU~A2cT0zjslW63Ax8GVHD5GgXIUwS0NNDPQifBtAfUiht1uEwnelvcDwDzSwGxweg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f2.gif?Expires=2147483647&Signature=EKwaRIoW4-52K6uuDktlZKmUCBVrxmzSl1m8QBt7W-1TMl21O6h1NALIrWNQNCbxHys9TiSDZD9NyUXR7Vrd6M5e1A5M8Gmbm65syx4tw3b64xjLfAJAw4sUsXjZq9sf-8AqsJoJmpwlyRrYUw2g4-EMw4qXAZpun-J02aRUAuCrCamqa0VvQXyKms5JC-EAy87pWA4Z-Y1uhelqVuEhrhMohDJe3UO10~R~LvPv1i0eVG1hmWPgSE~c8BBpPtG1bkEXAwQE-XR~ADAqbzM6MPGDU-ER9MGyObkp7AJ0~q1rsOsVh2Xx58gUu~iMpaajoL9mo58oxdERLLmhPBWI8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t5.png?Expires=2147483647&Signature=GDvXBn3xKhAA17wXHz3T5gnVx1wDKF-lr1zf~7bfLZyRxxRWjs1NphkiIuYtW0grflEwSnTVz63VIT3wKHl1H4dX1aIAa8gmqWFopTGZwqHqJ6bRBtTEq4-wPIZUqrs3vxuu~~lZoA8xx-QrhOJZ56~qvrPBxahtszW3ojedLK12lrAohwXelYqBfuD-5~47gUyS19ATzzKEgQknnoyQtR1G01tsvruCZx2B-fyhC3FIjAWED9TSF9iZ7~ou5QooCEfp~fhKep4pUKqn-zmQf4asIuJVBx9TDOk36OXaT6wlNAxzI5t6JYp4MjC~EQ8xexOcwNb-c~-yhnhNbO4lyQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f3.gif?Expires=2147483647&Signature=Lp59Xci9zWw4GUfcds1ja1zBebZGdjY4-8BZR0dC47s1RgSSaW~0iUxqeVER1ADBrtpazK6i17lOFnokM2nXgdZBgUFz9Bm8m~VoJ78TcNYVvEaGTz0B5eSR1NmXx79wi2aJOeJMFt5cHZRgR42vR8eOXHFc2nEBoPkJdLZpH0WuuFnQL0Qei4RQV5AdGFwoLQZMK9aGmFtZoDUc4rLCx0YnBEO~4pPJJ8nGPjxcAPOhTSTCynbTX59jciVlcg7MLGRX7kCd~72A7Jfgs2FlNgrqtnDq9c0~4hwgaOJXvBTYW8kS3nT5UHpFMxTXHb0UX8fqPlsItkOw4nBL2Zk9dQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f4.gif?Expires=2147483647&Signature=y4791ZtB479rXQZ4U0mRepGCrlfV~bgXsdEwpbx~2QU9vMBHYQedQB6TkrKX0l5DJtBmfPKHws10Wn994YM0JK66dZAc59-yUYlGtLHC0iPSZHxb-5Tg1m4CaMzP9zNY0bUn3P9X-8KhPTniOv5LIUzbS4~dUwgGphzs0aGpkZETQ56YbKyklZPM8H5ut5BydYVXA2mTThaPug-n6fB1iWRJT2M8vA3g2N0GeFI4-yYPuY-BMfi3TJUGrETzP1Gn~E6MY1mY9POJoaJ365j-absBgXBtASPT7ULab2HumL2g6dESoP6izHeUo3GBLg8Kdk~yGL6n5oeuhdN70j1wPg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f5.gif?Expires=2147483647&Signature=moLOtiVBlrZrBCJ9S0jWDv0wE5jHGz98728No26FVkgS7evNQFk7PST79gwPx4VRkttS2zFDa7lPQlFJJdFzUmWIRo~renhUaKjedo8ty5~joN~FW0bQ3PbwQKLOB~qdqH1W71~vOXGXQ46lcBxHzHEuDhZokDlK4vsnkASI6K70QKGK0Ootb8lqGiKMmxIzU4RUlb9Tm7bmqHEY-o8bcH2kNTRTxqLm89DbOJTEheqnNZUF3-~PkbTZ0aepJoG53CH8u2dkhdFXaKf7pCsxTQBEQ6opN7wh-KdMsysVOvj0nG0sb9uFxRNi1j~MauR~h-Vy6R5SK5cF7BJNGgAuug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t6.png?Expires=2147483647&Signature=yojT5ZW1s8lpAu0iSZ-xCpK5oAqsr-ZSU4hkBJBpWtzMylwP3RQ8lC0lbdpcst1KMJ6H-bqHPAuc2jt~lsI9YSPENOwuN3xoTRQNhqZxYp-rYivnA7oz9WHE0U2N7nlz-zHtcsgqIce~P2Wb~Pf5C~wFddAZlpCvb12GYPLZl8BCaaGim~gopvgEou8lh~cLIO0Vv1xVC0SPTC4YdlZYHFJWuTtkBGs6IsBeV1P4ZQdiQNhWUvdvibqHTS2CDZtp~ncfxOY2f1VxWNIeY4h9QkQSeqrC~o6Dp2wzV8KQxgs5Ar8Rsr4k55N7H-8tJoKxKuZUBI9w7LZVn3bCzcLOOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f6.gif?Expires=2147483647&Signature=VoNdNtOJ110qr13p86gVxETUfPIi1Nd~nNbLiZ46JismDdHs4jRuCW-~JbCnvsYrmCnGH-8zCkz4KlGuDbFkHpJCD3md0cxvp-Flx7Lq6bKgtLcZ4qnfi1NjzvikdmmmfksIXO0oPq125ktuiIVnCUFEGu701dX0-j1rT4qV97L18GCbmkRfif9UPy-95e3qhPa4ICaKTmqRtucDNw0c7YxLZq68~XTyj7K3SWN1Umt5EizppW4hFGLOLwm8clHd0qiS9nHwH4K9oTN8tt4Tdbt-8J19azErJt50DBuB-USFOv9D7GpJP9ny4SDF46aQH2Wgn1ze3Du77UIKYNAYgg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:description" content="Context Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.Objective To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of..." /> <meta property="fb:pages" content="87087958340" /> <meta property="fb:pages" content="122228711814384" /> <meta property="fb:pages" content="1648414928738217" /> <meta property="fb:pages" content="117506346528" /> <meta property="fb:pages" content="97538728726" /> <meta property="fb:pages" content="114116793520" /> <meta property="fb:pages" content="100679858757" /> <meta property="fb:pages" content="759822190741773" /> <meta property="fb:pages" content="100265333750" /> <meta property="fb:pages" content="234770525256" /> <meta property="fb:pages" content="98784919862" /> <meta property="fb:pages" content="120829458202" /> <meta property="fb:pages" content="124842870398" /> <meta property="fb:pages" content="110245330325636" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@JAMA_current" /> <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=2147483647&Signature=KoRSY0EWUIu5HtO-w1ovDZLX24CLar6rYu05Q021zvAc4zD4tjMRtIZJcrF0j9KxvjfNWBaynkpyAh76IAREzXoT-GrLVgaiQqucHVqs9Q66ZJacqxbo8i3qzYWsd4ZoaT8crfWUCygC-7Nr4wDxkYpXb3DmwJzXr0kjdElT9uINaWVNWJpHKcDVeXzDp0mvH2RRZjvSkjqEsRAMsa6Krr5--I0d8QNaQySGL~7rxlnQ0PIQU7w2BMjhIDZTC9T~O7YxW6Qo9az~XPG7dZ41wO7PKk-PV55bhASivOEdGBYtmDSSVl~NVGPQPOLOdsIM6LjQr-Rx9ODMjX9HltjfTQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "Article", "headline": "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or", "author": "The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group", "url": "https://jamanetwork.com/journals/jama/fullarticle/195626", "datePublished": "2002-12-18", "description": "Context Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown. Objective To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic. Design The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002. Setting and Participants A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers. Interventions Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years. Main Outcome Measures The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease). Results Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P = .03) and lisinopril (2 mm Hg, P <.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P <.001). For amlodipine vs...", "publisher": { "@type": "Organization", "name": "JAMA Network", "logo": { "@type": "ImageObject", "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico" } }, "image": [ "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=2147483647&Signature=KoRSY0EWUIu5HtO-w1ovDZLX24CLar6rYu05Q021zvAc4zD4tjMRtIZJcrF0j9KxvjfNWBaynkpyAh76IAREzXoT-GrLVgaiQqucHVqs9Q66ZJacqxbo8i3qzYWsd4ZoaT8crfWUCygC-7Nr4wDxkYpXb3DmwJzXr0kjdElT9uINaWVNWJpHKcDVeXzDp0mvH2RRZjvSkjqEsRAMsa6Krr5--I0d8QNaQySGL~7rxlnQ0PIQU7w2BMjhIDZTC9T~O7YxW6Qo9az~XPG7dZ41wO7PKk-PV55bhASivOEdGBYtmDSSVl~NVGPQPOLOdsIM6LjQr-Rx9ODMjX9HltjfTQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f1.gif?Expires=2147483647&Signature=guzzIKwBzvsfnWOJBHxp-xo8pwY2SQC8so14hS8bpOfXNzCbPEvmTvr7wR4CUJuJpardk9Fz5lQ85APrSiHYlmWgNdqLjnPOCl1lvgKjlXN6rBsAsZIYWMKoLN-jjBoq--nbz7ZjjJwYsWj0QWfKEvXxrU-K9OvhpjZTfuRf4Z5R9Zv8lCeY~0ezXCCrgX7M81Wovd2je~IjqnFxumc6nv9iQHmLcIi07CG~VGCS2RNRdYSRr-QRaAFBPUnKtikSoXN1e~H-EcTNfecjcTBEMuV8Dh8TMn3Bz5E8VdWR0j8OS3HKemcU2YrLZh7k89U1Upn4voLUazEpXGgus-8ipg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t2.png?Expires=2147483647&Signature=aU6G3f0BDp11LdIdI8BrqCRm9l~16KxzPkeOpj-b5ekxkBW2r-U24kJpd~HoKkVTM6sT6QiKNB4UXqArFEeHKDEOHO5gjh-bWhr9mqSraBS5zd~WgWRoACAonyqrdj-EYsf3qjFS5~s~XY~diwomsh0IE-zJU8gibosV7Lb9iTlepIjh4tc5CZjyXC986V25UKXdeekOI3aLdK5WwgQUI-kUsGbaXgapJ6IWmNfnesZpqpBEwkiUNXBnGVffpO6-LTHF~gubqzWgO~e~BdaFqsJ-ruxwdH8DVojjaM7ks3tgZct6ZMc0Lrp3hyZw4a1I4DtawKAEtwXtJh~tR1MaZw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t3.png?Expires=2147483647&Signature=qtw8qEuBqjeLZOTMKgegmq73qEJR-DPhxXTWyxmQrNTpDYr74D-e~Hl7O1jg-EkGtKKiPthk8DLp-W~QdLqK-ZOauzY5~trL216KGZoajo4x8MDL7bzGiD7pYYPGxa9~sVc3OOwWYjTxf8wCf~TFX7dFyNVQA4zA1gLGTbZbA2R63sPmGrveDh6Ey~W-LkYoRK4OSuKpB9k-Ym3vpAmFf3sa5E4e~U-zgiwQCyUYKlu~ebOAtghP7X-Xt-oazZ4eJ8hMgLnLh53hUchH4ZTtctiC~Q5D4cHq9WXkIlMQqMJmE7vDAHnZ06XSoxpnjIeEy1~YzmFFOMlpvxcaf4N~~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4a.png?Expires=2147483647&Signature=aNBIHBo~Xp1CiaQ4JK65efMo2CxyxiyAiN6tqhY6WjA2v2cBMOwPzO9Swoyv6ye-U5u6rQWMe7f4VXVJMI82b4ZTkxegRU8rn2ojCQtS8GfOt~Ry6ttkcohi0MMQgGqzaccKuFHI3NLYIvZJp7uS~cvRLllKWsM1JjAaxzLeBcZqqTdWJUc3f69ISzqpJamazDquo0AMXwMAsOk3bvQDIo8fXuCf0r4m2gZQBmpi7HbHMn~pvEDiWzt0knoqiJI1k~iorl3GfEtd73rSkLIR1i15F5Es47MEE7E49sNyf7cHKYciL61cPtPNRABxfjWKz91H8~1~ozrBdMqvLpzP4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4b.png?Expires=2147483647&Signature=TPY2ZcUNB4uBv40eHbDCPLek6fv-LJNHsa8PhFN9CynyxNhwriIGgHaCyvYZW7rmFedxCf1WlD0kNNb8FuybxstKwslR6Y2-ob6e097hNfi5fxJmXtQX8aIHxzxYmcjKIOhEOz1jkpmBSNvf-tyexx8yYV2EApI1crm95i1wDuPJamKU~2eZ9Ch5zyF2uaQa-YKoZ8F-vGIWG0-rhKOS-MOwisgmB9~IYFYX~KMdIly3Xad5Waa7WDuFe227zr3NKvRhu8qafsE4gGeIvu~xpU~A2cT0zjslW63Ax8GVHD5GgXIUwS0NNDPQifBtAfUiht1uEwnelvcDwDzSwGxweg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f2.gif?Expires=2147483647&Signature=EKwaRIoW4-52K6uuDktlZKmUCBVrxmzSl1m8QBt7W-1TMl21O6h1NALIrWNQNCbxHys9TiSDZD9NyUXR7Vrd6M5e1A5M8Gmbm65syx4tw3b64xjLfAJAw4sUsXjZq9sf-8AqsJoJmpwlyRrYUw2g4-EMw4qXAZpun-J02aRUAuCrCamqa0VvQXyKms5JC-EAy87pWA4Z-Y1uhelqVuEhrhMohDJe3UO10~R~LvPv1i0eVG1hmWPgSE~c8BBpPtG1bkEXAwQE-XR~ADAqbzM6MPGDU-ER9MGyObkp7AJ0~q1rsOsVh2Xx58gUu~iMpaajoL9mo58oxdERLLmhPBWI8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t5.png?Expires=2147483647&Signature=GDvXBn3xKhAA17wXHz3T5gnVx1wDKF-lr1zf~7bfLZyRxxRWjs1NphkiIuYtW0grflEwSnTVz63VIT3wKHl1H4dX1aIAa8gmqWFopTGZwqHqJ6bRBtTEq4-wPIZUqrs3vxuu~~lZoA8xx-QrhOJZ56~qvrPBxahtszW3ojedLK12lrAohwXelYqBfuD-5~47gUyS19ATzzKEgQknnoyQtR1G01tsvruCZx2B-fyhC3FIjAWED9TSF9iZ7~ou5QooCEfp~fhKep4pUKqn-zmQf4asIuJVBx9TDOk36OXaT6wlNAxzI5t6JYp4MjC~EQ8xexOcwNb-c~-yhnhNbO4lyQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f3.gif?Expires=2147483647&Signature=Lp59Xci9zWw4GUfcds1ja1zBebZGdjY4-8BZR0dC47s1RgSSaW~0iUxqeVER1ADBrtpazK6i17lOFnokM2nXgdZBgUFz9Bm8m~VoJ78TcNYVvEaGTz0B5eSR1NmXx79wi2aJOeJMFt5cHZRgR42vR8eOXHFc2nEBoPkJdLZpH0WuuFnQL0Qei4RQV5AdGFwoLQZMK9aGmFtZoDUc4rLCx0YnBEO~4pPJJ8nGPjxcAPOhTSTCynbTX59jciVlcg7MLGRX7kCd~72A7Jfgs2FlNgrqtnDq9c0~4hwgaOJXvBTYW8kS3nT5UHpFMxTXHb0UX8fqPlsItkOw4nBL2Zk9dQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f4.gif?Expires=2147483647&Signature=y4791ZtB479rXQZ4U0mRepGCrlfV~bgXsdEwpbx~2QU9vMBHYQedQB6TkrKX0l5DJtBmfPKHws10Wn994YM0JK66dZAc59-yUYlGtLHC0iPSZHxb-5Tg1m4CaMzP9zNY0bUn3P9X-8KhPTniOv5LIUzbS4~dUwgGphzs0aGpkZETQ56YbKyklZPM8H5ut5BydYVXA2mTThaPug-n6fB1iWRJT2M8vA3g2N0GeFI4-yYPuY-BMfi3TJUGrETzP1Gn~E6MY1mY9POJoaJ365j-absBgXBtASPT7ULab2HumL2g6dESoP6izHeUo3GBLg8Kdk~yGL6n5oeuhdN70j1wPg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f5.gif?Expires=2147483647&Signature=moLOtiVBlrZrBCJ9S0jWDv0wE5jHGz98728No26FVkgS7evNQFk7PST79gwPx4VRkttS2zFDa7lPQlFJJdFzUmWIRo~renhUaKjedo8ty5~joN~FW0bQ3PbwQKLOB~qdqH1W71~vOXGXQ46lcBxHzHEuDhZokDlK4vsnkASI6K70QKGK0Ootb8lqGiKMmxIzU4RUlb9Tm7bmqHEY-o8bcH2kNTRTxqLm89DbOJTEheqnNZUF3-~PkbTZ0aepJoG53CH8u2dkhdFXaKf7pCsxTQBEQ6opN7wh-KdMsysVOvj0nG0sb9uFxRNi1j~MauR~h-Vy6R5SK5cF7BJNGgAuug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t6.png?Expires=2147483647&Signature=yojT5ZW1s8lpAu0iSZ-xCpK5oAqsr-ZSU4hkBJBpWtzMylwP3RQ8lC0lbdpcst1KMJ6H-bqHPAuc2jt~lsI9YSPENOwuN3xoTRQNhqZxYp-rYivnA7oz9WHE0U2N7nlz-zHtcsgqIce~P2Wb~Pf5C~wFddAZlpCvb12GYPLZl8BCaaGim~gopvgEou8lh~cLIO0Vv1xVC0SPTC4YdlZYHFJWuTtkBGs6IsBeV1P4ZQdiQNhWUvdvibqHTS2CDZtp~ncfxOY2f1VxWNIeY4h9QkQSeqrC~o6Dp2wzV8KQxgs5Ar8Rsr4k55N7H-8tJoKxKuZUBI9w7LZVn3bCzcLOOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f6.gif?Expires=2147483647&Signature=VoNdNtOJ110qr13p86gVxETUfPIi1Nd~nNbLiZ46JismDdHs4jRuCW-~JbCnvsYrmCnGH-8zCkz4KlGuDbFkHpJCD3md0cxvp-Flx7Lq6bKgtLcZ4qnfi1NjzvikdmmmfksIXO0oPq125ktuiIVnCUFEGu701dX0-j1rT4qV97L18GCbmkRfif9UPy-95e3qhPa4ICaKTmqRtucDNw0c7YxLZq68~XTyj7K3SWN1Umt5EizppW4hFGLOLwm8clHd0qiS9nHwH4K9oTN8tt4Tdbt-8J19azErJt50DBuB-USFOv9D7GpJP9ny4SDF46aQH2Wgn1ze3Du77UIKYNAYgg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" ], "articleSection": [ "Abstract", "Methods", "Study Design", "Treatment", "Outcomes", "Statistical Methods", "Results", "Patient Characteristics", "Table 1. Baseline Characteristics of the ALLHAT Participants*", "Visit and Medication Adherence", "Table 2. Visits Expected and Completed and Antihypertensive Medication Use at Annual Visits", "Intermediate Outcomes", "Table 3. Number of Participants, Mean Blood Pressure, Achieved Blood Pressure Goal, and Blood Pressure Difference at Baseline and Annual Visits", "Table 4a. Biochemical Changes by Treatment Group*", "Table 4b", "Primary and Secondary Outcomes", "Table 5. Clinical Outcomes by Antihypertensive Treatment Group*", "Table 6. Causes of Death by Antihypertensive Treatment Group*", "Primary Safety Outcomes", "Comment", "References" ], "keyWords": "lisinopril, amlodipine, chlorthalidone, calcium channel blockers, myocardial infarction, cerebrovascular accident, heart failure, posttreatment followup, lipids, cardiovascular diseases, antihypertensive and lipid-lowering treatment to prevent heart attack trial, antihypertensive agents, hypertensive disease, diuretics, angina pectoris, coronary revascularisation, angiotensin-converting enzyme inhibitors, coronary heart disease, peripheral vascular diseases, thiazides" } </script> <meta name="citation_author" content="The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group" /><meta name="citation_title" content="Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)" /><meta name="citation_firstpage" content="2981" /><meta name="citation_lastpage" content="2997" /><meta name="citation_doi" content="10.1001/jama.288.23.2981" /><meta name="citation_keyword" content="myocardial infarction" /><meta name="citation_keyword" content="lisinopril" /><meta name="citation_keyword" content="amlodipine" /><meta name="citation_keyword" content="chlorthalidone" /><meta name="citation_keyword" content="calcium channel blockers" /><meta name="citation_keyword" content="cardiovascular diseases" /><meta name="citation_keyword" content="cerebrovascular accident" /><meta name="citation_keyword" content="heart failure" /><meta name="citation_keyword" content="follow-up" /><meta name="citation_keyword" content="lipids" /><meta name="citation_keyword" content="allhat trial" /><meta name="citation_keyword" content="antihypertensive agents" /><meta name="citation_keyword" content="hypertension" /><meta name="citation_keyword" content="diuretics" /><meta name="citation_keyword" content="angina pectoris" /><meta name="citation_keyword" content="coronary revascularization" /><meta name="citation_keyword" content="angiotensin-converting enzyme inhibitors" /><meta name="citation_keyword" content="coronary heart disease" /><meta name="citation_keyword" content="peripheral vascular diseases" /><meta name="citation_keyword" content="thiazide" /><meta name="citation_abstract" content="ContextAntihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.ObjectiveTo determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.DesignThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.Setting and ParticipantsA total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.InterventionsParticipants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years.Main Outcome MeasuresThe primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).ResultsMean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P = .03) and lisinopril (2 mm Hg, P&lt;.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P&lt;.001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25-1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31).ConclusionThiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy." /><meta name="citation_journal_title" content="JAMA" /><meta name="citation_journal_abbrev" content="JAMA" /><meta name="citation_volume" content="288" /><meta name="citation_issue" content="23" /><meta name="citation_publication_date" content="2002/12/18" /><meta name="citation_issn" content="0098-7484" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="citation_org=American Heart Association; citation_title=2002 Heart and Stroke Statistical Update.; citation_text=Dallas, Tex: American Heart Association; 2001.; " /><meta name="citation_reference" content="citation_title=Controlled clinical trials of drug treatment for hypertension: a review.; citation_authors=Cutler JA; MacMahon SW; Furberg CD; citation_journal_title=Hypertension.; citation_year=1989; citation_volume=13; citation_pages=I36-I44.; " /><meta name="citation_reference" content="citation_title=Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis.; citation_authors=Psaty BM; Smith NL; Siscovick DS; citation_journal_title=JAMA.; citation_year=1997; citation_volume=277; citation_pages=739-745.; " /><meta name="citation_reference" content="citation_org=Not Available; citation_title=The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.; citation_journal_title=Arch Intern Med.; citation_year=1997; citation_volume=157; citation_pages=2413-2446.; " /><meta name="citation_reference" content="citation_title=The 1996 report of a World Health Organization expert committee on hypertension control.; citation_authors=Chalmers J; Zanchetti A; citation_journal_title=J Hypertens.; citation_year=1996; citation_volume=14; citation_pages=929-933.; " /><meta name="citation_reference" content="citation_title=Blood pressure and coronary heart disease.; citation_authors=Collins R; Peto R; Godwin J; MacMahon S; citation_journal_title=Lancet.; citation_year=1990; citation_volume=336; citation_pages=370-371.; " /><meta name="citation_reference" content="citation_org=World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration; citation_title=Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments.; citation_journal_title=J Hypertens.; citation_year=1998; citation_volume=16; citation_pages=127-137.; " /><meta name="citation_reference" content="citation_org=SHEP Cooperative Research Group; citation_title=Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).; citation_journal_title=JAMA.; citation_year=1991; citation_volume=265; citation_pages=3255-3264.; " /><meta name="citation_reference" content="citation_title=Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.; citation_authors=Staessen JA; Fagard R; Thijs L; citation_journal_title=Lancet.; citation_year=1997; citation_volume=350; citation_pages=757-764.; " /><meta name="citation_reference" content="citation_title=Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators.; citation_authors=Yusuf S; Sleight P; Pogue J; citation_journal_title=N Engl J Med.; citation_year=2000; citation_volume=342; citation_pages=145-153.; " /><meta name="citation_reference" content="citation_org=PROGRESS Collaborative Group; citation_title=Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.; citation_journal_title=Lancet.; citation_year=2001; citation_volume=358; citation_pages=1033-1041.; " /><meta name="citation_reference" content="citation_title=Antihypertensive therapy: taking lipids into consideration.; citation_author=Grimm Jr RH; citation_journal_title=Am Heart J.; citation_year=1991; citation_volume=122; citation_pages=910-918.; " /><meta name="citation_reference" content="citation_title=Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trialists' Collaboration.; citation_authors=Neal B; MacMahon S; Chapman N; citation_journal_title=Lancet.; citation_year=2000; citation_volume=356; citation_pages=1955-1964.; " /><meta name="citation_reference" content="citation_title=Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.; citation_authors=Pahor M; Psaty BM; Alderman MH; citation_journal_title=Lancet.; citation_year=2000; citation_volume=356; citation_pages=1949-1954.; " /><meta name="citation_reference" content="citation_title=Treatment of hypertension: a clinical epidemiologist's view.; citation_author=Poulter NR; citation_journal_title=J Cardiovasc Pharmacol.; citation_year=1991; citation_volume=18(suppl 2); citation_pages=S35-S38.; " /><meta name="citation_reference" content="citation_title=Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group.; citation_authors=Neaton JD; Grimm Jr RH; Prineas RJ; citation_journal_title=JAMA.; citation_year=1993; citation_volume=270; citation_pages=713-724.; " /><meta name="citation_reference" content="citation_title=Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.; citation_authors=Materson BJ; Reda DJ; Cushman WC; citation_journal_title=N Engl J Med.; citation_year=1993; citation_volume=328; citation_pages=914-921.; " /><meta name="citation_reference" content="citation_title=Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).; citation_authors=Davis BR; Cutler JA; Gordon DJ; citation_journal_title=Am J Hypertens.; citation_year=1996; citation_volume=9; citation_pages=342-360.; " /><meta name="citation_reference" content="citation_org=The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; citation_title=Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).; citation_journal_title=JAMA.; citation_year=2000; citation_volume=283; citation_pages=1967-1975.; " /><meta name="citation_reference" content="citation_title=Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.; citation_authors=Davis BR; Cutler JA; Furberg CD; citation_journal_title=Ann Intern Med.; citation_year=2002; citation_volume=137; citation_pages=313-320.; " /><meta name="citation_reference" content="citation_org=The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; citation_title=Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.; citation_journal_title=JAMA.; citation_year=2002; citation_volume=288; citation_pages=2998-3007.; " /><meta name="citation_reference" content="citation_title=Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).; citation_authors=Grimm Jr RH; Margolis KL; Papademetriou V; citation_journal_title=Hypertension.; citation_year=2001; citation_volume=37; citation_pages=19-27.; " /><meta name="citation_reference" content="citation_org=Not Available; citation_title=The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).; citation_journal_title=Arch Intern Med.; citation_year=1993; citation_volume=153; citation_pages=154-183.; " /><meta name="citation_reference" content="citation_title=A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group.; citation_authors=Levey AS; Bosch JP; Lewis JB; citation_journal_title=Ann Intern Med.; citation_year=1999; citation_volume=130; citation_pages=461-470.; " /><meta name="citation_reference" content="citation_title=A simplified equation to predict glomerular filtration rate from serum creatinine.; citation_authors=Levey AS; Greene T; Kusek JW; citation_journal_title=J Am Soc Nephrol.; citation_year=2000; citation_volume=11; citation_pages=155A.; " /><meta name="citation_reference" content="citation_title=Validation of heart failure events in ALLHAT participants assigned to doxazosin.; citation_authors=Piller LB; Davis BR; Cutler JA; citation_journal_title=Curr Control Trials Cardiovasc Med.; citation_year=2002; citation_volume=3; citation_pages=10.; " /><meta name="citation_reference" content="citation_org=Public Health Service-Health Care Financing Administration; citation_title=International Classification of Diseases, Ninth Revision (ICD-9).; citation_text=6th ed. Bethesda, Md: US Dept of Health and Human Services; 2001. DHHS Publication No. (PHS) 80-1260.; " /><meta name="citation_reference" content="citation_title=A multiple comparisons procedure for comparing several treatments with a control.; citation_author=Dunnett CW; citation_journal_title=J Am Stat Assoc.; citation_year=1955; citation_volume=50; citation_pages=1096-1121.; " /><meta name="citation_reference" content="citation_title=Survival Analysis: Techniques for Censored and Truncated Regression.; citation_authors=Klein JP; Moeschberger ML; citation_text=New York, NY: Springer-Verlag; 1997.; " /><meta name="citation_reference" content="citation_title=Upper bounds for type I and II error rates in conditional power calculations.; citation_authors=Davis BR; Hardy RJ; citation_journal_title=Commun Stat.; citation_year=1990; citation_volume=19; citation_pages=3571-3584.; " /><meta name="citation_reference" content="citation_title=Discrete sequential boundaries for clinical trials.; citation_authors=Lan KKG; DeMets DL; citation_journal_title=Biometrika.; citation_year=1983; citation_volume=70; citation_pages=659-663.; " /><meta name="citation_reference" content="citation_title=Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study.; citation_authors=Hansson L; Lindholm LH; Ekbom T; citation_journal_title=Lancet.; citation_year=1999; citation_volume=354; citation_pages=1751-1756.; " /><meta name="citation_reference" content="citation_title=Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).; citation_authors=Brown MJ; Palmer CR; Castaigne A; citation_journal_title=Lancet.; citation_year=2000; citation_volume=356; citation_pages=366-372.; " /><meta name="citation_reference" content="citation_title=Differences between blood-pressure-lowering drugs.; citation_authors=MacMahon S; Neal B; citation_journal_title=Lancet.; citation_year=2000; citation_volume=356; citation_pages=352-353.; " /><meta name="citation_reference" content="citation_title=Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group.; citation_authors=Kostis JB; Davis BR; Cutler J; citation_journal_title=JAMA.; citation_year=1997; citation_volume=278; citation_pages=212-216.; " /><meta name="citation_reference" content="citation_org=Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension; citation_title=Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding.; citation_journal_title=J Hypertens.; citation_year=1997; citation_volume=15; citation_pages=105-115.; " /><meta name="citation_reference" content="citation_title=Nifedipine: dose-related increase in mortality in patients with coronary heart disease.; citation_authors=Furberg CD; Psaty BM; Meyer JV; citation_journal_title=Circulation.; citation_year=1995; citation_volume=92; citation_pages=1326-1331.; " /><meta name="citation_reference" content="citation_title=Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.; citation_authors=Agodoa LY; Appel L; Bakris GL; citation_journal_title=JAMA.; citation_year=2001; citation_volume=285; citation_pages=2719-2728.; " /><meta name="citation_reference" content="citation_title=Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.; citation_authors=Hall WD; Kusek JW; Kirk KA; citation_journal_title=Am J Kidney Dis.; citation_year=1997; citation_volume=29; citation_pages=720-728.; " /><meta name="citation_reference" content="citation_title=Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease.; citation_authors=ter Wee PM; De Micheli AG; Epstein M; citation_journal_title=Arch Intern Med.; citation_year=1994; citation_volume=154; citation_pages=1185-1202.; " /><meta name="citation_reference" content="citation_title=Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.; citation_authors=Lonn EM; Yusuf S; Jha P; citation_journal_title=Circulation.; citation_year=1994; citation_volume=90; citation_pages=2056-2069.; " /><meta name="citation_reference" content="citation_title=The renin-angiotensin-aldosterone system: a specific target for hypertension management.; citation_authors=Weir MR; Dzau VJ; citation_journal_title=Am J Hypertens.; citation_year=1999; citation_volume=12; citation_pages=205S-213S.; " /><meta name="citation_reference" content="citation_title=Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data.; citation_authors=Jafar TH; Schmid CH; Landa M; citation_journal_title=Ann Intern Med.; citation_year=2001; citation_volume=135; citation_pages=73-87.; " /><meta name="citation_reference" content="citation_org=Not Available; citation_title=Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators.; citation_journal_title=N Engl J Med.; citation_year=1992; citation_volume=327; citation_pages=685-691.; " /><meta name="citation_reference" content="citation_title=Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.; citation_authors=Collins R; Peto R; MacMahon S; citation_journal_title=Lancet.; citation_year=1990; citation_volume=335; citation_pages=827-838.; " /><meta name="citation_reference" content="citation_title=Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.; citation_authors=MacMahon S; Peto R; Cutler J; citation_journal_title=Lancet.; citation_year=1990; citation_volume=335; citation_pages=765-774.; " /><meta name="citation_reference" content="citation_title=Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial: Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.; citation_authors=Staessen JA; Byttebier G; Buntinx F; citation_journal_title=JAMA.; citation_year=1997; citation_volume=278; citation_pages=1065-1072.; " /><meta name="citation_reference" content="citation_title=Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist's point of view.; citation_author=Franklin SS; citation_journal_title=Pathol Biol (Paris).; citation_year=1999; citation_volume=47; citation_pages=594-603.; " /><meta name="citation_reference" content="citation_title=A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.; citation_authors=Saunders E; Weir MR; Kong BW; citation_journal_title=Arch Intern Med.; citation_year=1990; citation_volume=150; citation_pages=1707-1713.; " /><meta name="citation_reference" content="citation_title=Pathophysiology and treatment implications of hypertension in the African-American population.; citation_authors=Rahman M; Douglas JG; Wright JT; citation_journal_title=Endocrinol Metab Clin North Am.; citation_year=1997; citation_volume=26; citation_pages=125-144.; " /><meta name="citation_reference" content="citation_title=Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States.; citation_authors=Cushman WC; Reda DJ; Perry HM; citation_journal_title=Arch Intern Med.; citation_year=2000; citation_volume=160; citation_pages=825-831.; " /><meta name="citation_reference" content="citation_title=Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.; citation_authors=Exner DV; Dries DL; Domanski MJ; Cohn JN; citation_journal_title=N Engl J Med.; citation_year=2001; citation_volume=344; citation_pages=1351-1357.; " /><meta name="citation_reference" content="citation_title=Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group.; citation_authors=Carson P; Ziesche S; Johnson G; Cohn JN; citation_journal_title=J Card Fail.; citation_year=1999; citation_volume=5; citation_pages=178-187.; " /><meta name="citation_reference" content="citation_title=Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.; citation_authors=Dries DL; Strong MH; Cooper RS; Drazner MH; citation_journal_title=J Am Coll Cardiol.; citation_year=2002; citation_volume=40; citation_pages=311-317.; " /><meta name="citation_reference" content="citation_title=Trends in pharmacologic management of hypertension in the United States.; citation_authors=Manolio TA; Cutler JA; Furberg CD; citation_journal_title=Arch Intern Med.; citation_year=1995; citation_volume=155; citation_pages=829-837.; " /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jama/articlepdf/195626/joc21962.pdf" /> <title>Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Acute Coronary Syndromes | JAMA | JAMA Network</title> <meta name="description" content="ContextAntihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is"> <link rel="canonical" href="https://jamanetwork.com/journals/jama/fullarticle/195626" /> <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638677764511843155"></script> <script src="https://r451.jamanetwork.com/script.js" defer></script> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript"> <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{"parameters":{"siteName":"jama","siteId":3,"journalId":67,"adDisplay":0,"adSection":"scholarly","adPosition":"","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"> </div> </head> <body data-sitename="jama" class="pg_article " data-thm="jama"> <script> var App = App || {}; App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length; App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length; </script> <div id="ad-interstitial" class="ad-interstitial"> <script defer> googletag.cmd.push(function() { if (App.suppressAds) { return; } // Define a web interstitial ad slot. let interstitialSlot = googletag.defineOutOfPageSlot( App.Ads.adPath + '/scholarly', googletag.enums.OutOfPageFormat.INTERSTITIAL, ); if (interstitialSlot) { App.Ads.slots[13] = interstitialSlot; // Enable optional interstitial triggers and register the slot. interstitialSlot .setTargeting('pos', ['interstitial']) .addService(googletag.pubads()) .setConfig({ interstitial: { triggers: { navBar: true, unhideWindow: true, }, }, }); googletag.display(interstitialSlot); googletag.pubads().refresh([interstitialSlot], { changeCorrelator: false }); googletag.enableServices(); } }); </script> </div> <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a> <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script> <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA" data-type="string"></span> <form method="post" action="./195626" id="webform" class="m0"> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="3AKPBRjldC2v+gAmHo+p02OFSY9nH6IxLcGYWRwLJDdACnHUxXjPLBiC99aq5yEpw97UDtFFDPsyG2ZW5EbCNr6LKRI=" /> </div> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" /> </div> <input id="hdnSiteID" type="hidden" value="3" /> <input id="hdnDomain" type="hidden" value=".jamanetwork.com" /> <section class="master-header"> <script type='text/javascript'> var App = App || {}; App.LoginUserInfo = { isInstLoggedIn: [0], currentSessionId: 'ooymerycherxuss3hybo2rum' }; </script> <input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J67" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="false" /> <div class="header-wrap"> <header class="header"> <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner"> <div class="gdpr-cookie-wrapper js-gdpr-banner"> <div class="gdpr-cookie-body"> Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a> <span class="pipe">|</span> <a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a> </div> <input id="hdnDomain" type="hidden" value=".jamanetwork.com" /> <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" /> <input id="hdnClientIdGdpr" type="hidden" value="3" /> </div> </div> <div class="network-bar"> <a class="jama-network" href="/" title="JAMA Network Home"> <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg"> </a> </div> <a class="nav-toggler" href="#nav"> <div class="nav-toggler-indicator"> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> </div> <div class="nav-toggler-site"> <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span></span> </div> </a> <nav id="nav" class="nav hide" > <div class="nav-journal-level sb-nav-journal-level"> <a href="https://jamanetwork.com/journals/jama" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="https://jamanetwork.com/journals/jama/newonline" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="new-online">New Online</a><a href="https://jamanetwork.com/journals/jama/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="current-issue">Current Issue</a><a href="https://jamanetwork.com/journals/jama/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a> </div> <div class="nav-journals"> <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .nav-journals {margin-bottom: 1em;} .nav-heading {color: #B9B9B9;border-bottom: 0;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em .25em;text-transform: uppercase;} a.no-bullet:before {content:none !important;} .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;} /* .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;} .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;} .nav-journals a.theme-jama-network-open {border-bottom:0;} */ .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;} .fake-ribbon {border-left: 8px solid #BE1E32;} .fake-ribbon a:before {content:none;} .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;} .nav-journals a.theme-plus:before {background:#d71635;} .nav-journals a.theme-jama-network-open {border-bottom:0;} </style> <h2 class="nav-heading">JAMA+</h2> <a href="/channels/ai" class="theme-plus">AI</a> <h2 class="nav-heading">Journals</h2> <a href="/journals/jama" class="theme-jama">JAMA</a> <a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a> <a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a> <a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a> <a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a> <a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a> <a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a> <a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a> <a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a> <a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA Otolaryngology–Head & Neck Surgery</a> <a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a> <a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a> <a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a> <a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology & Psychiatry (1919-1959)</a> <h2 class="nav-heading">Podcasts</h2> <a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a> <a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a> <a href="/journals/jama/pages/jama-medical-news">Medical News</a> <a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a> <a href="/pages/audio" class="no-bullet">More</a> </div> </div> </div> <div class="nav-network-other"> <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com/index.aspx?productcode=64" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints & Permissions</a> </div> <div class="white text-xxs"> <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal"> <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a> <span class="pl1 pr1">| </span> <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a> <span class="pl1 pr1">| </span> <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a> </div> <div class="ta-c"> <span class="pb1">2024 American Medical Association. All Rights Reserved</span> </div> </div> </nav> <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a> <div id="site-search" role="search" class="site-search"> <div class="site-search-bar"> <div role="search"> <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel"> <option value="J*">Search All</option> <option value="3">JAMA</option> <option value="214">JAMA Network Open</option> <option value="192">JAMA Cardiology</option> <option value="12">JAMA Dermatology</option> <option value="261">JAMA Forum Archive</option> <option value="193">JAMA Health Forum</option> <option value="15">JAMA Internal Medicine</option> <option value="16">JAMA Neurology</option> <option value="159">JAMA Oncology</option> <option value="17">JAMA Ophthalmology</option> <option value="18">JAMA Otolaryngology–Head & Neck Surgery</option> <option value="19">JAMA Pediatrics</option> <option value="14">JAMA Psychiatry</option> <option value="20">JAMA Surgery</option> <option value="23">Archives of Neurology & Psychiatry</option> </select> </div> <div class="search-input-container"> <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term"> <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul> <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label> <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off"> </div>  <a name="button" role="button" class="search-button is-b js-search-button" alt="search button" href="/searchresults"></a> </div> </div> <div id="BodyContent_Header_GlobalSignIn_auth" class="auth"> <a class="auth--trigger is-b is-a" href="javascript:;"> <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span> </a> <div class="auth--dropdown js-signIn-dropdown"> <div class="auth--option auth--ind"> <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div> <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth"> <div class="auth--title">Individual Sign In</div> <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a> </div> </div> <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst"> <div class="auth--inst-auth"> <div class="auth--title">Access through your institution</div> <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a> </div> </div> <div id="BodyContent_Header_GlobalSignIn_divPurchaseOptions" class="auth--option auth--purchase"> <div class="auth--title">Purchase Options:</div> <a id="BodyContent_Header_GlobalSignIn_lnkSubscribeJournal" class="auth--subscribe" rel="nofollow" href="https://store.jamanetwork.com/index.aspx?productcode=64">Subscribe to the JAMA journal</a> </div> </div> </div> </header> </div> <div class="editors-choice-header"> </div> <div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark"> <div class="leader-ad desktop-only"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{"parameters":{"siteName":"jama","siteId":3,"journalId":67,"adDisplay":1,"adSection":"scholarly","adPosition":"atf","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> </div>  </section> <section class="master-main"> <div class="social-share hide" data-share-journal="JAMA_current" data-share-title="Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or..."></div> <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article"> <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"195626","type":"Article","date":"11/27/2024 9:38:50 PM"}'></div> </div> <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView"> <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView"> <script> (function () { var bodyElem = document.querySelector('body'); var className = 'split-screen'; if (bodyElem.classList) { bodyElem.classList.add(className); } else { el.className += ' ' + className; } })(); </script> <div id="resources-panel" class="resources-panel"> <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span> <div class="tab-nav"> <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab"> <i class="icon-full_text"><span class="sr-t">full text icon</span></i> <div class="tab-nav-tab-name">Full Text</div> </a> <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab"> <i class="icon-contents"><span class="sr-t">contents icon</span></i> <div class="tab-nav-tab-name">Contents</div> </a> <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab"> <i class="icon-figures"><span class="sr-t">figure icon</span></i> <div class="tab-nav-tab-name">Figures / <br> Tables</div> </a> <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab"> <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i> <div class="tab-nav-tab-name">Multimedia</div> </a> <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab"> <i class="icon-attach"><span class="sr-t">attach icon</span></i> <div class="tab-nav-tab-name">Supplemental <br> Content</div> </a> <a class="tab-nav-trigger tab-nav-references" href="#references-tab"> <i class="icon-references"><span class="sr-t">references icon</span></i> <div class="tab-nav-tab-name">References</div> </a> <a class="tab-nav-trigger tab-nav-related" href="#related-tab"> <i class="icon-related"><span class="sr-t">related icon</span></i> <div class="tab-nav-tab-name">Related</div> </a> <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab"> <i class="icon-user-comments"><span class="sr-t">comments icon</span></i> <div class="tab-nav-tab-name">Comments</div> </a> </div> <div class="resource-tabs"> <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active"> <div class="contents-tab-contents"> <a id="pdf-link" href="/journals/jama/articlepdf/195626/joc21962.pdf" class="toolbar-tool toolbar-pdf al-link pdfaccess js-pdfaccess" data-article-id="195626" data-article-url="/journals/jama/articlepdf/195626/joc21962.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span> </a> <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget"> <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a> <ul class="section-jump-links bullet ml2 pl1"> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25048567" data-tab-toggle=".tab-nav-full-text">Abstract</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25048571" data-tab-toggle=".tab-nav-full-text">Methods</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25048584" data-tab-toggle=".tab-nav-full-text">Results</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25048616" data-tab-toggle=".tab-nav-full-text">Comment</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25048634" data-tab-toggle=".tab-nav-full-text">References</a></li> </ul> </div> <div class="widget-SelfServeContent widget-instance-AMA_Contents_Tab_SelfServe"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="v2_article_content_tab" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="bc_rr_theme_promo"></div> <div class="bc_right_rail_article_promo"></div> </div> </div> </div> <div class="contents-tab-ad"> <div id="split-screen-contab"></div> </div> </div> <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad"> <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Figures_Tab"> <div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 1.</strong> Randomization and Follow-up of Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial<a id="Joc21962f1" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f1.gif?Expires=1735231448&Signature=g74M2cq-ROcBsEUVtPeKjoZ4WOdXEDfzdDvDgLQcB2o9r7AkqTEEOIHmhUxNFVe3T~cH6ILxImzaZjoTOREsrvqldycTmLSSq~yWm~g9Q5rZYhjoK5Uis7GdlVwXFv3qbmH~rD8btVcXEoo4dtVTQfHHfGREv3N~9fHqV5nuLx5DgOkJS1xLcTazNC03AiATZjYM8LafI4OTzJDu4-spWr8WaLWOyTX4j70y3lPhWd2Eu0Gyn~YzPrGPT-w1zkWgWcf3vwM1c8uJpXLjgS1Wqm5GwaUoAixjWII8rXM-GFEZMzxhQfdo8jKQWOl7mpC25E7jjF1Q~zvOAgyM3FayOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f1.gif?Expires=1735231448&Signature=g74M2cq-ROcBsEUVtPeKjoZ4WOdXEDfzdDvDgLQcB2o9r7AkqTEEOIHmhUxNFVe3T~cH6ILxImzaZjoTOREsrvqldycTmLSSq~yWm~g9Q5rZYhjoK5Uis7GdlVwXFv3qbmH~rD8btVcXEoo4dtVTQfHHfGREv3N~9fHqV5nuLx5DgOkJS1xLcTazNC03AiATZjYM8LafI4OTzJDu4-spWr8WaLWOyTX4j70y3lPhWd2Eu0Gyn~YzPrGPT-w1zkWgWcf3vwM1c8uJpXLjgS1Wqm5GwaUoAixjWII8rXM-GFEZMzxhQfdo8jKQWOl7mpC25E7jjF1Q~zvOAgyM3FayOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048590&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f1.gif?Expires=1735231448&Signature=g74M2cq-ROcBsEUVtPeKjoZ4WOdXEDfzdDvDgLQcB2o9r7AkqTEEOIHmhUxNFVe3T~cH6ILxImzaZjoTOREsrvqldycTmLSSq~yWm~g9Q5rZYhjoK5Uis7GdlVwXFv3qbmH~rD8btVcXEoo4dtVTQfHHfGREv3N~9fHqV5nuLx5DgOkJS1xLcTazNC03AiATZjYM8LafI4OTzJDu4-spWr8WaLWOyTX4j70y3lPhWd2Eu0Gyn~YzPrGPT-w1zkWgWcf3vwM1c8uJpXLjgS1Wqm5GwaUoAixjWII8rXM-GFEZMzxhQfdo8jKQWOl7mpC25E7jjF1Q~zvOAgyM3FayOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f1.gif?Expires=1735231448&Signature=QX8WrwyoT2zhY61xKwXKOU9G7nUO1uHp1VdpiGaQUxaaDjWV3Hky1CxTvekYRONuo-99dbI2iwvSezUQrfwgLCyLQKsQUcx-96yhtlJN1cCHB0MI~Un4n2VDdOloQCdkm9TDm0Ny-p0dKlWWkYPD8~lt9ftewT8PnJoVyxO1LSrcYblHmBY18oeyMGBrW8nEXE2ndoG172gOfTxNJHANRmBs9sPksP3y8c3J~AVBBg7dWdCRVEr5yDYEp0thi8A0IjXoZSBZ0YTXpoadnHTVC5MWgT3JiZPWS10Od9dPf6PbRLd-bVwrHMDikYL0PMstrYE-JogI2oafrDWqmivZdA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f1" /></a></div></div><div class="figure-caption clip-last-child">NA indicates not applicable. Eligibility data were not collected for nonrandomized screenees. All randomized participants were included in the analyses. A patient may have more than 1 reason for discontinuing study drug; therefore, numbers do not sum to total. On January 24, 2000, the National Heart, Lung, and Blood Institute decided to discontinue the doxazosin group and report results.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Study closeout for chlorthalidone, amlodipine, and lisinopril groups was from October 1, 2001, through March 31, 2002. Collection of last events for the doxazosin group had a closeout interval from October 15, 1999, through February 15, 2000, which captures more information than that reported previously.<sup><a href="#REF-JOC21962-24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 2.</strong> Mean Systolic and Diastolic Blood Pressure by Year During Follow-up<a id="Joc21962f2" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f2.gif?Expires=1735231448&Signature=KqvZAv0zixmkKNzikzLBi2u4JoXRnz7nVhkIw8pwLrCsku-kZV4fBQN0YEfgRS4MTEA0Tf9PGj7k5WGjUl~NbO458dJC6oBO29smpwc6v9DlR6ZNZVxvXukS0wHsUXNaYUnFQcCJLVckkdqIBa1kUuWzymLPdmjBPGLB2ERqGzL1zrEWG8P6mYPWYD5Q9WeJxS666tX6THuHlx5bCrSqRJ8Fpz44htoWf8XhKsQx3h5Lwyw7~NEYa0UgzJRcrVw2YZOe5PMsVnNbeaTO20vSwVx5dIziqfOREhbaDpJEU9jZIMja5IQ2QgtUOkx6nIlkrb50iXYKYDhCGySwFgEDVw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f2.gif?Expires=1735231448&Signature=KqvZAv0zixmkKNzikzLBi2u4JoXRnz7nVhkIw8pwLrCsku-kZV4fBQN0YEfgRS4MTEA0Tf9PGj7k5WGjUl~NbO458dJC6oBO29smpwc6v9DlR6ZNZVxvXukS0wHsUXNaYUnFQcCJLVckkdqIBa1kUuWzymLPdmjBPGLB2ERqGzL1zrEWG8P6mYPWYD5Q9WeJxS666tX6THuHlx5bCrSqRJ8Fpz44htoWf8XhKsQx3h5Lwyw7~NEYa0UgzJRcrVw2YZOe5PMsVnNbeaTO20vSwVx5dIziqfOREhbaDpJEU9jZIMja5IQ2QgtUOkx6nIlkrb50iXYKYDhCGySwFgEDVw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048601&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f2.gif?Expires=1735231448&Signature=KqvZAv0zixmkKNzikzLBi2u4JoXRnz7nVhkIw8pwLrCsku-kZV4fBQN0YEfgRS4MTEA0Tf9PGj7k5WGjUl~NbO458dJC6oBO29smpwc6v9DlR6ZNZVxvXukS0wHsUXNaYUnFQcCJLVckkdqIBa1kUuWzymLPdmjBPGLB2ERqGzL1zrEWG8P6mYPWYD5Q9WeJxS666tX6THuHlx5bCrSqRJ8Fpz44htoWf8XhKsQx3h5Lwyw7~NEYa0UgzJRcrVw2YZOe5PMsVnNbeaTO20vSwVx5dIziqfOREhbaDpJEU9jZIMja5IQ2QgtUOkx6nIlkrb50iXYKYDhCGySwFgEDVw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f2.gif?Expires=1735231448&Signature=O-gZ3PG8Etoi7wf9nKb9U6RBfG6suPQc2WZ0eQ1s05FCb0U8ohssDHU9eJLLwP7V4eqn9WySTlBJBkhkSHsB6mjgoLv9CnaRENRBPJp6J-bmGVrMktYQ7z~B-IRLK1k2ZMiWCAuWlrBMCfMMzAV82dr4gZOXarJqJJSczee1FWRDAW~KQ25bxFE2BxAqnie79IGq4IPksQGhwTn45l5zOOxb~jlqn6HnN07mWKrmYHBP4vsYSSpS7Rsg9KrdlOtCzNZIqF1yOiYeXy-Ko7QEJq-xuoWozbhc88FukHKS6G-5l4~~-NG1k7qiRN4VgLRrZv4Q~aQkqlXuPsR1nC1RTg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f2" /></a></div></div><div class="figure-caption clip-last-child">Number measured at baseline through 5 years is given in <a href="#JOC21962T3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>; numbers at 6 years for chlorthalidone, amlodipine, and lisinopril are 2721, 1656, and 1551, respectively.</div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 3.</strong> Cumulative Event Rates for the Primary Outcome (Fatal Coronary Heart Disease or Nonfatal Myocardial Infarction) by Treatment Group<a id="Joc21962f3" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f3.gif?Expires=1735231448&Signature=YViI99nxLRpUG52hXzM3ASmA1ZQ9qchMERzsA~zoIeA9YiMtIqAvaId2147mSscYkSobz8HgyFtVBRDPy4PP~ZNPNi9Ksofpw0z1cmxoG09EGun5z0FlZowSUI5lLCbTDyczFmmejGvrYjY2LNgxObTJZvi05YmMSKuY7TI2FFb8SIYQXBymrmr3lN5ddoSnidJ6s7EOMLOsteJUQsFgOpF~qHikUaBeONCqIWxst8v7s-V7N4nPs5Fy4Iw8JLbHg5Hinm~88p9AxbWJgYqONzS0evvd2119Ruo7Cf0l971GeuKaFQDFM-hVlMTE8gMtgzOp0kBi4o-SGWAK4F~Ybw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f3.gif?Expires=1735231448&Signature=YViI99nxLRpUG52hXzM3ASmA1ZQ9qchMERzsA~zoIeA9YiMtIqAvaId2147mSscYkSobz8HgyFtVBRDPy4PP~ZNPNi9Ksofpw0z1cmxoG09EGun5z0FlZowSUI5lLCbTDyczFmmejGvrYjY2LNgxObTJZvi05YmMSKuY7TI2FFb8SIYQXBymrmr3lN5ddoSnidJ6s7EOMLOsteJUQsFgOpF~qHikUaBeONCqIWxst8v7s-V7N4nPs5Fy4Iw8JLbHg5Hinm~88p9AxbWJgYqONzS0evvd2119Ruo7Cf0l971GeuKaFQDFM-hVlMTE8gMtgzOp0kBi4o-SGWAK4F~Ybw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048607&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f3.gif?Expires=1735231448&Signature=YViI99nxLRpUG52hXzM3ASmA1ZQ9qchMERzsA~zoIeA9YiMtIqAvaId2147mSscYkSobz8HgyFtVBRDPy4PP~ZNPNi9Ksofpw0z1cmxoG09EGun5z0FlZowSUI5lLCbTDyczFmmejGvrYjY2LNgxObTJZvi05YmMSKuY7TI2FFb8SIYQXBymrmr3lN5ddoSnidJ6s7EOMLOsteJUQsFgOpF~qHikUaBeONCqIWxst8v7s-V7N4nPs5Fy4Iw8JLbHg5Hinm~88p9AxbWJgYqONzS0evvd2119Ruo7Cf0l971GeuKaFQDFM-hVlMTE8gMtgzOp0kBi4o-SGWAK4F~Ybw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f3.gif?Expires=1735231448&Signature=AAmit~6CfS1lmT3FT~TtNuG9FL4ImnvoKS1zP12QF2kqOlWOHguoFYSwAxRvdWK7JpkcZ0zoBrKAKLglu4EOuRTfsaKxnwXKTv-LekEldX-JdbLYDXHOYwv-dLT-0FqRLQzt83Qn7DJDouUwRZokV2nrRVXdBUL1Ijmi9xuk22gWp511g2ZMnVSsfr7p9dL85knhM34X-f6K-jJPSeDqiQgy2T4c0QITzIY0BMsSF70hEPWWfcThNLbBTIogHk00mUB4gyI8aGaUTowAdylyxBsLERh1dHmVFA5qDshzjshvpO0AnwGkLZ69GyMcJVTHZNFvmWaQRNOfC-7cN6n61w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f3" /></a></div></div><div class="figure-caption clip-last-child">No significant difference was observed for amlodipine (relative risk [RR], 0.98; 95% confidence interval [CI], 0.90-1.07; <em>P</em> = .65) or lisinopril (RR, 0.99; 95% CI, 0.91-1.08; <em>P</em> = .81) vs chlorthalidone with a mean follow-up of 4.9 years.</div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 4.</strong> Cumulative Event Rates for All-Cause Mortality, Stroke, Combined Coronary Heart Disease, Combined Cardiovascular Disease, Heart Failure, and Hospitalized Plus Fatal Heart Failure by Treatment Group<a id="Joc21962f4" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f4.gif?Expires=1735231448&Signature=N1yeZ~tcFRBJtvH6n3Wmy9FGCa7~xhnUk4okqK~I62AlBT2YiXaC2v21v~~Zt4Om4KUC5z5Ga9~Y-qUhjjEaUGIGmSMVv49K3NH3AyLZUfU3YCSMnsv5Po~-U-IvUrtVxM707HNwq3Rv65WHYSCuOkWg~1xLGO6WGFfbbFSUQA97XjKLdDMhNfSBkJT0bKugUamMNDIBJIAI9mzi02M7JIwV5beUF111vH-hN1yG4EjRyCnsEUkpdQyjJ72BsvE~-0LOmfnU5A8xM80HU3JsLVlweuVpoUO5y7eIo7ALXlwiX1Y13N40QGmY8qsmxiVCQHGL9d68n3MmHn4tZgUJZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f4.gif?Expires=1735231448&Signature=N1yeZ~tcFRBJtvH6n3Wmy9FGCa7~xhnUk4okqK~I62AlBT2YiXaC2v21v~~Zt4Om4KUC5z5Ga9~Y-qUhjjEaUGIGmSMVv49K3NH3AyLZUfU3YCSMnsv5Po~-U-IvUrtVxM707HNwq3Rv65WHYSCuOkWg~1xLGO6WGFfbbFSUQA97XjKLdDMhNfSBkJT0bKugUamMNDIBJIAI9mzi02M7JIwV5beUF111vH-hN1yG4EjRyCnsEUkpdQyjJ72BsvE~-0LOmfnU5A8xM80HU3JsLVlweuVpoUO5y7eIo7ALXlwiX1Y13N40QGmY8qsmxiVCQHGL9d68n3MmHn4tZgUJZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048608&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f4.gif?Expires=1735231448&Signature=N1yeZ~tcFRBJtvH6n3Wmy9FGCa7~xhnUk4okqK~I62AlBT2YiXaC2v21v~~Zt4Om4KUC5z5Ga9~Y-qUhjjEaUGIGmSMVv49K3NH3AyLZUfU3YCSMnsv5Po~-U-IvUrtVxM707HNwq3Rv65WHYSCuOkWg~1xLGO6WGFfbbFSUQA97XjKLdDMhNfSBkJT0bKugUamMNDIBJIAI9mzi02M7JIwV5beUF111vH-hN1yG4EjRyCnsEUkpdQyjJ72BsvE~-0LOmfnU5A8xM80HU3JsLVlweuVpoUO5y7eIo7ALXlwiX1Y13N40QGmY8qsmxiVCQHGL9d68n3MmHn4tZgUJZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f4.gif?Expires=1735231448&Signature=T9F8D2GVwZNEQRpy-g6pjwrsCRGwqjS-jRhs4QsxSKbMpKeY8mhebwiuzekRIW9C41geEoWPyGxAvzJUJwpI28wgqIKPsyZx0fwWvsUVQRBUaMeOBxUkThf448iQ-3~QtCs3aNa0LOiK4jiB7AeMBtiBfcoKkbf6Eig8b4L8VHIAVlCii5ihydC0x-aP8ssIdr-nzckW87DaXG1CCPFS9JRcToE9RDr~1OWhGqRlYSaQmGXrrb4P41df8OrUxX6RTs8qpPtuXTK1fZHbD45xssZp9wPKOW5fMoITcXVgpunK0OBQX2uZ2iZyMh7Rbm4pFlJwwKN4D2Fvv-JYDfy-Fw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f4" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 5.</strong> Relative Risks and 95% Confidence Intervals (CIs) for Amlodipine/Chlorthalidone Comparisons in Prespecified Subgroups<a id="Joc21962f5" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f5" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f5.gif?Expires=1735231448&Signature=PJqF32NEPA~GstN-2MkVCJLXSNrdeBfYGo4y~nHdDQ46S4fiOMo0TyyDVfvcOUe3iNPXXZCx~49bVyZuyZXimdrgD4X5nyA9GdySq8Iys4PQS7y7Xq5V1tQeVjziZZZEMcVZvnvY7S~QxWTnlXxhCkjNBdMoiLh2XPIT8bWBZVg9Kqvj2AN2g3pi0DuGOnjvZGzqVseM1UPVN0nuzXyWj6T9v5NpxU25wR8~~DwfJhPbHxjmTmRDi8nTL6qKTsWwVRpw9-9KVrRO1zX0bMsmpQ9~8xwzbLiHFvHCdbFsCXiv6IAIsFsBYmhd0yS2X-JxoK5i3s53qLGpSr3p8PKbBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f5" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f5.gif?Expires=1735231448&Signature=PJqF32NEPA~GstN-2MkVCJLXSNrdeBfYGo4y~nHdDQ46S4fiOMo0TyyDVfvcOUe3iNPXXZCx~49bVyZuyZXimdrgD4X5nyA9GdySq8Iys4PQS7y7Xq5V1tQeVjziZZZEMcVZvnvY7S~QxWTnlXxhCkjNBdMoiLh2XPIT8bWBZVg9Kqvj2AN2g3pi0DuGOnjvZGzqVseM1UPVN0nuzXyWj6T9v5NpxU25wR8~~DwfJhPbHxjmTmRDi8nTL6qKTsWwVRpw9-9KVrRO1zX0bMsmpQ9~8xwzbLiHFvHCdbFsCXiv6IAIsFsBYmhd0yS2X-JxoK5i3s53qLGpSr3p8PKbBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048609&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f5.gif?Expires=1735231448&Signature=PJqF32NEPA~GstN-2MkVCJLXSNrdeBfYGo4y~nHdDQ46S4fiOMo0TyyDVfvcOUe3iNPXXZCx~49bVyZuyZXimdrgD4X5nyA9GdySq8Iys4PQS7y7Xq5V1tQeVjziZZZEMcVZvnvY7S~QxWTnlXxhCkjNBdMoiLh2XPIT8bWBZVg9Kqvj2AN2g3pi0DuGOnjvZGzqVseM1UPVN0nuzXyWj6T9v5NpxU25wR8~~DwfJhPbHxjmTmRDi8nTL6qKTsWwVRpw9-9KVrRO1zX0bMsmpQ9~8xwzbLiHFvHCdbFsCXiv6IAIsFsBYmhd0yS2X-JxoK5i3s53qLGpSr3p8PKbBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f5" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f5.gif?Expires=1735231448&Signature=FcUtjJ2LuIhKiozBmhmf~MZJ5TiaSaOzQIT1VhM03FGlqU-uoHa0p8ES6aQ7r-jIuX28vDAXskyTRVcOfzhUYtc6kq21KROlJd8slphXU7f6XwJakwB7V6WQevGi-U7iPjlALLAfbEdEx1TZPfJzzpPwdUrVpR4PuA~3oYXiutmSYdRXRkSAIyHsRwrygE2Vh0omaphFRE8i97oqovYwIGZ3xqLUPc18S5QNqMTuTyeWfwfQt24S7jBlo9SIdhimQEhnvmwVUomG~wONhIZ~Mg9C2d4NOMimu0vwsHlhOI8LneKpYUjICF~0QswZi4KvG5ePZw73mz-cqIuSuvYJHQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f5" /></a></div></div><div class="figure-caption clip-last-child">Scales are shown in natural logarithm.</div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 6.</strong> Relative Risks and 95% Confidence Intervals (CIs) for Lisinopril/Chlorthalidone Comparisons in Prespecified Subgroups<a id="Joc21962f6" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21962f6" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f6.gif?Expires=1735231448&Signature=jYP3dn9zHE9jTL1kKImDyioULxlpdbtyq8HL0AKAXzKHMjGhEgGsdZGN5QMGAQcAagC5bFVQNzC3PIgFwj5wxNi6HWmIkQN~xVOZthBtk3ItFiu~uqx-mIsIQOk8n0HKthwL28ESsVrgJVLfTGMDL-P~iz~FqrECRQBJL3YanjmUs2JQlODsUUz2KRl1htmrKNRimLoX1t0TrNe0l3RTePMS8T3bvDG38s4lSDYUBoMGhz5GGo22Unt-ifkEEHpQ9m0sOunPLiA2p8J9~GLEtG~q3z5Fz4Si0oFJ7hh2jVnxe3htb0wOWsK7igYXseXMfwPhs~06cfNGgy7xQrX3Rg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21962f6" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f6.gif?Expires=1735231448&Signature=jYP3dn9zHE9jTL1kKImDyioULxlpdbtyq8HL0AKAXzKHMjGhEgGsdZGN5QMGAQcAagC5bFVQNzC3PIgFwj5wxNi6HWmIkQN~xVOZthBtk3ItFiu~uqx-mIsIQOk8n0HKthwL28ESsVrgJVLfTGMDL-P~iz~FqrECRQBJL3YanjmUs2JQlODsUUz2KRl1htmrKNRimLoX1t0TrNe0l3RTePMS8T3bvDG38s4lSDYUBoMGhz5GGo22Unt-ifkEEHpQ9m0sOunPLiA2p8J9~GLEtG~q3z5Fz4Si0oFJ7hh2jVnxe3htb0wOWsK7igYXseXMfwPhs~06cfNGgy7xQrX3Rg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048612&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962f6.gif?Expires=1735231448&Signature=jYP3dn9zHE9jTL1kKImDyioULxlpdbtyq8HL0AKAXzKHMjGhEgGsdZGN5QMGAQcAagC5bFVQNzC3PIgFwj5wxNi6HWmIkQN~xVOZthBtk3ItFiu~uqx-mIsIQOk8n0HKthwL28ESsVrgJVLfTGMDL-P~iz~FqrECRQBJL3YanjmUs2JQlODsUUz2KRl1htmrKNRimLoX1t0TrNe0l3RTePMS8T3bvDG38s4lSDYUBoMGhz5GGo22Unt-ifkEEHpQ9m0sOunPLiA2p8J9~GLEtG~q3z5Fz4Si0oFJ7hh2jVnxe3htb0wOWsK7igYXseXMfwPhs~06cfNGgy7xQrX3Rg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21962f6" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962f6.gif?Expires=1735231448&Signature=071xlDbvtHu~s0GbZf9dalavV3X~YfldNYPe~sRt57~x1au1jApMQGG2~JCU-ivK1sK~7UD4l0GOQ9Dkyo8vHX~-XDEirg9kvc0eN0g92x3qcOAjJ43rltSo7HK7vY5jWDdNasxkvBqFQq5chLfOxke~H~souSxIqx0fGymc~DYNOtXeyMuSAjrrBzjTO5SkHrv7wssnP2oTqK-d1MP~OVOIjM~wr8zEU3pasLpXRclYr~ozwpuLSGHLgZDlA8zoPKNnR8Dpmy0MMN09Go~q2xohbFejIfJtllS5ltOn6s1xSyIkXaWBkffrQ~BE8B-T8D0HM7N96U8lgUTkU0Ldbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21962f6" /></a></div></div><div class="figure-caption clip-last-child">Scales are shown in natural logarithm.</div></div> </div> <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Tables_Tab"> <div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T1" class="figure-table-anchor"> </a><strong>Table 1.</strong> Baseline Characteristics of the ALLHAT Participants*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=1735231448&Signature=1kv4MtM~zWEIGZ1FX59lUv7kOt2xiowSPd5p1VAgMuaGXZpNFOTZUIKY0gkdszb6yTZUEJEQIpNN4bWCj0oftJvWuxBUjbdhrXprPSgF0Cf5GQ--gf5yd2xLQ1KEBEMW3RIGcFZSMOFnP8Tqxq~~vlo~XF1BqJXdZLFnU5eN3nH305bUTcKtPI9LQo8R~KY7GdJcquAcNIRsV3Yyo72fr~1CGKs-blCFsS4wRnDkTeIBvWz-w3Ef4ksjnHQLcbji-7ybETGe1vkqDbQHjVOBfAmTbKT1mORm3trNimgi7ZtjLAsR9zOKDfzLvvsLnl3TE4HvhYp06-uO7Dz6~s3pCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=1735231448&Signature=1kv4MtM~zWEIGZ1FX59lUv7kOt2xiowSPd5p1VAgMuaGXZpNFOTZUIKY0gkdszb6yTZUEJEQIpNN4bWCj0oftJvWuxBUjbdhrXprPSgF0Cf5GQ--gf5yd2xLQ1KEBEMW3RIGcFZSMOFnP8Tqxq~~vlo~XF1BqJXdZLFnU5eN3nH305bUTcKtPI9LQo8R~KY7GdJcquAcNIRsV3Yyo72fr~1CGKs-blCFsS4wRnDkTeIBvWz-w3Ef4ksjnHQLcbji-7ybETGe1vkqDbQHjVOBfAmTbKT1mORm3trNimgi7ZtjLAsR9zOKDfzLvvsLnl3TE4HvhYp06-uO7Dz6~s3pCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048587&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t1.png?Expires=1735231448&Signature=1kv4MtM~zWEIGZ1FX59lUv7kOt2xiowSPd5p1VAgMuaGXZpNFOTZUIKY0gkdszb6yTZUEJEQIpNN4bWCj0oftJvWuxBUjbdhrXprPSgF0Cf5GQ--gf5yd2xLQ1KEBEMW3RIGcFZSMOFnP8Tqxq~~vlo~XF1BqJXdZLFnU5eN3nH305bUTcKtPI9LQo8R~KY7GdJcquAcNIRsV3Yyo72fr~1CGKs-blCFsS4wRnDkTeIBvWz-w3Ef4ksjnHQLcbji-7ybETGe1vkqDbQHjVOBfAmTbKT1mORm3trNimgi7ZtjLAsR9zOKDfzLvvsLnl3TE4HvhYp06-uO7Dz6~s3pCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t1.png?Expires=1735231448&Signature=w-qxFSz52QzPkxqI4W8LE6omLhVJ~qL7Kp0IZyF-5AnjL~Yf7CCH3G7wUsbD9rgyk8yRQkxtUIPVzKibuaFYiB4QTO~J165hTK3ALJqtHLs71BzpJcdDO9ajrCIKLL49gjIUGZHzfC9VEdpL59uFEh4ChfOm65No-3SJs1iOzTUeIrgw4OX7IlWGUABs1KSvRrup7UMUGT1XoxL0L0jOZn4JOe9u4BEr~PeFva0KUHP9rrSMdMMSpQjrzsHqH7yefaaCdBMKrEG-LEURHhr-dKeH4XlZFw8lGCKwpKKyAjrF4NErRwRbsuCZPiHIs7kR1ww0yDJ786QrdP02qRle0g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T1" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T2" class="figure-table-anchor"> </a><strong>Table 2.</strong> Visits Expected and Completed and Antihypertensive Medication Use at Annual Visits<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t2.png?Expires=1735231448&Signature=TOTNjN-0hlIxrYfBm7BCseX2Yn0r2lEGrMfvyBJ8zsEL1Bcc27WjliE5HhISPWrUV4EEJsN0S6XrwAgvtsr~DkUNn2SjEahqAbVQLU1w5Ju0ew-vHMipQ~SG4DGF9HJqpfEfvstXjjBit--xbdcYiYiUcSlGlRuJzHHZVrU8Kxg3BLMUkwSiOUgpW8bwqxhgrEEZ~RNZzXj2DlFuLbB4tW6M7TxOFlTNLw-pFvGF-FUNEGMzCvmfzfpeEVJUv5~oAHeXd1BGVplTLrFk1Hjm6lm-5VahuF0BO77gHxTsa0NiXC2TaDnBe8n9ftBggR0WcrS0IM0fIovg1NbueiEsow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t2.png?Expires=1735231448&Signature=TOTNjN-0hlIxrYfBm7BCseX2Yn0r2lEGrMfvyBJ8zsEL1Bcc27WjliE5HhISPWrUV4EEJsN0S6XrwAgvtsr~DkUNn2SjEahqAbVQLU1w5Ju0ew-vHMipQ~SG4DGF9HJqpfEfvstXjjBit--xbdcYiYiUcSlGlRuJzHHZVrU8Kxg3BLMUkwSiOUgpW8bwqxhgrEEZ~RNZzXj2DlFuLbB4tW6M7TxOFlTNLw-pFvGF-FUNEGMzCvmfzfpeEVJUv5~oAHeXd1BGVplTLrFk1Hjm6lm-5VahuF0BO77gHxTsa0NiXC2TaDnBe8n9ftBggR0WcrS0IM0fIovg1NbueiEsow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048592&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t2.png?Expires=1735231448&Signature=TOTNjN-0hlIxrYfBm7BCseX2Yn0r2lEGrMfvyBJ8zsEL1Bcc27WjliE5HhISPWrUV4EEJsN0S6XrwAgvtsr~DkUNn2SjEahqAbVQLU1w5Ju0ew-vHMipQ~SG4DGF9HJqpfEfvstXjjBit--xbdcYiYiUcSlGlRuJzHHZVrU8Kxg3BLMUkwSiOUgpW8bwqxhgrEEZ~RNZzXj2DlFuLbB4tW6M7TxOFlTNLw-pFvGF-FUNEGMzCvmfzfpeEVJUv5~oAHeXd1BGVplTLrFk1Hjm6lm-5VahuF0BO77gHxTsa0NiXC2TaDnBe8n9ftBggR0WcrS0IM0fIovg1NbueiEsow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t2.png?Expires=1735231448&Signature=Rerryw~CJDKhKtT1xH5EcwBlYm8nLpxW387~uJzc-XDjBUx8ichFHcqh3HCCsSB0ebQu-c7JtDHk~IxZVVXIU1EBqSdIJQ6CIT6t0UqnTZ5kkrTkEKlx2uBFkiOZuqTQlLikZAm0EPBcFZaVik887M3gbQQbQHEEPQH6GrE5LOFShfE0NW2KfRpTSk02XHu69HdtHch0w7i7PqZxkqm7J7HdsZ4oibm5CYLY1~249aDNn96nPg3lbgfT11mBF8PNT703Fu8R2KyHZNec~6EoqXnYqUXmB75YPF8sLkjleavOUdupRmIqOI2LkX6i1kmlk4PCRRyQqCFlKPe1LmT~uQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T2" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T3" class="figure-table-anchor"> </a><strong>Table 3.</strong> Number of Participants, Mean Blood Pressure, Achieved Blood Pressure Goal, and Blood Pressure Difference at Baseline and Annual Visits<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t3.png?Expires=1735231448&Signature=bMV36bbs9VP4dWkHYzJmPTy2BF8v3YKi~-ACTuWHnP5~Kua6d9HRqyD0Vo~hbHkgP5JNMatu8oZKXWpNpHDKLqUZIhJayjMpCRABbjTCJnF2QAaDhjSzCP30Z~bVgqQ37tNJdRDqIOEiF6iOiS9BtO0HvxfBeI795BiEEWMNd8-2CaNvTYOLruF3yv7kmTCPtFfzR6hPmgrQMDuOReFrOG6o9JT-Nx1a-tUPicOpJDrLmnjy4m22xUIkZ4ue5lvsSHuD1OHnhKpBFXM-t15YTefDkHJ9g7eB8WbSeg1787wb1o2tVoepRgjT~QCvlUkJoeSdHC~XiOmEo17ZBbIxYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t3.png?Expires=1735231448&Signature=bMV36bbs9VP4dWkHYzJmPTy2BF8v3YKi~-ACTuWHnP5~Kua6d9HRqyD0Vo~hbHkgP5JNMatu8oZKXWpNpHDKLqUZIhJayjMpCRABbjTCJnF2QAaDhjSzCP30Z~bVgqQ37tNJdRDqIOEiF6iOiS9BtO0HvxfBeI795BiEEWMNd8-2CaNvTYOLruF3yv7kmTCPtFfzR6hPmgrQMDuOReFrOG6o9JT-Nx1a-tUPicOpJDrLmnjy4m22xUIkZ4ue5lvsSHuD1OHnhKpBFXM-t15YTefDkHJ9g7eB8WbSeg1787wb1o2tVoepRgjT~QCvlUkJoeSdHC~XiOmEo17ZBbIxYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048597&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t3.png?Expires=1735231448&Signature=bMV36bbs9VP4dWkHYzJmPTy2BF8v3YKi~-ACTuWHnP5~Kua6d9HRqyD0Vo~hbHkgP5JNMatu8oZKXWpNpHDKLqUZIhJayjMpCRABbjTCJnF2QAaDhjSzCP30Z~bVgqQ37tNJdRDqIOEiF6iOiS9BtO0HvxfBeI795BiEEWMNd8-2CaNvTYOLruF3yv7kmTCPtFfzR6hPmgrQMDuOReFrOG6o9JT-Nx1a-tUPicOpJDrLmnjy4m22xUIkZ4ue5lvsSHuD1OHnhKpBFXM-t15YTefDkHJ9g7eB8WbSeg1787wb1o2tVoepRgjT~QCvlUkJoeSdHC~XiOmEo17ZBbIxYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t3.png?Expires=1735231448&Signature=BhZ1xeVfIhmH28JOPIDljtHNVUW5~P7db8OXw9yf0VehiS5ENM0Ebrd7ueZz1HCxD5LXi~VQVpEp83Bj~i11R6N89t7RHGlH4Q856-Mt1zjXAKfA-~34Hv6J4SF00HaDhukjz8WxtsebiWVJL0khILLNC0mxKirCOpekQFgfJeC0wY4t6JCJCpxCdomIKXWazkxpnvpsHnAtNGgSybcdaN3M7LGSIJg9Xt~MN8BJ43fvS-fSqhNSXgMHKginLTwbYnM5MM499hhVmZPgYYOH3LZhr1UwfnQ17Boqk8xlGLZg3Cx2pD-iNhDnC~Kel-~zSNgYYaExt0YSINn4bk4etg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T3" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T4" class="figure-table-anchor"> </a><strong>Table 4a.</strong> Biochemical Changes by Treatment Group*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4a.png?Expires=1735231448&Signature=E5RlB78SIURTlqADiiXCYFBXnymS27QFw~Td1YQWn-aAAuxZAGEUvsvo0Rn-MLGz0zlv15k3JRFKgicK2-tJ39piNteraMD~l-qtluAl0fRoc0RPHzJCV5qxMYrpoHhpttIZGGV9I81syffnjvcV45gEKs4D4Ry9y68u5xtmrRw2YP7j3cWbOY2P10q-FdIIMTJhptago5oBFrBvvbZZ-9dss5OcxTTwKLJjiNrLTha03B~SBfgaefxsoa4u55Au1ldnXVxl88-405vUDmGYTN61~FmFaoxJNSNLkwsHJsnSAlBts2JNEGOyifBNc8xZif20UjQu1JMUVe4QRuabiw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4a.png?Expires=1735231448&Signature=E5RlB78SIURTlqADiiXCYFBXnymS27QFw~Td1YQWn-aAAuxZAGEUvsvo0Rn-MLGz0zlv15k3JRFKgicK2-tJ39piNteraMD~l-qtluAl0fRoc0RPHzJCV5qxMYrpoHhpttIZGGV9I81syffnjvcV45gEKs4D4Ry9y68u5xtmrRw2YP7j3cWbOY2P10q-FdIIMTJhptago5oBFrBvvbZZ-9dss5OcxTTwKLJjiNrLTha03B~SBfgaefxsoa4u55Au1ldnXVxl88-405vUDmGYTN61~FmFaoxJNSNLkwsHJsnSAlBts2JNEGOyifBNc8xZif20UjQu1JMUVe4QRuabiw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048598&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4a.png?Expires=1735231448&Signature=E5RlB78SIURTlqADiiXCYFBXnymS27QFw~Td1YQWn-aAAuxZAGEUvsvo0Rn-MLGz0zlv15k3JRFKgicK2-tJ39piNteraMD~l-qtluAl0fRoc0RPHzJCV5qxMYrpoHhpttIZGGV9I81syffnjvcV45gEKs4D4Ry9y68u5xtmrRw2YP7j3cWbOY2P10q-FdIIMTJhptago5oBFrBvvbZZ-9dss5OcxTTwKLJjiNrLTha03B~SBfgaefxsoa4u55Au1ldnXVxl88-405vUDmGYTN61~FmFaoxJNSNLkwsHJsnSAlBts2JNEGOyifBNc8xZif20UjQu1JMUVe4QRuabiw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t4a.png?Expires=1735231448&Signature=ixoBzo--UMjspdAurcQn3bNPrRfJcvSylv4EFUCPXJGX6gHFUweENp79hAm4dHgis9QeJ3CAHPe29eDGrSWyL7K-NObKkMlNSA7kAMTHZlI3KBpWCmJY~eLaSxJj3dLNh8f6VGnOEivodfQMIDaqj-iwDb1gOubkiBxyI0Ye7BTh3-saaqnb6j9~tZinp1lUZibOGd4lSxtVwz7azUgcADxZnVaWOvtTpeBfzGgSyle0MkKDoPCJr~nnFPx5UFWtHh34a3yN~XqJPnk-WcGLlNeqi3iazPXCGc6eGYtwyHqjUF9YMc8SK04he4hAO760Ity1BqKHu7vfd2zkiB-DhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T4" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="joc21962t4b" class="figure-table-anchor"> </a>Table 4b<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc21962t4b" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4b.png?Expires=1735231448&Signature=mgVGqI~0hQZBYRs0JNjko5slLohEkVNQmhX21jBTEsuxbWd2TqLsh6nGbWtj6POrNE5yRgXbL5mBVpB2soJYDSPi7qUldT9DxLV2vUck6HhSQMvLpoHQCpKDApDCyj1QwVa~wLcH5CRcuzKruHBQ3edR1kZOc4cPou7DhV2BnoB3lQyeo813Bna0DWpNFs3fCFEQeQqHg4ANh06EP28KIcUuafBs9tRTwChrXPOKjXGJJl6NE7EzTSQAjEpBSviswiu7vncVKkzQr8qsjaCvRPhU5~MP10lLDuAcgKIqQG19O1V5-UsOTAgGuu81OWhkCYnzR2oPm-UBX6sTCnogVg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc21962t4b" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4b.png?Expires=1735231448&Signature=mgVGqI~0hQZBYRs0JNjko5slLohEkVNQmhX21jBTEsuxbWd2TqLsh6nGbWtj6POrNE5yRgXbL5mBVpB2soJYDSPi7qUldT9DxLV2vUck6HhSQMvLpoHQCpKDApDCyj1QwVa~wLcH5CRcuzKruHBQ3edR1kZOc4cPou7DhV2BnoB3lQyeo813Bna0DWpNFs3fCFEQeQqHg4ANh06EP28KIcUuafBs9tRTwChrXPOKjXGJJl6NE7EzTSQAjEpBSviswiu7vncVKkzQr8qsjaCvRPhU5~MP10lLDuAcgKIqQG19O1V5-UsOTAgGuu81OWhkCYnzR2oPm-UBX6sTCnogVg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048600&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t4b.png?Expires=1735231448&Signature=mgVGqI~0hQZBYRs0JNjko5slLohEkVNQmhX21jBTEsuxbWd2TqLsh6nGbWtj6POrNE5yRgXbL5mBVpB2soJYDSPi7qUldT9DxLV2vUck6HhSQMvLpoHQCpKDApDCyj1QwVa~wLcH5CRcuzKruHBQ3edR1kZOc4cPou7DhV2BnoB3lQyeo813Bna0DWpNFs3fCFEQeQqHg4ANh06EP28KIcUuafBs9tRTwChrXPOKjXGJJl6NE7EzTSQAjEpBSviswiu7vncVKkzQr8qsjaCvRPhU5~MP10lLDuAcgKIqQG19O1V5-UsOTAgGuu81OWhkCYnzR2oPm-UBX6sTCnogVg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc21962t4b" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t4b.png?Expires=1735231448&Signature=qfGM2ndvPcUIzVHZrNGEyeH6NcjwqoEM-EGHk6pxeAS3Bmjvo0VHj28k-aIPfI5AXFxaOykfqZLOBK0MWYM6xv76bIqGl2n3wncw--pOEMGWy8XSTvxPVqKtzn9kvq4k5Wg3estafpNG73gp~RINHXJNqYxfFGhIxDacfxOVLc8TiDJzOgtr2leY9e8ztXLQZbdfSrBeev8HtroovYnhDcxn8TK6xnLPMq~FeO123gl~vh3F93z7yPVGvOO9xiU~HKa~kciUJxPlD~CAFfai8B3iusRZ6uY-Vb3dhHAIzdJGY-2r4ArOpi~I~4wLpPvPeeGmZrhZRH12GUzamHRsHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="joc21962t4b" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T5" class="figure-table-anchor"> </a><strong>Table 5.</strong> Clinical Outcomes by Antihypertensive Treatment Group*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T5" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t5.png?Expires=1735231448&Signature=q9mw6vrmU6qxsKoRvv07t-ItdCpUEign9tQ1kjSyiWUld7AWl5UQ-wGbzQrQ-cSw8FsOKyPD2BI3CTo2HkF6p5p~zU6tNayHW0nUHgoUKt~tpMCfjzjcd6Pvb9hbRdGn5KP91qTrkOHlkWOomP~QEfiS0W5YBkvBDdVA3kx1LZ0yshupI~YR9g0HhfLvfOiRj~eMY8ltCvFIk9voVdt2tiyOOci8lVBwssfc1xIzTCmVpJyHba6Y6PY8YvjAoMHO5zvLgFlFgQlW6cYAZWkHd7mxdrmHNTtG09BUtPFoEmvKDhY50x5Xm4IBookxEqjiuMQSnBEVQc7Q~TL3AkzhVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T5" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t5.png?Expires=1735231448&Signature=q9mw6vrmU6qxsKoRvv07t-ItdCpUEign9tQ1kjSyiWUld7AWl5UQ-wGbzQrQ-cSw8FsOKyPD2BI3CTo2HkF6p5p~zU6tNayHW0nUHgoUKt~tpMCfjzjcd6Pvb9hbRdGn5KP91qTrkOHlkWOomP~QEfiS0W5YBkvBDdVA3kx1LZ0yshupI~YR9g0HhfLvfOiRj~eMY8ltCvFIk9voVdt2tiyOOci8lVBwssfc1xIzTCmVpJyHba6Y6PY8YvjAoMHO5zvLgFlFgQlW6cYAZWkHd7mxdrmHNTtG09BUtPFoEmvKDhY50x5Xm4IBookxEqjiuMQSnBEVQc7Q~TL3AkzhVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048606&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t5.png?Expires=1735231448&Signature=q9mw6vrmU6qxsKoRvv07t-ItdCpUEign9tQ1kjSyiWUld7AWl5UQ-wGbzQrQ-cSw8FsOKyPD2BI3CTo2HkF6p5p~zU6tNayHW0nUHgoUKt~tpMCfjzjcd6Pvb9hbRdGn5KP91qTrkOHlkWOomP~QEfiS0W5YBkvBDdVA3kx1LZ0yshupI~YR9g0HhfLvfOiRj~eMY8ltCvFIk9voVdt2tiyOOci8lVBwssfc1xIzTCmVpJyHba6Y6PY8YvjAoMHO5zvLgFlFgQlW6cYAZWkHd7mxdrmHNTtG09BUtPFoEmvKDhY50x5Xm4IBookxEqjiuMQSnBEVQc7Q~TL3AkzhVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T5" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t5.png?Expires=1735231448&Signature=DpC5crYdm5uWwM5YHmRBV7G~ZVXr4dXxkxST9-3QFcwtL6Re-jZCRGrkI-N4JssfnnXnVniMytQAq8kQ6ud~TNwyQGiXdT1eWPJ6tuC6XCn1RiOtBHFbQQUR9nX6A8Yktz5u8xtfhuyAUix-nZOQ-ZkH2PiKN8BDqh7Z7r8f80HT2MWfyUKHt1l8BGV0AjZ8PylL3UbK53yL~AdpC5zB1-1mcrjpQCvzSLty6HE8OHdPCqKFgPST3Cr1FdW9Mu6jqA7BimLNwg4-GQ8yHkHosSzQ-tYOSfUckn-jO0mQZrfnbg3FRy6nrN~PiJeh-p16HlSpPkTeQBmwjN4nIHWSxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T5" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21962T6" class="figure-table-anchor"> </a><strong>Table 6.</strong> Causes of Death by Antihypertensive Treatment Group*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21962T6" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t6.png?Expires=1735231448&Signature=q052gVahqB1E443R1ey1x7ik5jq51ODyJwvseWdgDmOpAa~KUTphgiQqje4IjzzheXGGpOpABvPYEiuYKgJ33sW6Pc9qvTmYJIYgwjtdeA3MAC60hTc1w0iCMaSZx7cO12DQtScqMgmL0grdlNkITPEe0exs~A7E1lAaJjHLbhS-IkXSfIC6u~Kt5hzX4qlKxsXRLoHNrvEN-x4mSwI~YOZQ~807hbujbP-0sPF8QfirHbsagZSt70obPaxU9kTnp8yqqDQw5jJvkWWnAjpRbyekZlvQbGfxKhFh9pXNzzq3dyky-cWNUh8duD0COHRwDjIzXdYIjBMJZM4WN62~Bw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21962T6" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t6.png?Expires=1735231448&Signature=q052gVahqB1E443R1ey1x7ik5jq51ODyJwvseWdgDmOpAa~KUTphgiQqje4IjzzheXGGpOpABvPYEiuYKgJ33sW6Pc9qvTmYJIYgwjtdeA3MAC60hTc1w0iCMaSZx7cO12DQtScqMgmL0grdlNkITPEe0exs~A7E1lAaJjHLbhS-IkXSfIC6u~Kt5hzX4qlKxsXRLoHNrvEN-x4mSwI~YOZQ~807hbujbP-0sPF8QfirHbsagZSt70obPaxU9kTnp8yqqDQw5jJvkWWnAjpRbyekZlvQbGfxKhFh9pXNzzq3dyky-cWNUh8duD0COHRwDjIzXdYIjBMJZM4WN62~Bw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25048610&ar=195626&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/joc21962t6.png?Expires=1735231448&Signature=q052gVahqB1E443R1ey1x7ik5jq51ODyJwvseWdgDmOpAa~KUTphgiQqje4IjzzheXGGpOpABvPYEiuYKgJ33sW6Pc9qvTmYJIYgwjtdeA3MAC60hTc1w0iCMaSZx7cO12DQtScqMgmL0grdlNkITPEe0exs~A7E1lAaJjHLbhS-IkXSfIC6u~Kt5hzX4qlKxsXRLoHNrvEN-x4mSwI~YOZQ~807hbujbP-0sPF8QfirHbsagZSt70obPaxU9kTnp8yqqDQw5jJvkWWnAjpRbyekZlvQbGfxKhFh9pXNzzq3dyky-cWNUh8duD0COHRwDjIzXdYIjBMJZM4WN62~Bw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21962T6" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4860/m_joc21962t6.png?Expires=1735231448&Signature=U20eXng~TDfiRSVKigipD0myCYq1Zk~1u1mnFgHNzgK3nP6gtoOyfVsv9jEq-8idy7DwwQPd64y9gKZ7WVkEOaKDMBmyJaHTW~N5g1CVEECPGTTqvoWWw~7vzWorlZS7KalFpiGVGE7nx3WoTAIV0I878Fzlfjj9vQsRS7T1b1qIoDmBN19hrimEnw7kTE2kp3fS391OR64xmCbnMvk2k4YMi~dnYXSaZr33eSgy75u0ZUCrS3dt2wkcQd0wWJgoLk7SJSnAiPQYs42AiqynlQPXiGIiZjTOLZix~isOHidESH~-6hV0-FyW2Y4ohfu4xKAlpMXs9o2tW63oWaDQNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21962T6" /></a></div></div></div> </div> </div> <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad"> </div> <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad"> </div> <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad"> <div class="references-wrap"> <div class="widget-SectionDisplay widget-instance-AMA_References_Tab"> <div class="references"><div class="reference"><a class="reference-number" id="ref-joc21962-1">1.</a><div class="reference-content">American Heart Association. <em>2002 Heart and Stroke Statistical Update.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">Dallas, Tex: American Heart Association; 2001.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-2">2.</a><div class="reference-content">Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review. <I xmlns:helper="urn:XsltStringHelper"> Hypertension.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1989;13:I36-I44.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Controlled%20clinical%20trials%20of%20drug%20treatment%20for%20hypertension%3A%20a%20review.&author=JA%20Cutler&author=SW%20MacMahon&author=CD%20Furberg&publication_year=&journal=Hypertension.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-3">3.</a><div class="reference-content">Psaty BM, Smith NL, Siscovick DS. et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;277:739-745.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Health%20outcomes%20associated%20with%20antihypertensive%20therapies%20used%20as%20first-line%20agents%3A%20a%20systematic%20review%20and%20meta-analysis.&author=BM%20Psaty&author=NL%20Smith&author=DS%20Siscovick&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-4">4.</a><div class="reference-content"> The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;157:2413-2446.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20sixth%20report%20of%20the%20Joint%20National%20Committee%20on%20prevention%2C%20detection%2C%20evaluation%2C%20and%20treatment%20of%20high%20blood%20pressure.&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-5">5.</a><div class="reference-content">Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;14:929-933.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%201996%20report%20of%20a%20World%20Health%20Organization%20expert%20committee%20on%20hypertension%20control.&author=J%20Chalmers&author=A%20Zanchetti&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-6">6.</a><div class="reference-content">Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;336:370-371.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%20and%20coronary%20heart%20disease.&author=R%20Collins&author=R%20Peto&author=J%20Godwin&author=S%20MacMahon&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-7">7.</a><div class="reference-content">World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;16:127-137.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Protocol%20for%20prospective%20collaborative%20overviews%20of%20major%20randomized%20trials%20of%20blood%20pressure%20lowering%20treatments.&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-8">8.</a><div class="reference-content">SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;265:3255-3264.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevention%20of%20stroke%20by%20antihypertensive%20drug%20treatment%20in%20older%20persons%20with%20isolated%20systolic%20hypertension%3A%20final%20results%20of%20the%20Systolic%20Hypertension%20in%20the%20Elderly%20Program%20%28SHEP%29.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-9">9.</a><div class="reference-content">Staessen JA, Fagard R, Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;350:757-764.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20double-blind%20comparison%20of%20placebo%20and%20active%20treatment%20for%20older%20patients%20with%20isolated%20systolic%20hypertension%3A%20the%20Systolic%20Hypertension%20in%20Europe%20%28Syst-Eur%29%20Trial%20Investigators.&author=JA%20Staessen&author=R%20Fagard&author=L%20Thijs&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-10">10.</a><div class="reference-content">Yusuf S, Sleight P, Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;342:145-153.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20an%20angiotensin-converting-enzyme%20inhibitor%2C%20ramipril%2C%20on%20cardiovascular%20events%20in%20high-risk%20patients%3A%20the%20Heart%20Outcomes%20Prevention%20Evaluation%20Study%20Investigators.&author=S%20Yusuf&author=P%20Sleight&author=J%20Pogue&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-11">11.</a><div class="reference-content">PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;358:1033-1041.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20trial%20of%20a%20perindopril-based%20blood-pressure-lowering%20regimen%20among%206%2C105%20individuals%20with%20previous%20stroke%20or%20transient%20ischaemic%20attack.&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-12">12.</a><div class="reference-content">Grimm Jr RH. Antihypertensive therapy: taking lipids into consideration. <I xmlns:helper="urn:XsltStringHelper"> Am Heart J.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;122:910-918.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antihypertensive%20therapy%3A%20taking%20lipids%20into%20consideration.&author=RH%20Grimm Jr&publication_year=&journal=Am%20Heart%20J.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-13">13.</a><div class="reference-content">Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trialists' Collaboration. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:1955-1964.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20ACE%20inhibitors%2C%20calcium%20antagonists%2C%20and%20other%20blood-pressure-lowering%20drugs%3A%20results%20of%20prospectively%20designed%20overviews%20of%20randomised%20trials%3A%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%27%20Collaboration.&author=B%20Neal&author=S%20MacMahon&author=N%20Chapman&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-14">14.</a><div class="reference-content">Pahor M, Psaty BM, Alderman MH. et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:1949-1954.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Health%20outcomes%20associated%20with%20calcium%20antagonists%20compared%20with%20other%20first-line%20antihypertensive%20therapies%3A%20a%20meta-analysis%20of%20randomised%20controlled%20trials.&author=M%20Pahor&author=BM%20Psaty&author=MH%20Alderman&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-15">15.</a><div class="reference-content">Poulter NR. Treatment of hypertension: a clinical epidemiologist's view. <I xmlns:helper="urn:XsltStringHelper"> J Cardiovasc Pharmacol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;18(suppl 2):S35-S38.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Treatment%20of%20hypertension%3A%20a%20clinical%20epidemiologist%27s%20view.&author=NR%20Poulter&publication_year=&journal=J%20Cardiovasc%20Pharmacol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-16">16.</a><div class="reference-content">Neaton JD, Grimm Jr RH, Prineas RJ. et al. Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;270:713-724.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Treatment%20of%20mild%20hypertension%20study%3A%20final%20results%3A%20Treatment%20of%20Mild%20Hypertension%20Study%20Research%20Group.&author=JD%20Neaton&author=RH%20Grimm Jr&author=RJ%20Prineas&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-17">17.</a><div class="reference-content">Materson BJ, Reda DJ, Cushman WC. et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;328:914-921.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Single-drug%20therapy%20for%20hypertension%20in%20men%3A%20a%20comparison%20of%20six%20antihypertensive%20agents%20with%20placebo%3A%20the%20Department%20of%20Veterans%20Affairs%20Cooperative%20Study%20Group%20on%20Antihypertensive%20Agents.&author=BJ%20Materson&author=DJ%20Reda&author=WC%20Cushman&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-18">18.</a><div class="reference-content">Davis BR, Cutler JA, Gordon DJ. et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> Am J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;9:342-360.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rationale%20and%20design%20for%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&author=BR%20Davis&author=JA%20Cutler&author=DJ%20Gordon&publication_year=&journal=Am%20J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-19">19.</a><div class="reference-content">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;283:1967-1975.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Major%20cardiovascular%20events%20in%20hypertensive%20patients%20randomized%20to%20doxazosin%20vs%20chlorthalidone%3A%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-20">20.</a><div class="reference-content">Davis BR, Cutler JA, Furberg CD. et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;137:313-320.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20of%20antihypertensive%20treatment%20regimens%20and%20change%20in%20blood%20pressure%20to%20risk%20for%20heart%20failure%20in%20hypertensive%20patients%20randomly%20assigned%20to%20doxazosin%20or%20chlorthalidone%3A%20further%20analyses%20from%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial.&author=BR%20Davis&author=JA%20Cutler&author=CD%20Furberg&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-21">21.</a><div class="reference-content">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:2998-3007.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Major%20outcomes%20in%20moderately%20hypercholesterolemic%2C%20hypertensive%20patients%20randomized%20to%20pravastatin%20vs%20usual%20care%3A%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-22">22.</a><div class="reference-content">Grimm Jr RH, Margolis KL, Papademetriou V. et al. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> Hypertension.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;37:19-27.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Baseline%20characteristics%20of%20participants%20in%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&author=RH%20Grimm Jr&author=KL%20Margolis&author=V%20Papademetriou&publication_year=&journal=Hypertension.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-23">23.</a><div class="reference-content"> The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;153:154-183.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20fifth%20report%20of%20the%20Joint%20National%20Committee%20on%20Detection%2C%20Evaluation%2C%20and%20Treatment%20of%20High%20Blood%20Pressure%20%28JNC%20V%29.&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-24">24.</a><div class="reference-content">Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;130:461-470.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20more%20accurate%20method%20to%20estimate%20glomerular%20filtration%20rate%20from%20serum%20creatinine%3A%20a%20new%20prediction%20equation%3A%20Modification%20of%20Diet%20in%20Renal%20Disease%20Study%20Group.&author=AS%20Levey&author=JP%20Bosch&author=JB%20Lewis&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-25">25.</a><div class="reference-content">Levey AS, Greene T, Kusek JW. et al. A simplified equation to predict glomerular filtration rate from serum creatinine. <I xmlns:helper="urn:XsltStringHelper"> J Am Soc Nephrol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;11:155A.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20simplified%20equation%20to%20predict%20glomerular%20filtration%20rate%20from%20serum%20creatinine.&author=AS%20Levey&author=T%20Greene&author=JW%20Kusek&publication_year=&journal=J%20Am%20Soc%20Nephrol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-26">26.</a><div class="reference-content">Piller LB, Davis BR, Cutler JA. et al. Validation of heart failure events in ALLHAT participants assigned to doxazosin. <I xmlns:helper="urn:XsltStringHelper"> Curr Control Trials Cardiovasc Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;3:10.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Validation%20of%20heart%20failure%20events%20in%20ALLHAT%20participants%20assigned%20to%20doxazosin.&author=LB%20Piller&author=BR%20Davis&author=JA%20Cutler&publication_year=&journal=Curr%20Control%20Trials%20Cardiovasc%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-27">27.</a><div class="reference-content">Public Health Service-Health Care Financing Administration. <em>International Classification of Diseases, Ninth Revision (ICD-9).</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">6th ed. Bethesda, Md: US Dept of Health and Human Services; 2001. DHHS Publication No. (PHS) 80-1260.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-28">28.</a><div class="reference-content">Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. <I xmlns:helper="urn:XsltStringHelper"> J Am Stat Assoc.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1955;50:1096-1121.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20multiple%20comparisons%20procedure%20for%20comparing%20several%20treatments%20with%20a%20control.&author=CW%20Dunnett&publication_year=&journal=J%20Am%20Stat%20Assoc.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-29">29.</a><div class="reference-content">Klein JP, Moeschberger ML. <em>Survival Analysis: Techniques for Censored and Truncated Regression.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">New York, NY: Springer-Verlag; 1997.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-30">30.</a><div class="reference-content">Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations. <I xmlns:helper="urn:XsltStringHelper"> Commun Stat.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;19:3571-3584.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Upper%20bounds%20for%20type%20I%20and%20II%20error%20rates%20in%20conditional%20power%20calculations.&author=BR%20Davis&author=RJ%20Hardy&publication_year=&journal=Commun%20Stat.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-31">31.</a><div class="reference-content">Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. <I xmlns:helper="urn:XsltStringHelper"> Biometrika.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1983;70:659-663.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Discrete%20sequential%20boundaries%20for%20clinical%20trials.&author=KKG%20Lan&author=DL%20DeMets&publication_year=&journal=Biometrika.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-32">32.</a><div class="reference-content">Hansson L, Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;354:1751-1756.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20trial%20of%20old%20and%20new%20antihypertensive%20drugs%20in%20elderly%20patients%3A%20cardiovascular%20mortality%20and%20morbidity%3A%20the%20Swedish%20Trial%20in%20Old%20Patients%20with%20Hypertension-2%20study.&author=L%20Hansson&author=LH%20Lindholm&author=T%20Ekbom&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-33">33.</a><div class="reference-content">Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:366-372.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Morbidity%20and%20mortality%20in%20patients%20randomised%20to%20double-blind%20treatment%20with%20a%20long-acting%20calcium-channel%20blocker%20or%20diuretic%20in%20the%20International%20Nifedipine%20GITS%20study%3A%20Intervention%20as%20a%20Goal%20in%20Hypertension%20Treatment%20%28INSIGHT%29.&author=MJ%20Brown&author=CR%20Palmer&author=A%20Castaigne&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-34">34.</a><div class="reference-content">MacMahon S, Neal B. Differences between blood-pressure-lowering drugs. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:352-353.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Differences%20between%20blood-pressure-lowering%20drugs.&author=S%20MacMahon&author=B%20Neal&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-35">35.</a><div class="reference-content">Kostis JB, Davis BR, Cutler J. et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;278:212-216.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevention%20of%20heart%20failure%20by%20antihypertensive%20drug%20treatment%20in%20older%20persons%20with%20isolated%20systolic%20hypertension%3A%20SHEP%20Cooperative%20Research%20Group.&author=JB%20Kostis&author=BR%20Davis&author=J%20Cutler&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-36">36.</a><div class="reference-content">Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;15:105-115.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20calcium%20antagonists%20on%20the%20risks%20of%20coronary%20heart%20disease%2C%20cancer%20and%20bleeding.&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-37">37.</a><div class="reference-content">Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. <I xmlns:helper="urn:XsltStringHelper"> Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;92:1326-1331.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Nifedipine%3A%20dose-related%20increase%20in%20mortality%20in%20patients%20with%20coronary%20heart%20disease.&author=CD%20Furberg&author=BM%20Psaty&author=JV%20Meyer&publication_year=&journal=Circulation.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-38">38.</a><div class="reference-content">Agodoa LY, Appel L, Bakris GL. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;285:2719-2728.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20ramipril%20vs%20amlodipine%20on%20renal%20outcomes%20in%20hypertensive%20nephrosclerosis%3A%20a%20randomized%20controlled%20trial.&author=LY%20Agodoa&author=L%20Appel&author=GL%20Bakris&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-39">39.</a><div class="reference-content">Hall WD, Kusek JW, Kirk KA. et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. <I xmlns:helper="urn:XsltStringHelper"> Am J Kidney Dis.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;29:720-728.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Short-term%20effects%20of%20blood%20pressure%20control%20and%20antihypertensive%20drug%20regimen%20on%20glomerular%20filtration%20rate%3A%20the%20African-American%20Study%20of%20Kidney%20Disease%20and%20Hypertension%20Pilot%20Study.&author=WD%20Hall&author=JW%20Kusek&author=KA%20Kirk&publication_year=&journal=Am%20J%20Kidney%20Dis.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-40">40.</a><div class="reference-content">ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1994;154:1185-1202.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20calcium%20antagonists%20on%20renal%20hemodynamics%20and%20progression%20of%20nondiabetic%20chronic%20renal%20disease.&author=PM%20ter Wee&author=AG%20De Micheli&author=M%20Epstein&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-41">41.</a><div class="reference-content">Lonn EM, Yusuf S, Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. <I xmlns:helper="urn:XsltStringHelper"> Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1994;90:2056-2069.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Emerging%20role%20of%20angiotensin-converting%20enzyme%20inhibitors%20in%20cardiac%20and%20vascular%20protection.&author=EM%20Lonn&author=S%20Yusuf&author=P%20Jha&publication_year=&journal=Circulation.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-42">42.</a><div class="reference-content">Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. <I xmlns:helper="urn:XsltStringHelper"> Am J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;12:205S-213S.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20renin-angiotensin-aldosterone%20system%3A%20a%20specific%20target%20for%20hypertension%20management.&author=MR%20Weir&author=VJ%20Dzau&publication_year=&journal=Am%20J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-43">43.</a><div class="reference-content">Jafar TH, Schmid CH, Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:73-87.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Angiotensin-converting%20enzyme%20inhibitors%20and%20progression%20of%20nondiabetic%20renal%20disease%3A%20a%20meta-analysis%20of%20patient-level%20data.&author=TH%20Jafar&author=CH%20Schmid&author=M%20Landa&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-44">44.</a><div class="reference-content"> Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;327:685-691.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20enalapril%20on%20mortality%20and%20the%20development%20of%20heart%20failure%20in%20asymptomatic%20patients%20with%20reduced%20left%20ventricular%20ejection%20fractions%3A%20the%20SOLVD%20Investigators.&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-45">45.</a><div class="reference-content">Collins R, Peto R, MacMahon S. et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;335:827-838.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%2C%20stroke%2C%20and%20coronary%20heart%20disease%3A%20Part%202%2C%20short-term%20reductions%20in%20blood%20pressure%3A%20overview%20of%20randomised%20drug%20trials%20in%20their%20epidemiological%20context.&author=R%20Collins&author=R%20Peto&author=S%20MacMahon&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-46">46.</a><div class="reference-content">MacMahon S, Peto R, Cutler J. et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;335:765-774.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%2C%20stroke%2C%20and%20coronary%20heart%20disease%3A%20Part%201%2C%20prolonged%20differences%20in%20blood%20pressure%3A%20prospective%20observational%20studies%20corrected%20for%20the%20regression%20dilution%20bias.&author=S%20MacMahon&author=R%20Peto&author=J%20Cutler&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-47">47.</a><div class="reference-content">Staessen JA, Byttebier G, Buntinx F. et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial: Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;278:1065-1072.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antihypertensive%20treatment%20based%20on%20conventional%20or%20ambulatory%20blood%20pressure%20measurement%3A%20a%20randomized%20controlled%20trial%3A%20Ambulatory%20Blood%20Pressure%20Monitoring%20and%20Treatment%20of%20Hypertension%20Investigators.&author=JA%20Staessen&author=G%20Byttebier&author=F%20Buntinx&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-48">48.</a><div class="reference-content">Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist's point of view. <I xmlns:helper="urn:XsltStringHelper"> Pathol Biol (Paris).</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;47:594-603.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cardiovascular%20risks%20related%20to%20increased%20diastolic%2C%20systolic%20and%20pulse%20pressure%3A%20an%20epidemiologist%27s%20point%20of%20view.&author=SS%20Franklin&publication_year=&journal=Pathol%20Biol%20%28Paris%29.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-49">49.</a><div class="reference-content">Saunders E, Weir MR, Kong BW. et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;150:1707-1713.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20the%20efficacy%20and%20safety%20of%20a%20beta-blocker%2C%20a%20calcium%20channel%20blocker%2C%20and%20a%20converting%20enzyme%20inhibitor%20in%20hypertensive%20blacks.&author=E%20Saunders&author=MR%20Weir&author=BW%20Kong&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-50">50.</a><div class="reference-content">Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. <I xmlns:helper="urn:XsltStringHelper"> Endocrinol Metab Clin North Am.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;26:125-144.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pathophysiology%20and%20treatment%20implications%20of%20hypertension%20in%20the%20African-American%20population.&author=M%20Rahman&author=JG%20Douglas&author=JT%20Wright&publication_year=&journal=Endocrinol%20Metab%20Clin%20North%20Am.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-51">51.</a><div class="reference-content">Cushman WC, Reda DJ, Perry HM. et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;160:825-831.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Regional%20and%20racial%20differences%20in%20response%20to%20antihypertensive%20medication%20use%20in%20a%20randomized%20controlled%20trial%20of%20men%20with%20hypertension%20in%20the%20United%20States.&author=WC%20Cushman&author=DJ%20Reda&author=HM%20Perry&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-52">52.</a><div class="reference-content">Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;344:1351-1357.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Lesser%20response%20to%20angiotensin-converting-enzyme%20inhibitor%20therapy%20in%20black%20as%20compared%20with%20white%20patients%20with%20left%20ventricular%20dysfunction.&author=DV%20Exner&author=DL%20Dries&author=MJ%20Domanski&author=JN%20Cohn&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-53">53.</a><div class="reference-content">Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. <I xmlns:helper="urn:XsltStringHelper"> J Card Fail.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;5:178-187.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Racial%20differences%20in%20response%20to%20therapy%20for%20heart%20failure%3A%20analysis%20of%20the%20vasodilator-heart%20failure%20trials%3A%20Vasodilator-Heart%20Failure%20Trial%20Study%20Group.&author=P%20Carson&author=S%20Ziesche&author=G%20Johnson&author=JN%20Cohn&publication_year=&journal=J%20Card%20Fail.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-54">54.</a><div class="reference-content">Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. <I xmlns:helper="urn:XsltStringHelper"> J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;40:311-317.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20of%20angiotensin-converting%20enzyme%20inhibition%20in%20reducing%20progression%20from%20asymptomatic%20left%20ventricular%20dysfunction%20to%20symptomatic%20heart%20failure%20in%20black%20and%20white%20patients.&author=DL%20Dries&author=MH%20Strong&author=RS%20Cooper&author=MH%20Drazner&publication_year=&journal=J%20Am%20Coll%20Cardiol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-55">55.</a><div class="reference-content">Manolio TA, Cutler JA, Furberg CD. et al. Trends in pharmacologic management of hypertension in the United States. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;155:829-837.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20pharmacologic%20management%20of%20hypertension%20in%20the%20United%20States.&author=TA%20Manolio&author=JA%20Cutler&author=CD%20Furberg&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div></div> </div> </div> </div> <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad"> <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content"> <ul class="article-links related-content"> <li class="article-link related-article odd"> <a href="https://jamanetwork.com/journals/jama/fullarticle/195616" class="td-n"> <div class="related-article-title">The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension</div> <div class="related-journal-name">JAMA</div> <div class="related-article-type">Editorial</div> <div class="related-article-date">December 18, 2002</div> <div class="related-article-excerpt"></div> <div class="related-article-authors">Lawrence J. Appel, MD, MPH</div> </a> </li> <li class="article-link related-article even"> <a href="https://jamanetwork.com/journals/jama/fullarticle/195627" class="td-n"> <div class="related-article-title">Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care</div> <div class="related-journal-name">JAMA</div> <div class="related-article-type">Original Contribution</div> <div class="related-article-date">December 18, 2002</div> <div class="related-article-excerpt"></div> <div class="related-article-authors">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group</div> </a> </li> <li class="article-link related-article odd"> <a href="https://jamanetwork.com/journals/jama/fullarticle/195720" class="td-n"> <div class="related-article-title">Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)—Correction</div> <div class="related-journal-name">JAMA</div> <div class="related-article-type">Correction</div> <div class="related-article-date">January 8, 2003</div> <div class="related-article-excerpt"></div> <div class="related-article-authors"></div> </a> </li> </ul> </div> <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links"> <div class="sm-linked-content"> <div class="sm-linked-content--item"> <a href="https://sites.jamanetwork.com/jnc8/" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>Hypertension Guidelines Website</a> </div> </div> </div> <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics"> <div class="related-topics-block"> <h4 class="related-topics-heading topic-suggestions-heading sb-sc"> See More About </h4> <div class="related-topics topic-suggestions"> <a href="https://jamanetwork.com/collections/5492/acute-coronary-syndromes" id="item_Link" class="related-topic topic-suggestion no-wrap sb-anchor-light">Acute Coronary Syndromes</a> <a href="https://jamanetwork.com/collections/5548/cardiology" id="item_Link_1" class="related-topic topic-suggestion no-wrap sb-anchor-light">Cardiology</a> <a href="https://jamanetwork.com/collections/5697/hypertension" id="item_Link_2" class="related-topic topic-suggestion no-wrap sb-anchor-light">Hypertension</a> <a href="https://jamanetwork.com/collections/5721/dyslipidemia" id="item_Link_3" class="related-topic topic-suggestion no-wrap sb-anchor-light">Dyslipidemia</a> <a href="https://jamanetwork.com/collections/42101/cardiovascular-risk-factors" id="item_Link_4" class="related-topic topic-suggestion no-wrap sb-anchor-light">Cardiovascular Risk Factors</a> <a href="https://jamanetwork.com/collections/42118/ischemic-heart-disease" id="item_Link_5" class="related-topic topic-suggestion no-wrap sb-anchor-light">Ischemic Heart Disease</a> </div> </div> </div> <div class="ymal--footer"> <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer"> <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{"parameters":{"resourceIdToExclude":195626,"resourceTypeToExclude":3},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <hr /> <div class="manage-interest"> <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Select Your Interests</a></h4> <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen"> <div class="manage-interests-modal reveal-modal small modal" data-reveal> <div class="manage-interests--header"> <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style> h4 { font-size: 20px !important; } </style> <h4>Select Your Interests</h4> <p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p> </div> </div> </div><div class="manage-interests--categories"> <ul class="category-list"> <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li> <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li> <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li> <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li> <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li> <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li> <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li> <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li> <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li> <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li> <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li> <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li> <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li> <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li> <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li> <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li> <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li> <li><span class="category-list-item " data-categoryid="46499">Coaching</span></li> <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li> <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li> <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li> <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li> <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li> <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li> <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li> <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li> <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li> <li><span class="category-list-item " data-categoryid="46498">Digital Health</span></li> <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li> <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li> <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li> <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li> <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li> <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li> <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li> <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li> <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li> <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li> <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li> <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li> <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li> <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li> <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li> <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li> <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li> <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li> <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li> <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li> <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li> <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li> <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li> <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li> <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li> <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li> <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li> <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li> <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li> <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li> <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li> <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li> <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li> <li><span class="category-list-item " data-categoryid="46477">JAMA Forum</span></li> <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li> <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li> <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li> <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li> <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li> <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li> <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li> <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li> <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li> <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li> <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li> <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li> <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li> <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li> <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li> <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li> <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li> <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li> <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li> <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li> <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li> <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li> <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li> <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li> <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li> <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li> <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li> <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li> <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li> <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li> <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li> <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li> <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li> <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li> <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li> <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li> <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li> <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li> <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li> <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li> <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li> <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li> <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li> <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li> <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li> <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li> <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li> <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li> <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li> <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li> <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li> <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li> <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li> <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li> <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li> <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li> <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li> <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li> <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li> <li><span class="category-list-item " data-categoryid="46495">Sexual Health</span></li> <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li> <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li> <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li> <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li> <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li> <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li> <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li> <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li> <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li> <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li> <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li> <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li> <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li> <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li> <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li> <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li> <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li> <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li> <li><span class="category-list-item " data-categoryid="5947">Urology</span></li> <li><span class="category-list-item " data-categoryid="44069">Users' Guide to the Medical Literature</span></li> <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li> <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li> <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li> <li><span class="category-list-item " data-categoryid="5957">Violence</span></li> <li><span class="category-list-item " data-categoryid="42139">Women's Health</span></li> <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li> <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li> </ul> </div> <div class="manage-interests--save-preferences"> <div class="save-preferences-btn thm-bg "> <span class="save-preferences-btn-text fw-b">Save Preferences</span> </div> </div> <div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div> <a class="close-reveal-modal icon-close"></a> </div> </div> </div> <h4 class="thm-col-sec" align="center"> Others Also Liked </h4> <div id="trendmd-suggestions"></div> </div> <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view"> </div> </div> </div> <a id="skip-to-navigation" href="#" tabindex="-1"></a> <div id="content-panel" class="content-panel"> <a id="top"></a> <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab"> <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText"> </div> <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText"> <div class="errata-links "> <div class="errata-link"> <a class="errata-link--btn thm-col-sec" href="https://jamanetwork.com/journals/jama/fullarticle/195720">View Correction</a> </div> </div> </div> <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks"> <a class="toc-link btn" href="https://jamanetwork.com/journals/jama/issue/288/23">This Issue</a> </div> <div class="article-metrics-wrapper" id="divArticleLevelMetrics"> <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics"> <div class="artmet-condensed-wrap clearfix"> <div class="artmet-condensed-stats clearfix"> <div class="artmet-item artmet-citations"> <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=silverchair&SrcAuth=WosAPI&KeyUT=WOS:000179854200033&DestLinkType=FullRecord&DestApp=WOS_CPL" target="_blank"> <span class="artmet-text">Citations</span> <span class="artmet-number">1,929</span> </a> </div> </div> <div class="artmet-modal-trigger-wrap"> <a rel="nofollow" class="artmet-modal-trigger" data-article-id="195626"><i class="icon-metrics"></i><span>View Metrics</span></a> </div> </div> </div> </div> <ul class="toolbar"> <li class="toolbar-pdf-wrap toolbar-tool-wrap"> <a id="pdf-link" href="/journals/jama/articlepdf/195626/joc21962.pdf" class="toolbar-tool toolbar-pdf al-link pdfaccess js-pdfaccess" data-article-id="195626" data-article-url="/journals/jama/articlepdf/195626/joc21962.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span> </a> </li> <li class="toolbar-share-wrap toolbar-tool-wrap"> <div class="toolbar-tool"> <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share" data-network="twitter" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">X</span> </a> <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share" data-network="facebook" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">Facebook</span> </a> <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a> <div class="toolbar-share-more"> <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share" data-network="linkedin" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">LinkedIn</span> </a> </div> </div> </li> <li class="toolbar-citation-wrap toolbar-tool-wrap"> <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation"> <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal> <span class="toolbar-link-text">Cite</span> <span class="toolbar-link-text-extra">This</span> </a> <div id="get-citation" class="reveal-modal get-citation" data-reveal> <h3 class="get-citation-title">Citation</h3> <p class="get-citation-citation">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</span>. <em>JAMA.</em> 2002;288(23):2981–2997. doi:10.1001/jama.288.23.2981</p> <h4 class="get-citation-download-heading">Manage citations:</h4> <div class="get-citation-types"> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=0">Ris (Zotero)</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=1">EndNote</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=2">BibTex</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=3">Medlars</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=0">ProCite</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=3">RefWorks</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=0">Reference Manager</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195626&resourceType=3&citationFormat=0">Mendeley</a> </div> <p class="get-citation-copyright">© 2024 </p> <a class="close-reveal-modal icon-close" rel="nofollow"></a> </div> </div> </li> <li class="toolbar-permissions-wrap toolbar-tool-wrap"> <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions"> <a href="http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&publication=0098-7484&title=Major+Outcomes+in+High-Risk+Hypertensive+Patients+Randomized+to+Angiotensin-Converting+Enzyme+Inhibitor+or+Calcium+Channel+Blocker+vs+Diuretic%26lt%3bspan+class%3d%26quot%3bsubtitle%26quot%3b%26gt%3b%26lt%3bspan+class%3d%26quot%3bcolon-for-citation-subtitle%26quot%3b%26gt%3b%3a+%26lt%3b%2fspan%26gt%3bThe+Antihypertensive+and+Lipid-Lowering+Treatment+to+Prevent+Heart+Attack+Trial+(ALLHAT)%26lt%3b%2fspan%26gt%3b&publicationDate=2002-12-18&volumeNum=288&issueNum=23&author=The+ALLHAT+Officers+and+Coordinators+for+the+ALLHAT+Collaborative+Research%0d%0aGroup&startPage=2981&endPage=2997&contentId=10.1001%2fjama.288.23.2981&oa=&orderBeanReset=True" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a> </div> </li> </ul> <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget"> <div class="meta-access-type free-access is-b"></div> <span class="hide tagmanagervalue" data-attribute="articleId" data-value="195626" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="The%20ALLHAT%20Officers%20and%20Coordinators%20for%20the%20ALLHAT%20Collaborative%20Research%0D%0AGroup" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jama.288.23.2981" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</span>" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="type" data-value="Original Contribution" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="288" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="23" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="December 18, 2002" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="topics" data-value="Acute Coronary Syndromes, Cardiology, Hypertension, Dyslipidemia, Cardiovascular Risk Factors, Ischemic Heart Disease" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="topicCode" data-value="5492, 5548, 5697, 5721, 42101, 42118" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="category" data-value="Research" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Free" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span> <div class="meta-article-type-wrap"> <div class="meta-article-type thm-col">Original Contribution </div> </div> <div class="meta-date">December 18, 2002</div> <div class="meta-article-title-wrap"> <h1 class="meta-article-title ">Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</span></h1> </div> <div class="meta-authors"> <span class="wi-fullname brand-fg"><a href="/searchresults?author=The+ALLHAT+Officers+and+Coordinators+for+the+ALLHAT+Collaborative+Research%0d%0aGroup&q=The+ALLHAT+Officers+and+Coordinators+for+the+ALLHAT+Collaborative+Research%0d%0aGroup" rel=nofollow target="_blank">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group<sup></sup></a></span> </div> <div class="meta-author"> <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a> <div class="meta-author-content"> <div class="meta-author-notes"><p class="para"><strong>ALLHAT Authors/Officers and Coordinators:</strong> Curt D. Furberg, MD, PhD; Jackson T. Wright, Jr, MD, PhD; Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD, MPH; Michael Alderman, MD; Henry Black, MD; William Cushman, MD; Richard Grimm, MD, PhD; L. Julian Haywood, MD; Frans Leenen, MD; Suzanne Oparil, MD; Jeffrey Probstfield, MD; Paul Whelton, MD, MSc; Chuke Nwachuku, MA, MPH; David Gordon, MD, PhD; Michael Proschan, PhD; Paula Einhorn, MD, MS; Charles E. Ford, PhD; Linda B. Piller, MD, MPH; J. Kay Dunn, PhD; David Goff, MD, PhD; Sara Pressel, MS; Judy Bettencourt, MPH; Barbara deLeon, BA; Lara M. Simpson, MS; Joe Blanton, MS; Therese Geraci, MSN, RN, CS; Sandra M. Walsh, RN; Christine Nelson, RN, BSN; Mahboob Rahman, MD; Anne Juratovac, RN; Robert Pospisil, RN; Lillian Carroll, RN; Sheila Sullivan, BA; Jeanne Russo, BSN; Gail Barone, RN; Rudy Christian, MPH; Sharon Feldman, MPH; Tracy Lucente, MPH; David Calhoun, MD; Kim Jenkins, MPH; Peggy McDowell, RN; Janice Johnson, BS; Connie Kingry, RN, BSN; Juan Alzate, MD; Karen L. Margolis, MD; Leslie Ann Holland-Klemme, BA; Brenda Jaeger; Jeffrey Williamson, MD, MHS; Gail Louis, RN; Pamela Ragusa, RN, BSN; Angela Williard, RN, BSN; R. L. Sue Ferguson, RN; Joanna Tanner; John Eckfeldt, MD, PhD; Richard Crow, MD; John Pelosi, RPh, MS.</p></div> </div> </div> <div class="meta-citation-wrap"> <span class="meta-citation-journal-name">JAMA. </span><span class="meta-citation"> 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981</span> </div> </div> <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links"> <div class="sm-linked-content"> <div class="sm-linked-content--item"> <a href="https://sites.jamanetwork.com/jnc8/" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>Hypertension Guidelines Website</a> </div> </div> </div> <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar"> <div class="linked-content-toolbar"> <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div> <div class="linked-content-controls"> <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab"> <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div> </a> <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab"> <i class="icon-document"><span class="sr-t">editorial comment icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div> </a> <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab"> <i class="icon-related"><span class="sr-t">related articles icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div> </a> <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab"> <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div> </a> <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab"> <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div> </a> <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab"> <i class="icon-audio"><span class="sr-t">audio icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div> </a> </div> <div class="linked-content-tabs"> <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab"> <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab"> </div> </div> <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab"> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments"> <ul class="article-abstract-links related-abstract-content"> <li class="article-link related-abstract-article"> <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/195616"> <div class="related-article-type">Editorial</div> <div class="related-article-title sb-tc">The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension</div> </a> <div class="related-article-authors">Lawrence J. Appel, MD, MPH</div> <div class="related-article-journal-name">JAMA</div> </li> </ul> </div> </div> <div id="related-articles-tab" class="linked-content-tab related-article-tab"> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle"> <ul class="article-abstract-links related-abstract-content"> <li class="article-link related-abstract-article"> <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/195627"> <div class="related-article-type">Original Contribution</div> <div class="related-article-title sb-tc">Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care</div> </a> <div class="related-article-authors">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group</div> <div class="related-article-journal-name">JAMA</div> </li> <li class="article-link related-abstract-article"> <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/195720"> <div class="related-article-type">Correction</div> <div class="related-article-title sb-tc">Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)—Correction</div> </a> <div class="related-article-authors"></div> <div class="related-article-journal-name">JAMA</div> </li> </ul> </div> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices"> </div> </div> <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab"> <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews"> </div> </div> <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab"> <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle"> </div> </div> <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab"> </div> </div> </div> </div> <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget"> <div class="article-full-text" data-userHasAccess="True"> <a class="article-section-id-anchor" id="25048567"></a> <div class="h3 cb section-type-abstract decorated-hed "> <div class="heading-text thm-col sb-sc"> Abstract </div> </div> <p><strong>Context</strong> Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.</p><p><strong>Objective</strong> To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.</p><p><strong>Design</strong> The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.</p><p><strong>Setting and Participants</strong> A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.</p><p><strong>Interventions</strong> Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years.</p><p><strong>Main Outcome Measures</strong> The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).</p><p><strong>Results</strong> Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, <em>P</em> = .03) and lisinopril (2 mm Hg, <em>P</em><.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, <em>P</em><.001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25-1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31).</p><p><strong>Conclusion</strong> Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.</p> <div class="movable-ad-target bta"> </div> <a class="article-section-id-anchor" id="25048568"></a> <p class="para">Treatment and complications among the 50 to 60 million people in the United States with hypertension are estimated to cost $37 billion annually, with antihypertensive drug costs alone accounting for an estimated $15.5 billion per year.<sup><a href="#REF-JOC21962-1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Antihypertensive drug therapy substantially reduces the risk of hypertension-related morbidity and mortality.<sup><a href="#REF-JOC21962-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup><sup>-<a href="#REF-JOC21962-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup> However, the optimal choice for initial pharmacotherapy of hypertension is uncertain.<sup><a href="#REF-JOC21962-7" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">7</a></sup></p> <a class="article-section-id-anchor" id="25048569"></a> <p class="para">Earlier clinical trials documented the benefit of lowering blood pressure (BP) using primarily thiazide diuretics or β-blockers.<sup><a href="#REF-JOC21962-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup><sup>,<a href="#REF-JOC21962-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a>,<a href="#REF-JOC21962-8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> After these studies, several newer classes of antihypertensive agents (ie, angiotensin-converting enzyme [ACE] inhibitors, calcium channel blockers [CCBs], α-adrenergic blockers, and more recently angiotensin-receptor blockers) became available. Over the past decade, major placebo-controlled trials have documented that ACE inhibitors and CCBs reduce cardiovascular events in individuals with hypertension.<sup><a href="#REF-JOC21962-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>-<a href="#REF-JOC21962-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup> However, their relative value compared with older, less expensive agents remains unclear. There has been considerable uncertainty regarding effects of some classes of antihypertensive drugs on risk of coronary heart disease (CHD).<sup><a href="#REF-JOC21962-6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup><sup>,<a href="#REF-JOC21962-12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup><sup>-<a href="#REF-JOC21962-12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a></sup> The relative benefit of various agents in high-risk hypertensive subgroups such as older patients, black patients, and patients with diabetes also needed to be established.<sup><a href="#REF-JOC21962-17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup></p> <a class="article-section-id-anchor" id="25048570"></a> <p class="para">The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, multicenter clinical trial sponsored by the National Heart, Lung, and Blood Institute, was designed to determine whether the occurrence of fatal CHD or nonfatal myocardial infarction is lower for high-risk patients with hypertension treated with a CCB (represented by amlodipine), an ACE inhibitor (represented by lisinopril), or an α-blocker (represented by doxazosin), each compared with diuretic treatment (represented by chlorthalidone).<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Chlorthalidone was found to be superior to doxazosin and was previously reported after early termination of the doxazosin arm of the trial.<sup><a href="#REF-JOC21962-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup><sup>,<a href="#REF-JOC21962-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup> Secondary outcomes included all-cause mortality, stroke, and other cardiovascular disease (CVD) events. A lipid-lowering subtrial was designed to determine whether lowering cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (pravastatin) compared with usual care reduced all-cause mortality in a moderately hypercholesterolemic subset of ALLHAT participants.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup><sup>,<a href="#REF-JOC21962-21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> To evaluate differences in CVD effects of the various first-step drugs, ALLHAT was designed with a large sample size (9000-15 000 participants/intervention arm) and long follow-up (4-8 years). This study presents results of the amlodipine and lisinopril vs chlorthalidone comparisons on major CVD outcomes.</p> <a class="article-section-id-anchor" id="25048571"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Methods </div> </div> <a class="article-section-id-anchor" id="25048572"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Study Design </div> </div> <a class="article-section-id-anchor" id="25048573"></a> <p class="para">The rationale and design of ALLHAT have been presented elsewhere.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Participants were men and women aged 55 years or older who had stage 1 or stage 2 hypertension with at least 1 additional risk factor for CHD events.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup><sup>,<a href="#REF-JOC21962-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup> The risk factors included previous (>6 months) myocardial infarction or stroke, left ventricular hypertrophy demonstrated by electrocardiography or echocardiography, history of type 2 diabetes, current cigarette smoking, high-density lipoprotein cholesterol of less than 35 mg/dL (<0.91 mmol/L), or documentation of other atherosclerotic CVD. Individuals with a history of hospitalized or treated symptomatic heart failure (HF) and/or known left ventricular ejection fraction of less than 35% were excluded.</p> <a class="article-section-id-anchor" id="25048574"></a> <p class="para">Unless the drug regimen had to be tapered for safety reasons, individuals continued any prior antihypertensive medications until they received randomized study drug, at which point they stopped taking all previous medications. Treatment with the study drug was initiated the day after randomization. By telephone, participants were randomly assigned to chlorthalidone, amlodipine, or lisinopril in a ratio of 1.7:1:1. The concealed randomization scheme was generated by computer, implemented at the clinical trials center, stratified by center and blocked in random block sizes of 5 or 9 to maintain balance. Participants (n = 33 357) were recruited at 623 centers in the United States, Canada, Puerto Rico, and the US Virgin Islands between February 1994 and January 1998. (The original reported number of 625 sites changed because 2 sites and their patients with poor documentation of informed consent were excluded.<sup><a href="#REF-JOC21962-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup>) All participants gave written informed consent, and all centers obtained institutional review board approval. Follow-up visits were at 1 month; 3, 6, 9, and 12 months; and every 4 months thereafter. The range of possible follow-up was 3 years 8 months to 8 years 1 month. The closeout phase began on October 1, 2001, and ended on March 31, 2002.</p> <a class="article-section-id-anchor" id="25048575"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Treatment </div> </div> <a class="article-section-id-anchor" id="25048576"></a> <p class="para">Trained observers using standardized techniques measured BPs during the trial.<sup><a href="#REF-JOC21962-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup> Visit BP was the average of 2 seated measurements. Goal BP in each randomized group was less than 140/90 mm Hg achieved by titrating the assigned study drug (step 1) and adding open-label agents (step 2 or 3) when necessary. The choice of step 2 drugs (atenolol, clonidine, or reserpine) was at the physician's discretion. Nonpharmacologic approaches to treatment of hypertension were recommended according to national guidelines.<sup><a href="#REF-JOC21962-4" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">4</a></sup><sup>,<a href="#REF-JOC21962-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup> Step 1 drugs were encapsulated and identical in appearance so that the identity of each agent was double-masked at each dosage level. Dosages were 12.5, 12.5 (sham titration), and 25 mg/d for chlorthalidone; 2.5, 5, and 10 mg/d for amlodipine; and 10, 20, and 40 mg/d for lisinopril. Doses of study-supplied open-label step 2 drugs were 25 to 100 mg/d of atenolol; 0.05 to 0.2 mg/d of reserpine; or 0.1 to 0.3 mg twice a day of clonidine; step 3 was 25 to 100 mg twice a day of hydralazine. Other drugs, including low doses of open-label step 1 drug classes, were permitted if clinically indicated.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup><sup>,<a href="#REF-JOC21962-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup></p> <a class="article-section-id-anchor" id="25048577"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Outcomes </div> </div> <a class="article-section-id-anchor" id="25048578"></a> <p class="para">The primary outcome was fatal CHD or nonfatal myocardial infarction combined.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Four major prespecified secondary outcomes were all-cause mortality, fatal and nonfatal stroke, combined CHD (the primary outcome, coronary revascularization, hospitalized angina), and combined CVD (combined CHD, stroke, other treated angina, HF [fatal, hospitalized, or treated nonhospitalized], and peripheral arterial disease). Coronary revascularization included coronary artery bypass graft, percutaneous angioplasty, insertion of stents, and atherectomy. Individual components of the combined outcomes were prespecified and examined, as were other secondary outcomes including cancer, incident electrocardiographic left ventricular hypertrophy, end-stage renal disease (ESRD) (dialysis, renal transplant, or death), and slope of the reciprocal of longitudinal serum creatinine measurements. Change in estimated glomerular filtration rate<sup><a href="#REF-JOC21962-24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup><sup>,<a href="#REF-JOC21962-25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup> was examined post hoc.</p> <a class="article-section-id-anchor" id="25048579"></a> <p class="para">Study outcomes were assessed at follow-up visits and reported to the clinical trials center.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Hospitalized outcomes were primarily based on clinic investigator reports, and copies of death certificates and hospital discharge summaries were requested. Among all combined CVD events that resulted in deaths, hospitalizations, or both, the proportion with documentation (ie, a death certificate or a hospital discharge summary) was 99% in all 3 treatment groups. In addition, searches for outcomes were accomplished through the Center for Medicare and Medicaid Services, the Department of Veterans Affairs, the National Death Index, and the Social Security Administration databases. A death was ascertained by clinic report or by match with the aforementioned databases plus a confirmatory death certificate. A death pending confirmation is one found using databases but for which a confirmatory death certificate has not yet been obtained. Medical reviewers from the clinical trials center verified the physician-assigned diagnoses of outcomes using death certificates and hospital discharge summaries. More detailed information was collected on a random (10%) subset of CHD and stroke events to validate the procedure of using physician diagnoses.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> When a large excess of HF became evident in the doxazosin arm, a 1-time sample of HF hospitalizations was reviewed by the ALLHAT Endpoints Subcommittee. Agreement rates between the subcommittee and clinic investigators were 90% (155/172) for the primary outcome, 85% (33/39) for HF hospitalizations,<sup><a href="#REF-JOC21962-26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup> and 84% (129/153) for stroke, and were similar in all treatment groups.</p> <a class="article-section-id-anchor" id="25048580"></a> <p class="para">Two major safety outcomes, angioedema and hospitalization for gastrointestinal bleeding, were prespecified. Occurrence of gastrointestinal bleeding was ascertained from Center for Medicare and Medicaid Services and Department of Veterans Affairs hospitalization databases, representing 74% of ALLHAT participants (persons ≥65 years, Department of Veterans Affairs participants, or both).<sup><a href="#REF-JOC21962-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup> Angioedema was ascertained using a solicited event question on a serious adverse event form.</p> <a class="article-section-id-anchor" id="25048581"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Statistical Methods </div> </div> <a class="article-section-id-anchor" id="25048582"></a> <p class="para">To maximize statistical power, 1.7 times as many participants were assigned to the diuretic group as to each of the other 3 groups.<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Given the achieved sample size and expected event rate, treatment crossovers, and losses to follow-up, ALLHAT had 83% power to detect a 16% reduction in risk of the primary outcome between chlorthalidone and each other group at a 2-sided α = .0178 (<em>z</em> = 2.37) to account for the 3 original comparisons.<sup><a href="#REF-JOC21962-28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup> Data were analyzed according to participants' randomized treatment assignments regardless of their subsequent medications (intent-to-treat analysis). Cumulative event rates were calculated using the Kaplan-Meier method. Although rates are presented only through 6 years, both the log-rank test and Cox proportional hazards regression model incorporated the participant's entire trial experience to evaluate differences between cumulative event curves and to obtain 2-sided <em>P</em> values. Only the Cox proportional hazard regression results are presented, because <em>P</em> values were essentially identical. Hazard ratios (relative risks [RRs]) and 95% confidence intervals (CIs) were obtained from the Cox proportional hazards regression model.<sup><a href="#REF-JOC21962-29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup> For consistency with α = .0178, 95% CIs may be converted to 98.2% limits by multiplying the upper limit and dividing the lower limit by RR<sup>(0.41/Z)</sup>, where Z is the value of the test statistic for the RR estimate. The Cox proportional hazards regression model assumption was examined by using log-log plots and testing a treatment × time (time-dependent) interaction term; if it was violated, the RR estimate from a 2-by-2 table was used.<sup><a href="#REF-JOC21962-29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup> Heterogeneity of effects in prespecified subgroups, (1) men and women, (2) participants less than 65 and 65 years or older, (3) black and nonblack participants, and (4) diabetic and nondiabetic participants, and the post hoc subgroups presence or absence of CHD at baseline, was examined by testing for treatment-covariate interaction with the Cox proportional hazards regression model by using <em>P</em><.05. SAS version 8.0 (SAS Institute, Cary, NC) and STATA version 7 (Stata Corp, College Station, Tex) were used for statistical analyses.</p> <a class="article-section-id-anchor" id="25048583"></a> <p class="para">A National Heart, Lung, and Blood Institute–appointed data and safety monitoring board met at least annually to review the accumulating data and to monitor for safety and efficacy. The Lan-DeMets version of the O'Brien-Fleming group sequential boundaries was used to assess treatment group differences, and conditional power was used to assess futility.<sup><a href="#REF-JOC21962-30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup><sup>,<a href="#REF-JOC21962-31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup></p> <a class="article-section-id-anchor" id="25048584"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Results </div> </div> <a class="article-section-id-anchor" id="25048585"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Patient Characteristics </div> </div> <a class="article-section-id-anchor" id="25048586"></a> <p class="para"><a href="#JOC21962T1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a> presents baseline characteristics for the 33 357 participants in the chlorthalidone, amlodipine, and lisinopril treatment groups. The mean age was 67 years; 47% were women, 35% were black, 19% were Hispanic, and 36% were diabetic. There were nearly identical distributions of baseline factors in the 3 treatment groups.<sup><a href="#REF-JOC21962-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup></p> <a class="article-section-id-anchor" id="25048588"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Visit and Medication Adherence </div> </div> <a class="article-section-id-anchor" id="25048589"></a> <p class="para"><a href="#joc21962f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a> shows the number of participants randomized and followed up to the time of closeout. In all 3 treatment groups, the mean (SD) length of follow-up was 4.9 years (1.4 years), and 99% of expected person-years were observed. The maximum range of follow-up was 8.0, 7.9, and 8.1 years in the chlorthalidone, amlodipine, and lisinopril groups, respectively. At trial closeout, 419 (2.7%) of the chlorthalidone group, 258 (2.8%) of the amlodipine group, and 276 (3.0%) of the lisinopril group had unknown vital status. Among participants with unknown vital status, the distributions of most baseline factors were similar among the 3 treatment groups, but participants assigned to lisinopril were less likely to be black and more likely to be women, have untreated hypertension, evidence of CHD or atherosclerotic CVD, and a lower mean serum glucose.</p> <a class="article-section-id-anchor" id="25048591"></a> <p class="para">Visit adherence decreased over time from about 92% at 1 year to 84% to 87% at 5 years in all 3 treatment groups (<a href="#JOC21962T2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). Among participants in the chlorthalidone group who were contacted in the clinic or by telephone within 12 months of annual scheduled visits, 87.1% were taking chlorthalidone or another diuretic at 1 year, decreasing to 80.5% at 5 years; 67.5% (n = 4387) were taking a diuretic without a CCB or an ACE inhibitor; and 13.2% were taking a diuretic with a CCB (5.8% [n = 399]) or an ACE inhibitor (9.3% [n = 641]). Only 9.0% were taking either a CCB (5.8% [n = 399]) or an ACE inhibitor (5.6% [n = 385]) without a diuretic at 5 years.</p> <a class="article-section-id-anchor" id="25048593"></a> <p class="para">Among participants in the amlodipine group, 87.6% were taking amlodipine or another CCB at 1 year, decreasing to 80.4% at 5 years; and 63.8% (n = 2502) were taking a CCB alone without a diuretic. Another 16.6% were taking a CCB with a diuretic, and only 6.9% were taking a diuretic without a CCB. Among participants in the lisinopril group, 82.4% were taking lisinopril or another ACE inhibitor at 1 year, decreasing to 72.6% at 5 years; 56.9% (n = 2143) were taking an ACE inhibitor alone without a diuretic; and 15.7% were taking an ACE inhibitor with a diuretic at 5 years. About 8.5% were taking a diuretic without an ACE inhibitor.</p> <a class="article-section-id-anchor" id="25048594"></a> <p class="para">The most common reasons for not taking step 1 medication at 5 years in the chlorthalidone, amlodipine, and lisinopril groups were unspecified refusals (41.4% [n = 775], 40.5% [n = 443], and 37.9% [n = 552], respectively) and symptomatic adverse effects (15.0% [n = 282], 16.4% [n = 180], and 18.1% [n = 264], respectively). Elevated BP (4.5% [n = 84], 3.5% [n = 38], and 9.0% [n = 131]) or other adverse effects such as abnormal laboratory values (3.8% [n = 71], 1.6% [n = 17], and 2.3% [n = 34]) were other reasons given for discontinuation of step 1 medications. Among participants with available medication information at 1 year, 26.7%, 25.9%, and 32.6% of those assigned to chlorthalidone, amlodipine, and lisinopril, respectively, were taking a step 2 or step 3 drug. At 5 years, the corresponding percentages were 40.7%, 39.5%, and 43.0%, respectively. Usage patterns of specific step 2 drugs were similar among groups. Participants could be taking more than 1 step-up drug. At 1 year, 40.0% (n = 4645), 44.0% (n = 3017), and 43.8% (n = 2764) of participants assigned to chlorthalidone, amlodipine, and lisinopril, respectively, still taking their blinded medication were receiving the maximal study dose. At 5 years, the percentages were 56.9% (n = 2629), 65.7% (n = 1856), and 60.3% (n = 1391), respectively.</p> <a class="article-section-id-anchor" id="25048595"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Intermediate Outcomes </div> </div> <a class="article-section-id-anchor" id="25048596"></a> <p class="para">Given the large sample size in ALLHAT, almost all differences in follow-up BP and biochemical measurements were statistically significant (<a href="#JOC21962T3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a> and <a href="#JOC21962T4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 4a</a>). Mean seated BP at randomization was about 146/84 mm Hg in all 3 groups, with 90% of participants reporting current antihypertensive drug treatment (<a href="#JOC21962T1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a>). Follow-up BPs in all 3 groups are shown in <a href="#JOC21962T3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a> and <a href="#joc21962f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>.</p> <a class="article-section-id-anchor" id="25048602"></a> <p class="para">Mean total serum cholesterol levels at baseline and 4 years follow-up are shown in <a href="#JOC21962T4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 4</a>. At 4 years, about 35% to 36% of participants in all 3 groups reported taking lipid-lowering drugs, largely statins, some as a result of participation in the ALLHAT lipid trial. Mean serum potassium levels at baseline and follow-up are also shown; about 8% of the chlorthalidone group were receiving potassium supplementation at 5 years compared with 4% in the amlodipine group and 2% in the lisinopril group. Among individuals classified as nondiabetic at baseline, with baseline fasting serum glucose less than 126 mg/dL (7.0 mmol/L), incidence of diabetes (fasting serum glucose, ≥126 mg/dL [7.0 mmol/L]) at 4 years was 11.6%, 9.8%, and 8.1%, respectively.</p> <a class="article-section-id-anchor" id="25048603"></a> <p class="para">Mean estimated glomerular filtration rate at baseline was about 78 mL/min per 1.73 m<sup>2</sup> in all groups. At 4 years, it was 70.0, 75.1, and 70.7 mL/min per 1.73 m<sup>2</sup> in the chlorthalidone, amlodipine, and lisinopril groups, respectively. The slopes of the reciprocal of serum creatinine over time were virtually identical in the chlorthalidone and lisinopril groups (–0.018 and –0.019 dL/mg per year), whereas the decline in the amlodipine slope (–0.012 dL/mg per year) was less than that of the chlorthalidone slope (<em>P</em><.001).</p> <a class="article-section-id-anchor" id="25048604"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Primary and Secondary Outcomes </div> </div> <a class="article-section-id-anchor" id="25048605"></a> <p class="para"><strong>Amlodipine vs Chlorthalidone.</strong> No significant difference was observed between amlodipine and chlorthalidone for the primary outcome (RR, 0.98; 95% CI, 0.90-1.07) or for the secondary outcomes of all-cause mortality, combined CHD, stroke, combined CVD, angina, coronary revascularization, peripheral arterial disease, cancer, or ESRD (<a href="#JOC21962T5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 5</a>, <a href="#joc21962f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>, and <a href="#joc21962f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a>). The amlodipine group had a 38% higher risk of HF (<em>P</em><.001) with a 6-year absolute risk difference of 2.5% and a 35% higher risk of hospitalized/fatal HF (<em>P</em><.001). The treatment effects for all outcomes were consistent across the predefined subgroups (<a href="#joc21962f5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 5</a>) and by absence or presence of CHD at baseline. Cause-specific mortality rates (except for unintentional injuries/suicides/homicides in amlodipine compared with chlorthalidone, not a prespecified hypothesis) were similar for the 2 groups (<a href="#JOC21962T6" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 6</a>).</p> <a class="article-section-id-anchor" id="25048611"></a> <p class="para"><strong>Lisinopril vs Chlorthalidone.</strong> No significant difference was observed between lisinopril and chlorthalidone for the primary outcome (RR, 0.99; 95% CI, 0.91-1.08) or for the secondary outcomes of all-cause mortality, combined CHD, peripheral arterial disease, cancer, or ESRD (<a href="#JOC21962T5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 5</a>, <a href="#joc21962f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a> and <a href="#joc21962f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a>). Cause-specific mortality rates were also similar in the 2 groups (<a href="#JOC21962T6" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 6</a>). The lisinopril group had a 15% higher risk for stroke (<em>P</em> = .02) and a 10% higher risk of combined CVD (<em>P</em><.001), with a 6-year absolute risk difference for combined CVD of 2.4%. Included in this analysis was a 19% higher risk of HF (<em>P</em><.001), a 10% higher risk of hospitalized/fatal HF (<em>P</em> = .11), an 11% higher risk of hospitalized/treated angina (<em>P</em> = .01), and a 10% higher risk of coronary revascularization (<em>P</em> = .05). The treatment effects for all outcomes were consistent across subgroups by sex, diabetic status (<a href="#joc21962f6" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 6</a>), and baseline CHD status. For combined CHD, there was a significant differential effect by age (<em>P</em> = .01 for interaction) with RRs (lisinopril vs chlorthalidone) of 0.94 for those less than 65 years vs 1.11 in those 65 years or older. However, when age was modeled as a continuous variable, there was no significant interaction. For stroke and combined CVD, there was a significant differential effect by race (<em>P</em> = .01 and <em>P</em> = .04 for interaction, respectively). The RRs (lisinopril vs chlorthalidone) were 1.40 (95% CI, 1.17-1.68) and 1.00 (95% CI, 0.85-1.17) for stroke and 1.19 (95% CI, 1.09-1.30) and 1.06 (95% CI, 1.00-1.13) for combined CVD in blacks and nonblacks, respectively.</p> <a class="article-section-id-anchor" id="25048613"></a> <p class="para">The mean follow-up systolic BP for all participants was 2 mm Hg higher in the lisinopril group than the chlorthalidone group, 4 mm Hg higher in blacks, and 3 mm Hg higher in those 65 years or older. Adjustment for follow-up BP as time-dependent covariates in a Cox proportional hazards regression model slightly reduced the RRs for stroke (1.15 to 1.12) and HF (1.20 to 1.17) overall and in the black subgroup (stroke, 1.40 to 1.35; and HF, 1.32 to 1.26), but the results remained statistically significant.</p> <a class="article-section-id-anchor" id="25048614"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Primary Safety Outcomes </div> </div> <a class="article-section-id-anchor" id="25048615"></a> <p class="para">Six-year rates of hospitalization for gastrointestinal bleeding, available only in Medicare and Department of Veterans Affairs participants, occurred in 8.8%, 8.0%, and 9.6% participants in the chlorthalidone, amlodipine, and lisinopril treatment groups, respectively, with no significant differences (<a href="#JOC21962T5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 5</a>). Angioedema occurred in 8 of 15 255 (0.1%), 3 of 9048 (<0.1%), and 38 of 9054 (0.4%) persons in the chlorthalidone, amlodipine, and lisinopril treatment groups, respectively. Significant differences were seen for the lisinopril vs chlorthalidone comparison overall (<em>P</em><.001), in blacks (2 of 5369 [<0.1%] for chlorthalidone, 23 of 3210 [0.7%] for lisinopril; <em>P</em><.001), and in nonblacks (6 of 9886 [0.1%] for chlorthalidone, 15 of 5844 for lisinopril [0.3%]; <em>P</em> = .002). The only death from angioedema was in the lisinopril group.</p> <a class="article-section-id-anchor" id="25048616"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Comment </div> </div> <a class="article-section-id-anchor" id="25048617"></a> <p class="para">Neither amlodipine (representing CCBs, particularly dihydropyridine [DHP]–CCBs) nor lisinopril (representing ACE inhibitors) was superior to chlorthalidone (representing thiazide-type diuretics) in preventing major coronary events or in increasing survival. Chlorthalidone was superior to amlodipine (by about 25%) in preventing HF, overall, and for hospitalized or fatal cases, although it did not differ from amlodipine in overall CVD prevention. Chlorthalidone was superior to lisinopril in lowering BP and in preventing aggregate cardiovascular events, principally stroke, HF, angina, and coronary revascularization. ALLHAT previously reported that chlorthalidone was superior to doxazosin (representing α-blockers) in reducing BP and preventing cardiovascular events, particularly HF.<sup><a href="#REF-JOC21962-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup><sup>,<a href="#REF-JOC21962-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup></p> <a class="article-section-id-anchor" id="25048618"></a> <p class="para">It is not surprising that no significant differences in CHD and stroke rates were found between chlorthalidone and amlodipine-based therapy in ALLHAT. In the Systolic Hypertension in the Elderly Program and the Systolic Hypertension in Europe trial, in which a thiazide-like diuretic (chlorthalidone) or a DHP-CCB was compared with a placebo, major CHD events were reduced by 27% and 30%, and stroke by 37% and 42%, respectively.<sup><a href="#REF-JOC21962-8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup><sup>,<a href="#REF-JOC21962-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> More direct evidence comes from 2 large active-controlled trials that compared DHP-CCB and traditional first-step drugs. The Swedish Trial in Old Patients with Hypertension-2 and the International Nifedipine GITS (long-acting gastrointestinal formulation) Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), found no significant differences for major CHD or stroke rates between the treatment groups.<sup><a href="#REF-JOC21962-32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup><sup>,<a href="#REF-JOC21962-33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> Some of these individual trials have had limited power to evaluate differences between treatments.<sup><a href="#REF-JOC21962-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> In meta-analyses of 5 positive-controlled trials, which included both DHP-CCB and non–DHP-CCB trials, there were trends that favored CCB-based therapy for stroke and traditional treatment for CHD, with no difference for all-cause mortality.<sup><a href="#REF-JOC21962-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup><sup>,<a href="#REF-JOC21962-14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup> However, ALLHAT observed approximately the same number of strokes and nearly twice as many CHD events as all 5 trials combined, which suggests that the aggregate of the evidence would indicate no difference between CCB-based treatment and diuretic-based treatment for these outcomes.</p> <a class="article-section-id-anchor" id="25048619"></a> <p class="para">The amlodipine vs chlorthalidone findings for HF reinforce previous trial results. In the diuretic-based Systolic Hypertension in the Elderly Program, active therapy reduced HF occurrence by 49% compared with placebo (<em>P</em><.001), although in the DHP-CCB–based Systolic Hypertension in Europe trial, it was reduced by 29% (not statistically significant).<sup><a href="#REF-JOC21962-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#REF-JOC21962-35" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">35</a></sup> In the INSIGHT trial, HF was approximately twice as frequent in the CCB vs the diuretic arm.<sup><a href="#REF-JOC21962-33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> The previously cited meta-analyses reported a higher rate of HF with CCB-based treatment than traditional regimens, with no difference in RR for DHPs compared with non–DHPs.<sup><a href="#REF-JOC21962-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup><sup>,<a href="#REF-JOC21962-14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup></p> <a class="article-section-id-anchor" id="25048620"></a> <p class="para">A body of literature based on observational studies and secondary CHD prevention trials of short-acting CCBs has suggested that CCBs, especially DHP-CCBs, may increase the risk of cancer, gastrointestinal bleeding, and all-cause mortality.<sup><a href="#REF-JOC21962-14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup><sup>,<a href="#REF-JOC21962-36" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">36</a></sup><sup>,<a href="#REF-JOC21962-37" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">37</a></sup> The results of ALLHAT do not support these findings. In fact, the mortality from noncardiovascular causes was significantly lower in the CCB group (<a href="#JOC21962T6" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 6</a>).</p> <a class="article-section-id-anchor" id="25048621"></a> <p class="para">There were no significant differences in the incidence of ESRD between chlorthalidone and amlodipine, consistent with findings from the INSIGHT trial.<sup><a href="#REF-JOC21962-33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> Comparison of the reciprocal serum creatinine slopes suggested a slower decline in kidney function in the amlodipine group. However, this finding requires cautious interpretation because studies assessing glomerular filtration rate more directly have shown a hemodynamically mediated acute increase in glomerular filtration rate followed by a more rapid rate of decline with chronic therapy using amlodipine and other CCBs.<sup><a href="#REF-JOC21962-38" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">38</a></sup><sup>-<a href="#REF-JOC21962-38" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">40</a></sup></p> <a class="article-section-id-anchor" id="25048622"></a> <p class="para">Comparison of the lisinopril and chlorthalidone groups revealed better drug tolerance and BP control with chlorthalidone. Angioedema, a rare but potentially serious adverse effect of ACE inhibitor use, occurred 4 times more frequently in participants randomized to lisinopril than in those randomized to chlorthalidone. Cholesterol levels, the prevalence of hypokalemia (serum potassium <3.5 mEq/L), and new diabetes (fasting glucose ≥126 mg/dL [≥7.0 mmol/L]) were higher in the chlorthalidone than the other groups following 2 and 4 years of follow-up. Overall, these metabolic differences did not translate into more cardiovascular events or into higher all-cause mortality in the chlorthalidone group compared with the other 2 groups.</p> <a class="article-section-id-anchor" id="25048623"></a> <p class="para">The ALLHAT findings for some major outcomes are consistent with predictions from placebo-controlled trials involving ACE inhibitors and diuretics. Specifically, for ACE inhibitor and diuretic trials, respectively, the reductions in CHD rates were 20% and 18%, and for all-cause mortality, 16% and 10%.<sup><a href="#REF-JOC21962-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> The 10% greater rate of combined CVD in the lisinopril than in the chlorthalidone group was due to increased occurrences of stroke, HF, angina, and coronary revascularization. Results for some of these outcomes may seem surprising, because of reports of beneficial effects of ACE inhibitors on surrogate markers of atherosclerosis and reductions in vascular and renal events in individuals with HF, diabetes, kidney disease, and cerebrovascular disease in placebo-controlled trials.<sup><a href="#REF-JOC21962-41" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">41</a></sup><sup>-<a href="#REF-JOC21962-41" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">43</a></sup> However, the finding in ALLHAT that HF incidence was lower in the diuretic vs the ACE inhibitor group is also consistent with previous reports. In the Systolic Hypertension in the Elderly Program trial (chlorthalidone vs placebo), there was a 49% decrease in the development of HF, whereas in the Studies of Left Ventricular Dysfunction Prevention (enalapril vs placebo) and Heart Outcomes Prevention Evaluation trials (ramipril vs placebo), there were only 20% and 23% reductions, respectively.<sup><a href="#REF-JOC21962-8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup><sup>,<a href="#REF-JOC21962-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#REF-JOC21962-44" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">44</a></sup> In published meta-analyses of placebo-controlled trials, the reductions in rates for stroke with ACE inhibitor and diuretics were 30% and 34%, translating into nearly equivalent results.<sup><a href="#REF-JOC21962-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>,<a href="#REF-JOC21962-13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> The 15% relative increase in stroke incidence for lisinopril compared with chlorthalidone treatment in ALLHAT must be considered in the context of heterogeneity of the results by race. The Swedish Trial in Old Patients with Hypertension-2 trial, which compared ACE inhibitors with conventional treatment (diuretics and/or β-blockers), showed no significant differences in CHD, stroke, HF, or all-cause mortality.<sup><a href="#REF-JOC21962-32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup> Although these findings are somewhat different from the experience in ALLHAT, consideration needs to be given to respective confidence limits, population differences (especially race), and study designs (open vs double-blind).</p> <a class="article-section-id-anchor" id="25048624"></a> <p class="para">No substantial differences in incidence of ESRD, glomerular filtration rate, or reciprocal creatinine slopes were noted for the lisinopril vs chlorthalidone comparisons. The ALLHAT study population was selected for high CVD risk and had a baseline mean creatinine of only 1.0 mg/dL (88.4 µmol/L). More detailed analyses of high renal risk subgroups (ie, diabetic, renal-impaired, and black patients) will be the subject of subsequent reports.</p> <a class="article-section-id-anchor" id="25048625"></a> <p class="para">Analyses of RRs for stroke and HF adjusted for follow-up BP suggest that the 2-mm Hg systolic BP difference overall (4 mm Hg in black patients) between the lisinopril and chlorthalidone groups only partially accounts for the observed CVD event difference. However, such analyses are limited by the infrequency and imprecision of BP measurements for individual participants and regression dilution, which underestimates CVD risk associated with BP differences based on single-visit (or even visit-averaged) measurements.<sup><a href="#REF-JOC21962-45" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">45</a></sup> Such modeling is also unable to account for differences among individuals due to other unmeasured or poorly represented risk factors; thus, participants who lower their BP by a given amount with one drug may not be comparable to those who lower their BP by the same magnitude with another drug.</p> <a class="article-section-id-anchor" id="25048626"></a> <p class="para">Using an external standard of pooled results of long-term hypertension treatment trials and observational studies (10-12 mm Hg systolic BP difference associated with 38% stroke reduction), a 2- to 3-mm Hg difference in BP might account for a 6% to 12% difference in stroke rates.<sup><a href="#REF-JOC21962-45" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">45</a></sup><sup>,<a href="#REF-JOC21962-46" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">46</a></sup> This is consistent with the observed 15% difference for stroke overall but not with the difference seen in black patients (13%-16% expected, 40% observed). For the HF outcome, trial results in isolated systolic hypertension suggest that a 3-mm Hg higher systolic BP could explain a 10% to 20% increase in risk.<sup><a href="#REF-JOC21962-8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup><sup>,<a href="#REF-JOC21962-47" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">47</a></sup> The forgoing ignores the absence of a diastolic BP difference in ALLHAT; however, the relationship of diastolic pressure and CVD events in elderly persons who often have increased pulse pressure is not entirely clear.<sup><a href="#REF-JOC21962-48" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">48</a></sup></p> <a class="article-section-id-anchor" id="25048627"></a> <p class="para">The primary and secondary outcome results for the amlodipine vs chlorthalidone group comparisons were consistent for all subgroups of participants: older and younger, men and women, black and nonblack, diabetic and nondiabetic. For the lisinopril vs chlorthalidone comparisons, results were generally consistent by age, sex, and diabetic status. Thus, for the important diabetic population, lisinopril appeared to have no special advantage (and amlodipine no particular detrimental effect) for most CVD and renal outcomes when compared with chlorthalidone. In fact, chlorthalidone was superior to lisinopril for several CVD outcomes and superior to amlodipine for HF in both diabetic and nondiabetic participants. The consistency of the ALLHAT findings across multiple patient subgroups provides confidence in the ability to generalize the findings to most patients with hypertension.</p> <a class="article-section-id-anchor" id="25048628"></a> <p class="para">In the lisinopril vs chlorthalidone comparisons, there were 2 outcomes with significant interactions. The greater differences observed in black vs nonblack patients for combined CVD and stroke, along with a similar trend for HF and lesser BP lowering with lisinopril, are in accord with the multiple reports of poorer BP response with ACE inhibitor in black patients.<sup><a href="#REF-JOC21962-49" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">49</a></sup><sup>-<a href="#REF-JOC21962-49" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">51</a></sup> They are also consistent with reports of lesser effects of ACE inhibitors in secondary prevention of HF in this population,<sup><a href="#REF-JOC21962-52" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">52</a></sup><sup>,<a href="#REF-JOC21962-53" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">53</a></sup> although these findings have been recently questioned.<sup><a href="#REF-JOC21962-54" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">54</a></sup> The differential responses for disease outcomes parallel the lesser response in the black subgroup for BP, although the differences in outcomes are not substantially reduced by statistically adjusting for systolic BP.</p> <a class="article-section-id-anchor" id="25048629"></a> <p class="para">Although subordinate to safety and efficacy, the cost of drugs and medical care for the individual and society is a factor that should be considered in the selection of antihypertensives. One of the stated objectives of ALLHAT was to answer the question, "Are newer types of antihypertensive agents, which are currently more costly, as good or better than diuretics in reducing CHD incidence and progression?"<sup><a href="#REF-JOC21962-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> Consideration of drug cost could have a major impact on the nation's health care expenditures. Based on previous data that showed that diuretic use declined from 56% to 27% of antihypertensive prescriptions between 1982 and 1992, the health care system would have saved $3.1 billion in estimated cost of antihypertensive drugs had the pattern of prescriptions for treatment of hypertension remained at the 1982 level.<sup><a href="#REF-JOC21962-55" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">55</a></sup> Further economic analyses based on the results of ALLHAT are under way.</p> <a class="article-section-id-anchor" id="25048630"></a> <p class="para">The strengths of ALLHAT include its randomized double-blind design, statistical power to detect clinically meaningful differences in CVD outcomes of interest, diverse population with adequate representation from subgroups of special interest in the treatment of hypertension, and varied practice-based settings. In addition, the agents that were directly compared represent 3 of the most commonly used newer classes of antihypertensives vs the best studied of the older classes.</p> <a class="article-section-id-anchor" id="25048631"></a> <p class="para">Some limitations are worth noting. After ALLHAT was designed, newer agents have been or may soon be released (eg, angiotensin-receptor blockers, selective aldosterone antagonists), which were not evaluated. Although clinical centers were blinded to the regimen and urged to achieve recommended BP goals, equivalent BP reduction was not fully achieved in the treatment groups. Furthermore, because diuretics, ACE inhibitors, CCBs, and α-blockers were evaluated in the trial, the agents available for step-up led to a somewhat artificial regimen (use of sympatholytics rather than diuretics and CCBs) of step-up drugs in the ACE inhibitor group. This may have contributed to the higher BPs in the ACE inhibitor group, especially in the black subgroup. However, mean follow-up BPs were well below 140/90 mm Hg in all treatment groups. Although ALLHAT did not compare a β-blocker to chlorthalidone, previous trials have suggested equivalence<sup><a href="#REF-JOC21962-45" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">45</a></sup> or even inferiority<sup><a href="#REF-JOC21962-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup> for major CVD events.</p> <a class="article-section-id-anchor" id="25048632"></a> <p class="para">The ALLHAT results apply directly to chlorthalidone, amlodipine, and lisinopril. Combined with evidence from other trials, we infer that the findings also broadly apply to the drug classes (or subclass in the case of the dihydropyridine CCBs) that the study drugs represent. The evidence base for selection of antihypertensive agents has been markedly strengthened by the addition of ALLHAT.</p> <a class="article-section-id-anchor" id="25048633"></a> <p class="para">In conclusion, the results of ALLHAT indicate that thiazide-type diuretics should be considered first for pharmacologic therapy in patients with hypertension. They are unsurpassed in lowering BP, reducing clinical events, and tolerability, and they are less costly. For patients who cannot take a diuretic (which should be an unusual circumstance), first-step therapy with CCBs and ACE inhibitors could be considered with due regard for their higher risk of 1 or more major manifestations of CVD. Since a large proportion of participants required more than 1 drug to control their BP, it is reasonable to infer that a diuretic be included in all multidrug regimens, if possible. Although diuretics already play a key role in most antihypertensive treatment recommendations, the findings of ALLHAT should be carefully evaluated by those responsible for clinical guidelines and be widely applied in patient care.</p> <a class="article-section-id-anchor" id="25048634"></a> <div class="h3 cb section-type-references "> <div class="heading-text thm-col sb-sc"> References </div> </div> <div class="references"><div class="reference"><a class="reference-number" id="ref-joc21962-1">1.</a><div class="reference-content">American Heart Association. <em>2002 Heart and Stroke Statistical Update.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">Dallas, Tex: American Heart Association; 2001.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-2">2.</a><div class="reference-content">Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review. <I xmlns:helper="urn:XsltStringHelper"> Hypertension.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1989;13:I36-I44.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Controlled%20clinical%20trials%20of%20drug%20treatment%20for%20hypertension%3A%20a%20review.&author=JA%20Cutler&author=SW%20MacMahon&author=CD%20Furberg&publication_year=&journal=Hypertension.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-3">3.</a><div class="reference-content">Psaty BM, Smith NL, Siscovick DS. et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;277:739-745.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Health%20outcomes%20associated%20with%20antihypertensive%20therapies%20used%20as%20first-line%20agents%3A%20a%20systematic%20review%20and%20meta-analysis.&author=BM%20Psaty&author=NL%20Smith&author=DS%20Siscovick&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-4">4.</a><div class="reference-content"> The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;157:2413-2446.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20sixth%20report%20of%20the%20Joint%20National%20Committee%20on%20prevention%2C%20detection%2C%20evaluation%2C%20and%20treatment%20of%20high%20blood%20pressure.&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-5">5.</a><div class="reference-content">Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;14:929-933.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%201996%20report%20of%20a%20World%20Health%20Organization%20expert%20committee%20on%20hypertension%20control.&author=J%20Chalmers&author=A%20Zanchetti&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-6">6.</a><div class="reference-content">Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;336:370-371.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%20and%20coronary%20heart%20disease.&author=R%20Collins&author=R%20Peto&author=J%20Godwin&author=S%20MacMahon&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-7">7.</a><div class="reference-content">World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;16:127-137.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Protocol%20for%20prospective%20collaborative%20overviews%20of%20major%20randomized%20trials%20of%20blood%20pressure%20lowering%20treatments.&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-8">8.</a><div class="reference-content">SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;265:3255-3264.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevention%20of%20stroke%20by%20antihypertensive%20drug%20treatment%20in%20older%20persons%20with%20isolated%20systolic%20hypertension%3A%20final%20results%20of%20the%20Systolic%20Hypertension%20in%20the%20Elderly%20Program%20%28SHEP%29.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-9">9.</a><div class="reference-content">Staessen JA, Fagard R, Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;350:757-764.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20double-blind%20comparison%20of%20placebo%20and%20active%20treatment%20for%20older%20patients%20with%20isolated%20systolic%20hypertension%3A%20the%20Systolic%20Hypertension%20in%20Europe%20%28Syst-Eur%29%20Trial%20Investigators.&author=JA%20Staessen&author=R%20Fagard&author=L%20Thijs&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-10">10.</a><div class="reference-content">Yusuf S, Sleight P, Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;342:145-153.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20an%20angiotensin-converting-enzyme%20inhibitor%2C%20ramipril%2C%20on%20cardiovascular%20events%20in%20high-risk%20patients%3A%20the%20Heart%20Outcomes%20Prevention%20Evaluation%20Study%20Investigators.&author=S%20Yusuf&author=P%20Sleight&author=J%20Pogue&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-11">11.</a><div class="reference-content">PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;358:1033-1041.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20trial%20of%20a%20perindopril-based%20blood-pressure-lowering%20regimen%20among%206%2C105%20individuals%20with%20previous%20stroke%20or%20transient%20ischaemic%20attack.&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-12">12.</a><div class="reference-content">Grimm Jr RH. Antihypertensive therapy: taking lipids into consideration. <I xmlns:helper="urn:XsltStringHelper"> Am Heart J.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;122:910-918.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antihypertensive%20therapy%3A%20taking%20lipids%20into%20consideration.&author=RH%20Grimm Jr&publication_year=&journal=Am%20Heart%20J.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-13">13.</a><div class="reference-content">Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trialists' Collaboration. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:1955-1964.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20ACE%20inhibitors%2C%20calcium%20antagonists%2C%20and%20other%20blood-pressure-lowering%20drugs%3A%20results%20of%20prospectively%20designed%20overviews%20of%20randomised%20trials%3A%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%27%20Collaboration.&author=B%20Neal&author=S%20MacMahon&author=N%20Chapman&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-14">14.</a><div class="reference-content">Pahor M, Psaty BM, Alderman MH. et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:1949-1954.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Health%20outcomes%20associated%20with%20calcium%20antagonists%20compared%20with%20other%20first-line%20antihypertensive%20therapies%3A%20a%20meta-analysis%20of%20randomised%20controlled%20trials.&author=M%20Pahor&author=BM%20Psaty&author=MH%20Alderman&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-15">15.</a><div class="reference-content">Poulter NR. Treatment of hypertension: a clinical epidemiologist's view. <I xmlns:helper="urn:XsltStringHelper"> J Cardiovasc Pharmacol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;18(suppl 2):S35-S38.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Treatment%20of%20hypertension%3A%20a%20clinical%20epidemiologist%27s%20view.&author=NR%20Poulter&publication_year=&journal=J%20Cardiovasc%20Pharmacol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-16">16.</a><div class="reference-content">Neaton JD, Grimm Jr RH, Prineas RJ. et al. Treatment of mild hypertension study: final results: Treatment of Mild Hypertension Study Research Group. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;270:713-724.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Treatment%20of%20mild%20hypertension%20study%3A%20final%20results%3A%20Treatment%20of%20Mild%20Hypertension%20Study%20Research%20Group.&author=JD%20Neaton&author=RH%20Grimm Jr&author=RJ%20Prineas&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-17">17.</a><div class="reference-content">Materson BJ, Reda DJ, Cushman WC. et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;328:914-921.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Single-drug%20therapy%20for%20hypertension%20in%20men%3A%20a%20comparison%20of%20six%20antihypertensive%20agents%20with%20placebo%3A%20the%20Department%20of%20Veterans%20Affairs%20Cooperative%20Study%20Group%20on%20Antihypertensive%20Agents.&author=BJ%20Materson&author=DJ%20Reda&author=WC%20Cushman&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-18">18.</a><div class="reference-content">Davis BR, Cutler JA, Gordon DJ. et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> Am J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;9:342-360.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rationale%20and%20design%20for%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&author=BR%20Davis&author=JA%20Cutler&author=DJ%20Gordon&publication_year=&journal=Am%20J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-19">19.</a><div class="reference-content">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;283:1967-1975.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Major%20cardiovascular%20events%20in%20hypertensive%20patients%20randomized%20to%20doxazosin%20vs%20chlorthalidone%3A%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-20">20.</a><div class="reference-content">Davis BR, Cutler JA, Furberg CD. et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;137:313-320.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20of%20antihypertensive%20treatment%20regimens%20and%20change%20in%20blood%20pressure%20to%20risk%20for%20heart%20failure%20in%20hypertensive%20patients%20randomly%20assigned%20to%20doxazosin%20or%20chlorthalidone%3A%20further%20analyses%20from%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial.&author=BR%20Davis&author=JA%20Cutler&author=CD%20Furberg&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-21">21.</a><div class="reference-content">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:2998-3007.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Major%20outcomes%20in%20moderately%20hypercholesterolemic%2C%20hypertensive%20patients%20randomized%20to%20pravastatin%20vs%20usual%20care%3A%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial.&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-22">22.</a><div class="reference-content">Grimm Jr RH, Margolis KL, Papademetriou V. et al. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <I xmlns:helper="urn:XsltStringHelper"> Hypertension.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;37:19-27.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Baseline%20characteristics%20of%20participants%20in%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29.&author=RH%20Grimm Jr&author=KL%20Margolis&author=V%20Papademetriou&publication_year=&journal=Hypertension.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-23">23.</a><div class="reference-content"> The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1993;153:154-183.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20fifth%20report%20of%20the%20Joint%20National%20Committee%20on%20Detection%2C%20Evaluation%2C%20and%20Treatment%20of%20High%20Blood%20Pressure%20%28JNC%20V%29.&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-24">24.</a><div class="reference-content">Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;130:461-470.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20more%20accurate%20method%20to%20estimate%20glomerular%20filtration%20rate%20from%20serum%20creatinine%3A%20a%20new%20prediction%20equation%3A%20Modification%20of%20Diet%20in%20Renal%20Disease%20Study%20Group.&author=AS%20Levey&author=JP%20Bosch&author=JB%20Lewis&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-25">25.</a><div class="reference-content">Levey AS, Greene T, Kusek JW. et al. A simplified equation to predict glomerular filtration rate from serum creatinine. <I xmlns:helper="urn:XsltStringHelper"> J Am Soc Nephrol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;11:155A.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20simplified%20equation%20to%20predict%20glomerular%20filtration%20rate%20from%20serum%20creatinine.&author=AS%20Levey&author=T%20Greene&author=JW%20Kusek&publication_year=&journal=J%20Am%20Soc%20Nephrol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-26">26.</a><div class="reference-content">Piller LB, Davis BR, Cutler JA. et al. Validation of heart failure events in ALLHAT participants assigned to doxazosin. <I xmlns:helper="urn:XsltStringHelper"> Curr Control Trials Cardiovasc Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;3:10.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Validation%20of%20heart%20failure%20events%20in%20ALLHAT%20participants%20assigned%20to%20doxazosin.&author=LB%20Piller&author=BR%20Davis&author=JA%20Cutler&publication_year=&journal=Curr%20Control%20Trials%20Cardiovasc%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-27">27.</a><div class="reference-content">Public Health Service-Health Care Financing Administration. <em>International Classification of Diseases, Ninth Revision (ICD-9).</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">6th ed. Bethesda, Md: US Dept of Health and Human Services; 2001. DHHS Publication No. (PHS) 80-1260.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-28">28.</a><div class="reference-content">Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. <I xmlns:helper="urn:XsltStringHelper"> J Am Stat Assoc.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1955;50:1096-1121.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20multiple%20comparisons%20procedure%20for%20comparing%20several%20treatments%20with%20a%20control.&author=CW%20Dunnett&publication_year=&journal=J%20Am%20Stat%20Assoc.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-29">29.</a><div class="reference-content">Klein JP, Moeschberger ML. <em>Survival Analysis: Techniques for Censored and Truncated Regression.</em> <span class="ref-text" xmlns:helper="urn:XsltStringHelper">New York, NY: Springer-Verlag; 1997.</span></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-30">30.</a><div class="reference-content">Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations. <I xmlns:helper="urn:XsltStringHelper"> Commun Stat.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;19:3571-3584.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Upper%20bounds%20for%20type%20I%20and%20II%20error%20rates%20in%20conditional%20power%20calculations.&author=BR%20Davis&author=RJ%20Hardy&publication_year=&journal=Commun%20Stat.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-31">31.</a><div class="reference-content">Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. <I xmlns:helper="urn:XsltStringHelper"> Biometrika.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1983;70:659-663.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Discrete%20sequential%20boundaries%20for%20clinical%20trials.&author=KKG%20Lan&author=DL%20DeMets&publication_year=&journal=Biometrika.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-32">32.</a><div class="reference-content">Hansson L, Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;354:1751-1756.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomised%20trial%20of%20old%20and%20new%20antihypertensive%20drugs%20in%20elderly%20patients%3A%20cardiovascular%20mortality%20and%20morbidity%3A%20the%20Swedish%20Trial%20in%20Old%20Patients%20with%20Hypertension-2%20study.&author=L%20Hansson&author=LH%20Lindholm&author=T%20Ekbom&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-33">33.</a><div class="reference-content">Brown MJ, Palmer CR, Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:366-372.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Morbidity%20and%20mortality%20in%20patients%20randomised%20to%20double-blind%20treatment%20with%20a%20long-acting%20calcium-channel%20blocker%20or%20diuretic%20in%20the%20International%20Nifedipine%20GITS%20study%3A%20Intervention%20as%20a%20Goal%20in%20Hypertension%20Treatment%20%28INSIGHT%29.&author=MJ%20Brown&author=CR%20Palmer&author=A%20Castaigne&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-34">34.</a><div class="reference-content">MacMahon S, Neal B. Differences between blood-pressure-lowering drugs. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;356:352-353.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Differences%20between%20blood-pressure-lowering%20drugs.&author=S%20MacMahon&author=B%20Neal&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-35">35.</a><div class="reference-content">Kostis JB, Davis BR, Cutler J. et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;278:212-216.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevention%20of%20heart%20failure%20by%20antihypertensive%20drug%20treatment%20in%20older%20persons%20with%20isolated%20systolic%20hypertension%3A%20SHEP%20Cooperative%20Research%20Group.&author=JB%20Kostis&author=BR%20Davis&author=J%20Cutler&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-36">36.</a><div class="reference-content">Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. <I xmlns:helper="urn:XsltStringHelper"> J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;15:105-115.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20calcium%20antagonists%20on%20the%20risks%20of%20coronary%20heart%20disease%2C%20cancer%20and%20bleeding.&publication_year=&journal=J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-37">37.</a><div class="reference-content">Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. <I xmlns:helper="urn:XsltStringHelper"> Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;92:1326-1331.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Nifedipine%3A%20dose-related%20increase%20in%20mortality%20in%20patients%20with%20coronary%20heart%20disease.&author=CD%20Furberg&author=BM%20Psaty&author=JV%20Meyer&publication_year=&journal=Circulation.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-38">38.</a><div class="reference-content">Agodoa LY, Appel L, Bakris GL. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;285:2719-2728.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20ramipril%20vs%20amlodipine%20on%20renal%20outcomes%20in%20hypertensive%20nephrosclerosis%3A%20a%20randomized%20controlled%20trial.&author=LY%20Agodoa&author=L%20Appel&author=GL%20Bakris&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-39">39.</a><div class="reference-content">Hall WD, Kusek JW, Kirk KA. et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. <I xmlns:helper="urn:XsltStringHelper"> Am J Kidney Dis.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;29:720-728.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Short-term%20effects%20of%20blood%20pressure%20control%20and%20antihypertensive%20drug%20regimen%20on%20glomerular%20filtration%20rate%3A%20the%20African-American%20Study%20of%20Kidney%20Disease%20and%20Hypertension%20Pilot%20Study.&author=WD%20Hall&author=JW%20Kusek&author=KA%20Kirk&publication_year=&journal=Am%20J%20Kidney%20Dis.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-40">40.</a><div class="reference-content">ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1994;154:1185-1202.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20calcium%20antagonists%20on%20renal%20hemodynamics%20and%20progression%20of%20nondiabetic%20chronic%20renal%20disease.&author=PM%20ter Wee&author=AG%20De Micheli&author=M%20Epstein&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-41">41.</a><div class="reference-content">Lonn EM, Yusuf S, Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. <I xmlns:helper="urn:XsltStringHelper"> Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1994;90:2056-2069.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Emerging%20role%20of%20angiotensin-converting%20enzyme%20inhibitors%20in%20cardiac%20and%20vascular%20protection.&author=EM%20Lonn&author=S%20Yusuf&author=P%20Jha&publication_year=&journal=Circulation.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-42">42.</a><div class="reference-content">Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. <I xmlns:helper="urn:XsltStringHelper"> Am J Hypertens.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;12:205S-213S.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20renin-angiotensin-aldosterone%20system%3A%20a%20specific%20target%20for%20hypertension%20management.&author=MR%20Weir&author=VJ%20Dzau&publication_year=&journal=Am%20J%20Hypertens.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-43">43.</a><div class="reference-content">Jafar TH, Schmid CH, Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. <I xmlns:helper="urn:XsltStringHelper"> Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:73-87.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Angiotensin-converting%20enzyme%20inhibitors%20and%20progression%20of%20nondiabetic%20renal%20disease%3A%20a%20meta-analysis%20of%20patient-level%20data.&author=TH%20Jafar&author=CH%20Schmid&author=M%20Landa&publication_year=&journal=Ann%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-44">44.</a><div class="reference-content"> Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;327:685-691.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20enalapril%20on%20mortality%20and%20the%20development%20of%20heart%20failure%20in%20asymptomatic%20patients%20with%20reduced%20left%20ventricular%20ejection%20fractions%3A%20the%20SOLVD%20Investigators.&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-45">45.</a><div class="reference-content">Collins R, Peto R, MacMahon S. et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;335:827-838.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%2C%20stroke%2C%20and%20coronary%20heart%20disease%3A%20Part%202%2C%20short-term%20reductions%20in%20blood%20pressure%3A%20overview%20of%20randomised%20drug%20trials%20in%20their%20epidemiological%20context.&author=R%20Collins&author=R%20Peto&author=S%20MacMahon&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-46">46.</a><div class="reference-content">MacMahon S, Peto R, Cutler J. et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. <I xmlns:helper="urn:XsltStringHelper"> Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;335:765-774.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Blood%20pressure%2C%20stroke%2C%20and%20coronary%20heart%20disease%3A%20Part%201%2C%20prolonged%20differences%20in%20blood%20pressure%3A%20prospective%20observational%20studies%20corrected%20for%20the%20regression%20dilution%20bias.&author=S%20MacMahon&author=R%20Peto&author=J%20Cutler&publication_year=&journal=Lancet.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-47">47.</a><div class="reference-content">Staessen JA, Byttebier G, Buntinx F. et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial: Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. <I xmlns:helper="urn:XsltStringHelper"> JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;278:1065-1072.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antihypertensive%20treatment%20based%20on%20conventional%20or%20ambulatory%20blood%20pressure%20measurement%3A%20a%20randomized%20controlled%20trial%3A%20Ambulatory%20Blood%20Pressure%20Monitoring%20and%20Treatment%20of%20Hypertension%20Investigators.&author=JA%20Staessen&author=G%20Byttebier&author=F%20Buntinx&publication_year=&journal=JAMA.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-48">48.</a><div class="reference-content">Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist's point of view. <I xmlns:helper="urn:XsltStringHelper"> Pathol Biol (Paris).</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;47:594-603.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cardiovascular%20risks%20related%20to%20increased%20diastolic%2C%20systolic%20and%20pulse%20pressure%3A%20an%20epidemiologist%27s%20point%20of%20view.&author=SS%20Franklin&publication_year=&journal=Pathol%20Biol%20%28Paris%29.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-49">49.</a><div class="reference-content">Saunders E, Weir MR, Kong BW. et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;150:1707-1713.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20the%20efficacy%20and%20safety%20of%20a%20beta-blocker%2C%20a%20calcium%20channel%20blocker%2C%20and%20a%20converting%20enzyme%20inhibitor%20in%20hypertensive%20blacks.&author=E%20Saunders&author=MR%20Weir&author=BW%20Kong&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-50">50.</a><div class="reference-content">Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. <I xmlns:helper="urn:XsltStringHelper"> Endocrinol Metab Clin North Am.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;26:125-144.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pathophysiology%20and%20treatment%20implications%20of%20hypertension%20in%20the%20African-American%20population.&author=M%20Rahman&author=JG%20Douglas&author=JT%20Wright&publication_year=&journal=Endocrinol%20Metab%20Clin%20North%20Am.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-51">51.</a><div class="reference-content">Cushman WC, Reda DJ, Perry HM. et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;160:825-831.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Regional%20and%20racial%20differences%20in%20response%20to%20antihypertensive%20medication%20use%20in%20a%20randomized%20controlled%20trial%20of%20men%20with%20hypertension%20in%20the%20United%20States.&author=WC%20Cushman&author=DJ%20Reda&author=HM%20Perry&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-52">52.</a><div class="reference-content">Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. <I xmlns:helper="urn:XsltStringHelper"> N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;344:1351-1357.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Lesser%20response%20to%20angiotensin-converting-enzyme%20inhibitor%20therapy%20in%20black%20as%20compared%20with%20white%20patients%20with%20left%20ventricular%20dysfunction.&author=DV%20Exner&author=DL%20Dries&author=MJ%20Domanski&author=JN%20Cohn&publication_year=&journal=N%20Engl%20J%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-53">53.</a><div class="reference-content">Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. <I xmlns:helper="urn:XsltStringHelper"> J Card Fail.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;5:178-187.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Racial%20differences%20in%20response%20to%20therapy%20for%20heart%20failure%3A%20analysis%20of%20the%20vasodilator-heart%20failure%20trials%3A%20Vasodilator-Heart%20Failure%20Trial%20Study%20Group.&author=P%20Carson&author=S%20Ziesche&author=G%20Johnson&author=JN%20Cohn&publication_year=&journal=J%20Card%20Fail.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-54">54.</a><div class="reference-content">Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. <I xmlns:helper="urn:XsltStringHelper"> J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;40:311-317.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20of%20angiotensin-converting%20enzyme%20inhibition%20in%20reducing%20progression%20from%20asymptomatic%20left%20ventricular%20dysfunction%20to%20symptomatic%20heart%20failure%20in%20black%20and%20white%20patients.&author=DL%20Dries&author=MH%20Strong&author=RS%20Cooper&author=MH%20Drazner&publication_year=&journal=J%20Am%20Coll%20Cardiol.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21962-55">55.</a><div class="reference-content">Manolio TA, Cutler JA, Furberg CD. et al. Trends in pharmacologic management of hypertension in the United States. <I xmlns:helper="urn:XsltStringHelper"> Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;155:829-837.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20pharmacologic%20management%20of%20hypertension%20in%20the%20United%20States.&author=TA%20Manolio&author=JA%20Cutler&author=CD%20Furberg&publication_year=&journal=Arch%20Intern%20Med.&volume=&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div></div> </div> </div> <div class="movable-ad bta"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{"parameters":{"siteName":"jama","siteId":3,"journalId":67,"adDisplay":8,"adSection":"textbreak","adPosition":"bta","fromGoogle":false},"dynamicParameters":{}}"></div> </div> </div> </div> </div> <div class="hidden-jobs-ad hide"> <div class="widget-WidgetLoader widget-instance-AMA_JobsAd"> <div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{"parameters":{"SiteId":3},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <script> var App = App || {}; App.ArticleSplitScreen = App.ArticleSplitScreen || {}; App.ArticleSplitScreen.siteName = 'jama'; App.ArticleSplitScreen.siteId = 3; App.ArticleSplitScreen.journalId = 67; App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox'; App.ArticleSplitScreen.adSection = "scholarly"; App.ArticleSplitScreen.adPosition = "contab"; App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox"; App.ArticleSplitScreen.fromGoogle = "False"; App.ArticleSplitScreen.slotLocationOverride = "50"; </script> </div> </div> </section> <section id="secFooterControl" class="master-footer"> <script> var App = App || {}; function scmByClass(className) { return document.getElementsByClassName(className); } function scmById(id) { return document.getElementById(id); } function scmquery(selector) { return document.querySelector(selector); } function queryAll(selector) { return document.querySelectorAll(selector); } function isTrueString(string) { if (typeof string === 'string') { return string.toLowerCase() === 'true'; } return undefined; } function updateViewportDimensions() { var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight; return { width: x, height: y }; } var viewport = updateViewportDimensions(); var debounce = function (func, wait, immediate) { var timeout; return function () { var context = this, args = arguments; var later = function () { timeout = null; if (!immediate) func.apply(context, args); }; var callNow = immediate && !timeout; clearTimeout(timeout); timeout = setTimeout(later, wait); if (callNow) func.apply(context, args); }; }; (function (App) { App.mobileUpperBreakpoint = 767; App.mobileAltBreakpoint = 640; App.mobileMinBreakpoint = 547; App.tabletUpperBreakpoint = 1023; function setVariables() { viewport = updateViewportDimensions(); App.isMobile = (viewport.width <= App.mobileUpperBreakpoint); App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint); App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint); App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint); App.isDesktop = (viewport.width > App.tabletUpperBreakpoint); App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large'; } setVariables(); App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large'; App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length); App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length; App.isArticleRedesign = !!scmByClass('widget-ArticleWrapper').length; App.isAbstract = !!scmByClass('pg_abstract').length; App.isMag = !!(scmByClass('widget-MagazineView').length); App.isChannel = !!(scmByClass('channel-site').length); App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length); App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') || scmquery('.widget-ArticleTopInfo .open-access') || scmquery('.widget-ArticleTopInfo .icon-free') || scmquery('.widget-ChannelsMagazineView .free-access')); App.isTollFreeAccess = false; App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length; App.isNewOnline = !!scmByClass('pg_newonline').length; App.isCurrentIssue = !!scmByClass('pg_currentissue').length; App.isPastIssues = !!scmByClass('pg_pastissues').length; App.isJournal = !!scmByClass('pg_journal').length; App.isNetworkHome = !!scmByClass('pg_index').length; App.isSearch = !!scmByClass('pg_searchresults').length; App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length; App.isPlayer= !!scmByClass('pg_multimediaplayer').length; App.isSelfServe = !!scmByClass('pg_sspage').length; App.isCmsPage = !!scmByClass('pg_cmspage').length; App.isMyAccount = !!scmByClass('pg_myaccount').length; App.supportsFlexbox = !!scmByClass('flexbox').length; App.isCollection = !!scmByClass('pg_collection').length; App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value')); App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value')); App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value')); App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value')); App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value')); var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value'); App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined; App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value')); App.currentJournalCount = 27; App.isChannelPage = !!(scmByClass('channels-page')); App.updateAppVariables = debounce(function () { setVariables(); }, 50, false); })(App); </script> <div class="footer-ad-wrapper"> <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{"parameters":{"siteName":"jama","siteId":3,"journalId":67,"adDisplay":11,"adSection":"scholarly","adPosition":"btf","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> </div> <div class="ad-riser-wrap desktop-only"> <div class="ad-riser--dismiss t-c">X</div> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{"parameters":{"siteName":"jama","siteId":3,"journalId":67,"adDisplay":12,"adSection":"scholarly","adPosition":"Riser","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <div class="footer-wrap"> <footer class="footer" id="footer"> <div id="footer-microsite" class="footer-microsite"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}} .footer-microsite-contents {margin-bottom:1em;width:100%;} .footer-network-other .link-apps:before {width: 23px;} .footer-network-other .link-institutions-librarians:before {width: 23px;} .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;} .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;padding-right:3px;} </style> <div class="footer-heading-wrap"> <h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA</h3> </div> <div class="footer-microsite-links-wrap"> <div class="footer-microsite-contents jn-ss-footer-border-bottom"> <h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4> <a href="/journals/jama">Home</a> <a href="/journals/jama/newonline">New Online</a> <a href="/journals/jama/currentissue">Current Issue</a> </div> <div class="footer-microsite-contents jn-ss-footer-border-bottom"> <h4 class="footer-subheading">Podcasts</h4> <a href="/journals/jama/pages/covid-19-interviews#audio">Coronavirus (COVID-19) Q&A</a> <a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a> <a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a> <a href="/journals/jama/pages/jama-medical-news">Medical News</a> <a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a> <a href="/journals/jama/pages/jamaevidence-jama-guide-to-statistics-and-methods">JAMAevidence: <em>JAMA Guide to Statistics and Methods</em></a> <a href="/journals/jama/pages/jamaevidence-the-rational-clinical-examination">JAMAevidence: The Rational Clinical Examination</a> <a href="/journals/jama/pages/jamaevidence-users-guides-to-the-medical-literature">JAMAevidence: Users' Guides to the Medical Literature</a> </div> <div class="footer-microsite-services cf"> <h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4> <a href="/journals/jama/pages/for-authors">For Authors</a> <a href="/journals/jama/pages/jama-editors">JAMA Editors</a> <a href="/journals/jama/editors-and-publishers">Editors & Publishers</a> <a href="/pages/rss">RSS</a> <a href="/journals/jama/pages/contact-us">Contact Us</a> </div> <div class="footer-network-other jn-ss-footer-border-bottom"> <a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a> <a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a> <a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a> <a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a> <a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a> <a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints & Permissions</a> </div> <div id="BodyContent_Footer_divSubscribe" class="footer-microsite-subscribe"> <img src="//cdn.jamanetwork.com/UI/app/img/covers/jama.jpg" class="subscribe-image" alt="Journal Cover"> <div class="subscribe-meta"> <h4 class="subscribe-heading footer-subheading">Subscribe</h4> <a href="https://store.jamanetwork.com/productDetails.aspx?productcodeID=64" class="subscribe-submit btn">Go</a> </div> </div> </div> </div> <div id="footer-network" class="footer-network"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .footer-network-sites {width: 62.85542%;} .footer-network-info {width: 35.93976%} .jn-ss-subheading-mt {margin-top: 1.5em;} .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;} .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;} .nav-logo-cme-signin-container .nav-logo .site-logo img { min-width:50px;} </style> <div class="footer-heading-wrap"> <h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3> </div> <div class="footer-network-links-wrap"> <div class="footer-network-sites"> <div class="internal"> <h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4> <a href="/journals/jama">JAMA</a> <a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a> <a href="/journals/jamacardiology">JAMA Cardiology</a> <a href="/journals/jamadermatology">JAMA Dermatology</a> <a href="/journals/jama-health-forum">JAMA Health Forum</a> <a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a> <a href="/journals/jamaneurology">JAMA Neurology</a> <a href="/journals/jamaoncology">JAMA Oncology</a> <a href="/journals/jamaophthalmology">JAMA Ophthalmology</a> <a href="/journals/jamaotolaryngology">JAMA Otolaryngology–Head & Neck Surgery</a> <a href="/journals/jamapediatrics">JAMA Pediatrics</a> <a href="/journals/jamapsychiatry">JAMA Psychiatry</a> <a href="/journals/jamasurgery">JAMA Surgery</a> <a href="/journals/archneurpsyc">Archives of Neurology & Psychiatry (1919-1959)</a> </div> <div class="external"> <h4 class="footer-subheading">Sites</h4> <div id="BodyContent_Footer_ssFooterSiteMenu"> <div class="selfServe"> <a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a> <a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a> <a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a> <a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a> <a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a> <a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a> <a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a> <a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a> <a target="_blank" href="/pages/health-and-the-2024-us-election">Health and the 2024 US Election</a> <a target="_blank" href="/channels/hypertension">Hypertension</a> <a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a> <a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a> <a target="_blank" href="/pages/video">JAMA Network Video</a> <a target="_blank" href="/pages/conferences">JAMA Network Conferences </a> <a target="_blank" href="/channels/ai">JAMA+ AI</a> <a target="_blank" href="/pages/jama-summit">JAMA Summit </a> <a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a> <a target="_blank" href="/channels/medical-news">Medical News</a> <a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a> <a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a> <a target="_blank" href="/pages/collections">Topics and Collections</a> <a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a> <a target="_blank" href="/channels/war">War and Health</a> <a target="_blank" href="/channels/womens-health">Women's Health</a> <h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4> <a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a> <a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in Medicine</a> <a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a> <a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a> <a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a> <a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a> <a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a> <a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a> <a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a> <a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a> <a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a> <a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a> <a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a> <a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a> <a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a> <a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a> <a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Children’s Rights in the US</a> <a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a> <a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a> <h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4> <a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a> <a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a> <a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a> <a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a> <a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a> <a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a> <a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a> <h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4> <a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a> </div> </div> </div> </div> <div id="footer-network-info" class="footer-network-info"> <div class="information-for-links"> <h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4> <a href="/pages/for-authors">For Authors</a> <a href="/pages/resources-for-librarians">For Institutions & Librarians</a> <a href="/pages/advertisers">For Advertisers</a> <a href="/pages/subscription-agents">For Subscription Agents</a> <a href="https://careers.jamanetwork.com/" target="_blank">For Employers & Job Seekers</a> <a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a> <a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a> <a href="/pages/commenting-policy">Online Commenting Policy</a> <a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a> <a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a> </div> <div class="services-links"> <h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4> <a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a> <a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a> <a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a> </div> <div class="learning-links"> <h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4> <a href="https://edhub.ama-assn.org/jn-learning">Home</a> <a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a> <a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a> <a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a> <a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a> <a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a> <a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME & MOC</a> </div> </div> </div> </div> <div id="footer-resources-wrap" class="footer-resources-wrap"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;} </style> <div class="footer-heading-wrap"> <h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3> </div> <div class="footer-resources"> <a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions & Renewals</a> <a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a> <a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a> <a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a> <a href="/myaccount " class="footer-service-link">My Account</a> <h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4> <a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a> </div> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .widget-instance-AMA_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;} .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;} .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;} .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;} .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;} .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;} #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; } </style> <div id="BodyContent_Footer_divSocial" class="social-links footer-social-links"> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.facebook.com/JAMAJournal/" class="social-link is-b facebook"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://twitter.com/JAMA_current" class="social-link is-b twitter"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.linkedin.com/company/jamanetwork/" class="social-link is-b linked-in"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.youtube.com/jamanetwork" class="social-link is-b you-tube"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="/rss/site_3/67.xml" class="social-link is-b rss"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://jamanetwork.com/journals/jama/pages/jama-editors-summary" class="social-link is-b podcast"></a> <div id="load-instagram-image"> </div> </div> <div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates"> <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer"> <div class="email-signup"> <div class="email-signup--text sb-pc">Get the latest from JAMA</div> <div class="email-signup--input-wrap is-b"> <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" /> <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a> </div> <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div> <div class="email-signup--user-message"></div> </div> </div> </div> </div> <div class="footer-bar" itemscope itemtype="https://schema.org/Organization"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .network-bar .auth--inst {color:#B8B8B8;} .multimedia-caption-container div.video-caption {color: #262626;font-size: 15px;font-weight: 700;line-height: 1.5;} .nav-journals a.theme-jama-health-forum:before {background: #133763;} .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;} .jn-bottom-bar p {line-height: 2;} @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}} .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;} .jn-footer-pipe {margin:0 10px;} .footer-bar-jn-logo img {width: 230px;} @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}} [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;} [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;} [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;} [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;} [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;} [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;} [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;} [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;} [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;} [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;} [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;} [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;} [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;} [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;} [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;} .blockquote .para {margin: 0 0 1em 1em;} .jn-footer-copyright {display: block;} .inline-block {display: inline-block;} </style> <a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=82308" alt="Jama Network Logo"></a> <div class="jn-bottom-bar"> <p> <span class="jn-footer-copyright">© 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span> </p> </div>  <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a> </div> </footer> </div> <div class="ss-ui-only"> <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SsUiOnly" /> <input type="hidden" class="SelfServeVersionId" value="0" /> . </div> </div> </div> </section> <div id="revealModal" class="reveal-modal" data-reveal> <div id="revealContent"></div> <a class="close-reveal-modal icon-close"></a> </div> <div class="artmet-modal" id="MetricsModal"> <div class="artmet-modal-contents"> <a class="artmet-close-modal">×</a> </div> </div> <div class="widget-SigninModals widget-instance-AMA_SigninModals"> <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Access your subscriptions</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr> <button class="modal--btn js-btn-subscribe-journal" type="button" role="button"> <div class="text-truncate">Subscribe to journal</div> </button> <div class="modal--btn-desc">Get full journal access for 1 year</div> <button class="modal--btn js-btn-purchase-article" type="button" role="button"> <div class="text-truncate">Buy article</div> </button> <div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br> <em>Sign in or create a free account</em></div>  </div> </div> <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve"> <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.288.23.2981&fieldName=journal_doi&affiliateId=JAMA" data-doi="10.1001/jama.288.23.2981" data-fieldname="journal_doi" data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button> <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Access your subscriptions</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr> <button class="modal--btn js-btn-subscribe-journal" type="button" role="button"> <div class="text-truncate">Subscribe to journal</div> </button> <div class="modal--btn-desc">Get full journal access for 1 year</div> <button class="modal--btn js-btn-purchase-article" type="button" role="button"> <div class="text-truncate">Buy article</div> </button> <div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br> <em>Sign in or create a free account</em></div>  </div> </div> <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve"> <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.288.23.2981&fieldName=journal_doi&affiliateId=JAMA" data-doi="10.1001/jama.288.23.2981" data-fieldname="journal_doi" data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button> <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Sign in to access free PDF</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Save your search</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr /> <button class="modal--btn js-btn-subscribe-now">Subscribe now</button>  </div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Customize your interests</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--sub-title">Create a personal account or sign in to:</div> <ul> <li>Register for email alerts with links to free full-text articles</li> <li>Access PDFs of free articles</li> <li>Manage your interests</li> <li>Save searches and receive search alerts</li> <ul>  </div> </div> <div class="modal--link-wrap"> <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Make a comment</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195626"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--sub-title">Create a personal account or sign in to:</div> <ul> <li>Register for email alerts with links to free full-text articles</li> <li>Access PDFs of free articles</li> <li>Manage your interests</li> <li>Save searches and receive search alerts</li> <ul>  </div> </div> <div class="modal--link-wrap"> <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="hidden-true js-modal-page-data" data-store-url="https://store.jamanetwork.com" data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com" data-store-subscribe-url="https://store.jamanetwork.com/index.aspx?productcode=64"> </div> </div> <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638654734634555810"></script> <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script> <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638677764559592887" defer></script> <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script> <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script> <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&product=sop' async='async'></script> <script> var App = App || {}; App.showCmePromo = false; </script> </form> <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css"> <div class="widget-CustomJSScript widget-instance-"> <script src="//cdn.jamanetwork.com/ama/ama.proxylogging.js" async></script> </div> </body> </html>